

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 October 2020 (15.10.2020)



(10) International Publication Number
WO 2020/208510 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A01N 43/90 (2006.01)

(21) International Application Number:

PCT/IB2020/053296

(22) International Filing Date:

07 April 2020 (07.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201911014148 08 April 2019 (08.04.2019) IN

(71) Applicant: **PI INDUSTRIES LIMITED** [IN/IN]; Udaigar Road, 313001 Udaipur-Rajasthan (IN).

(72) Inventors: **BHUJADE, Paras Raybhan**; House no-189, Bhujade Vasti, Apegaon, Taluka-Kopargaon, 423603 Ahmednagar - Maharashtra (IN). **NAIK, Maruti N**; Bunder road 6th cross, Hanuman Nagar, 581320 Bhatkal - Karnataka (IN). **TEMBHARE, Nitin Ramesh**; At-Mendha, PO-Thaneagaon, Tehsil-Tirora, 441911 Gondia - Maharashtra (IN). **AUTKAR, Santosh Shridhar**; At Post: Vyala, Taluka: Balapur, 444302 Akola - Maharashtra (IN). **GARG, Ruchi**; B 38/47 C-1-K, Tulsipur, Mahmoorganj, 221010 Varanasi - UP (IN). **GADE, Vishwanath**; Flat No. 2504, J wing, Rustimjee Azziano, Majiwada, Nasik Road, 400601 Thane West - Maharashtra (IN). **KLAUSENER, Alexander G.M.**; Schiffgesweg 18, 50259 Pulheim (DE). **RAMAKRISHNA, Visannagari**; Village-Papiredy-guda, Mandal-Keshampet, 509216 Rangareddy - Telangana (IN). **SWARNKAR, Sonali**; Near Kailash talkies, Dhamana Road, Kapasan- Rajasthan (IN). **WAGHMARE, Vinod Sunil**; At-Navdare, Po-Walchandnagar, Tal-Indapur, 413114 Pune - Maharashtra (IN).

(74) Agent: **VUTTS, Vaibhav** et al.; Vutts & Associates LLP, Advocates, No. 704, The Castle, Plot 36-A, Sector 56, 122011 Gurgaon, Haryana (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI



Formula (I)

(57) Abstract: The present invention discloses a compound of formula(I), Formula (I) wherein, R¹, L¹, A, k, R⁸, R⁹L² and R⁵ are as defined in the detailed description. The present invention also discloses a process for preparing the compound of formula (I).



WO 2020/208510 A1

TITLE OF THE INVENTION: NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI

FIELD OF THE INVENTION:

The present invention relates to novel oxadiazole compounds useful for combating phytopathogenic fungi, a combination thereof and to a composition comprising novel oxadiazole compounds. The present invention also relates to a method for controlling or preventing phytopathogenic fungi.

BACKGROUND OF THE INVENTION:

Oxadiazoles have already been disclosed in the literature. For example in JPS5665881, JPS63162680, JPS6296480, JPS6051188, WO2005051932, EP3165093, EP3167716, EP3165093, WO2017076740, WO2017102006, WO2017110861, WO2017110862, WO2017110864, WO2017157962, WO2017174158, WO2017198852, WO2017207757, WO2017211650, WO2017211652, WO2017220485, WO2017072247, WO2017076742, WO2017076757, WO2017076935, WO2018015447, WO2018065414, WO2018118781, WO2018187553 and WO2018202491 various oxadiazoles have been disclosed.


The oxadiazole compounds reported in the above literature have disadvantages in certain aspects, such as that they exhibit a narrow spectrum of application or that they do not have satisfactory fungicidal activity, particularly at low application rates.

Therefore, it is an object of the present invention to provide compounds having an improved/enhanced activity and/or a broader activity spectrum against phytopathogenic fungi.

This objective is achieved by using a compound of formula (I) of the present invention for controlling or preventing phytopathogenic fungi.

SUMMARY OF THE INVENTION:

The present invention relates to a compound of formula (I),



Formula (I)

wherein, R^1 , L^1 , A , k , R^8 , R^9 , L^2 and R^5 are as defined in the detailed description. The present invention also relates to a process for preparing the compound of formula (I).

The compounds of formula (I) have now been found to be advantages over the compounds reported in the literature in either of improved fungicidal efficacy, broader spectrum of biological activity, lower

application rates, more favourable biological or environmental properties, or enhanced plant compatibility.

The present invention further relates to a combination comprising the compound of formula (I) of the present invention and at least one further pesticidally active substance for effectively controlling or preventing phytopathogenic fungi which are difficult to combat.

The present invention still further relates to a composition comprising the compound of formula (I) or the compound of formula (I) in combination with a further pesticidally active substance.

The present invention still further relates to a method and use of the compound of formula (I), the combination or the composition thereof for controlling and or preventing plant diseases, particularly phytopathogenic fungi.

DETAILED DESCRIPTION OF THE INVENTION:

DEFINITIONS:

The definitions provided herein for the terminologies used in the present disclosure are for illustrative purpose only and in no manner limit the scope of the present invention disclosed in the present disclosure.

As used herein, the terms “comprises”, “comprising”, “includes”, “including”, “has”, “having”, “contains”, “containing”, “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.

The transitional phrase “consisting of” excludes any element, step or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The transitional phrase “consisting essentially of” is used to define a composition or method that includes materials, steps, features, components or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”.

Further, unless expressly stated to the contrary, “or” refers to an inclusive “or” and not to an exclusive “or”. For example, a condition A “or” B is satisfied by any one of the following: A is true (or present)

and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles “a” and “an” preceding an element or component of the present invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

As referred to in this disclosure, the term “invertebrate pest” includes arthropods, gastropods and nematodes of economic importance as pests. The term “arthropod” includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans. The term “gastropod” includes snails, slugs and other Stylommatophora. The term “nematode” refers to a living organism of the Phylum Nematoda. The term “helminths” includes roundworms, heartworms, phytophagous nematodes (Nematoda), flukes (Tematoda), acanthocephala and tapeworms (Cestoda).

In the context of this disclosure “invertebrate pest control” means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.

The term “agronomic” refers to the production of field crops such as for food, feed and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives).

The term “nonagronomic” refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.

Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasitically effective (i.e. biologically effective) amount of a compound of the present invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected. As referred to in the present disclosure and claims, the terms “parasitidal” and “parasitically” refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasitidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest. Such effects on the pest include necrosis, death, retarded

growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.

Compounds of the present disclosure may be present either in pure form or as mixtures of different possible isomeric forms such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present disclosure. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technology to separate, enrich, and/or to selectively prepare said isomers.

The meaning of various terms used in the description shall now be illustrated.

The term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” or -N(alkyl) or alkylcarbonylalkyl or alkylsulphonylamino includes straight-chain or branched C₁ to C₂₄ alkyl, preferably C₁ to C₁₅ alkyl, more preferably C₁ to C₁₀ alkyl, most preferably C₁ to C₆ alkyl. Non-limiting examples of alkyl include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl or the different isomers. If the alkyl is at the end of a composite substituent, as, for example, in alkylcycloalkyl, the part of the composite substituent at the start, for example the cycloalkyl, may be mono- or polysubstituted identically or differently and independently by alkyl. The same also applies to composite substituents in which other radicals, for example alkenyl, alkynyl, hydroxyl, halogen, carbonyl, carbonyloxy and the like, are at the end.

The term “alkenyl”, used either alone or in compound words includes straight-chain or branched C₂ to C₂₄ alkenes, preferably C₂ to C₁₅ alkenes, more preferably C₂ to C₁₀ alkenes, most preferably C₂ to C₆ alkenes. Non-limiting examples of alkenes include ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-

hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2-methyl-2-propenyl and the different isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. This definition also applies to alkenyl as a part of a composite substituent, for example haloalkenyl and the like, unless defined specifically elsewhere.

Non-limiting examples of alkynes include ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butylnyl, 1-methyl-3-butylnyl, 2-methyl-3-butylnyl, 3-methyl-1-butylnyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butylnyl, 1,1-dimethyl-3-butylnyl, 1,2-dimethyl-3-butylnyl, 2,2-dimethyl-3-butylnyl, 3,3-dimethyl-1-butylnyl, 1-ethyl-2-butylnyl, 1-ethyl-3-butylnyl, 2-ethyl-3-butylnyl and 1-ethyl-1-methyl-2-propynyl and the different isomers. This definition also applies to alkynyl as a part of a composite substituent, for example haloalkynyl etc., unless specifically defined elsewhere. The term "alkynyl" can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.

The term "cycloalkyl" means alkyl closed to form a ring. Non-limiting examples include cyclopropyl, cyclopentyl and cyclohexyl. This definition also applies to cycloalkyl as a part of a composite substituent, for example cycloalkylalkyl etc., unless specifically defined elsewhere.

The term "cycloalkenyl" means alkenyl closed to form a ring including monocyclic, partially unsaturated hydrocarbyl groups. Non-limiting examples include cyclopropenyl, cyclopentenyl and cyclohexenyl. This definition also applies to cycloalkenyl as a part of a composite substituent, for example cycloalkenylalkyl etc., unless specifically defined elsewhere.

The term "cycloalkynyl" means alkynyl closed to form a ring including monocyclic, partially unsaturated groups. Non-limiting examples include cyclopropynyl, cyclopentynyl and cyclohexynyl. This definition also applies to cycloalkynyl as a part of a composite substituent, for example cycloalkynylalkyl etc., unless specifically defined elsewhere.

The term “cycloalkoxy”, “cycloalkenyloxy” and the like are defined analogously. Non limiting examples of cycloalkoxy include cyclopropyloxy, cyclopentyloxy and cyclohexyloxy. This definition also applies to cycloalkoxy as a part of a composite substituent, for example cycloalkoxy alkyl etc., unless specifically defined elsewhere.

- 5 The term “halogen”, either alone or in compound words such as “haloalkyl”, includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Non-limiting examples of “haloalkyl” include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, 10 dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1,1-dichloro-2,2,2-trifluoroethyl, and 1,1,1-trifluoroprop-2-yl. This definition also applies to haloalkyl as a part of a composite substituent, for example haloalkylaminoalkyl etc., unless specifically defined elsewhere.
- 15 The terms “haloalkenyl”, “haloalkynyl” are defined analogously except that, instead of alkyl groups, alkenyl and alkynyl groups are present as a part of the substituent.

The term “haloalkoxy” means straight-chain or branched alkoxy groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkoxy include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, 20 fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and 1,1,1-trifluoroprop-2-oxy. This definition also applies to haloalkoxy as a part of a composite substituent, for example haloalkoxyalkyl 25 etc., unless specifically defined elsewhere.

The term “haloalkylthio” means straight-chain or branched alkylthio groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkylthio include chloromethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, 30 chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1-bromoethylthio, 1-fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2-fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio, pentafluoroethylthio and 1,1,1-trifluoroprop-2-ylthio. This definition also applies to haloalkylthio as a part of a composite substituent, for example haloalkylthioalkyl etc., unless 35 specifically defined elsewhere.

Non-limiting examples of “haloalkylsulfinyl” include $\text{CF}_3\text{S}(\text{O})$, $\text{CCl}_3\text{S}(\text{O})$, $\text{CF}_3\text{CH}_2\text{S}(\text{O})$ and $\text{CF}_3\text{CF}_2\text{S}(\text{O})$. Non-limiting examples of “haloalkylsulfonyl” include $\text{CF}_3\text{S}(\text{O})_2$, $\text{CCl}_3\text{S}(\text{O})_2$, $\text{CF}_3\text{CH}_2\text{S}(\text{O})_2$ and $\text{CF}_3\text{CF}_2\text{S}(\text{O})_2$.

5 The term “hydroxy” means $-\text{OH}$, Amino means $-\text{NRR}$, wherein R can be H or any possible substituent such as alkyl. Carbonyl means $-\text{C}(=\text{O})-$, carbonyloxy means $-\text{OC}(=\text{O})-$, sulfinyl means SO , sulfonyl means $\text{S}(\text{O})_2$.

The term “alkoxy” used either alone or in compound words included C_1 to C_{24} alkoxy, preferably C_1 to C_{15} alkoxy, more preferably C_1 to C_{10} alkoxy, most preferably C_1 to C_6 alkoxy. Examples of alkoxy include methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-
10 dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and 1-ethyl-2-
15 methylpropoxy and the different isomers. This definition also applies to alkoxy as a part of a composite substituent, for example haloalkoxy, alkynylalkoxy, etc., unless specifically defined elsewhere.

The term “alkoxyalkyl” denotes alkoxy substitution on alkyl. Non-limiting examples of “alkoxyalkyl” include CH_3OCH_2 , $\text{CH}_3\text{OCH}_2\text{CH}_2$, $\text{CH}_3\text{CH}_2\text{OCH}_2$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}_2\text{OCH}_2$ and $\text{CH}_3\text{CH}_2\text{OCH}_2\text{CH}_2$.

20 The term “alkoxyalkoxy” denotes alkoxy substitution on alkoxy.

The term “alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-
25 dimethylethylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1-methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2-trimethylpropylthio, 1,2,2-trimethylpropylthio, 1-ethyl-1-methylpropylthio and 1-ethyl-2-methylpropylthio and the different isomers.

30 Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylcarbonyl, cycloalkylcarbonyl, haloalkoxyalkyl, and the like, are defined analogously to the above examples.

The term “alkylthioalkyl” denotes alkylthio substitution on alkyl. Non-limiting examples of “alkylthioalkyl” include $-\text{CH}_2\text{SCH}_2$, $-\text{CH}_2\text{SCH}_2\text{CH}_2$, $\text{CH}_3\text{CH}_2\text{SCH}_2$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}_2\text{SCH}_2$ and

$\text{CH}_3\text{CH}_2\text{SCH}_2\text{CH}_2$. “Alkylthioalkoxy” denotes alkylthio substitution on alkoxy. The term “cycloalkylalkylamino” denotes cycloalkyl substitution on alkyl amino.

The terms “alkoxyalkoxyalkyl”, “alkylaminoalkyl”, “dialkylaminoalkyl”, “cycloalkylaminoalkyl”, “cycloalkylaminocarbonyl” and the like, are defined analogously to “alkylthioalkyl” or
5 “cycloalkylalkylamino”.

The term “alkoxycarbonyl” is an alkoxy group bonded to a skeleton via a carbonyl group (-CO-). This definition also applies to alkoxycarbonyl as a part of a composite substituent, for example cycloalkylalkoxycarbonyl and the like, unless specifically defined elsewhere.

The term “alkoxycarbonylalkylamino” denotes alkoxy carbonyl substitution on alkyl amino.
10 “Alkylcarbonylalkylamino” denotes alkyl carbonyl substitution on alkyl amino. The terms alkylthioalkoxycarbonyl, cycloalkylalkylaminoalkyl and the like are defined analogously.

Non-limiting examples of “alkylsulfinyl” include methylsulphinyl, ethylsulphinyl, propylsulphinyl, 1-methylethylsulphinyl, butylsulphinyl, 1-methylpropylsulphinyl, 2-methylpropylsulphinyl, 1,1-dimethylethylsulphinyl, pentylsulphinyl, 1-methylbutylsulphinyl, 2-methylbutylsulphinyl, 3-
15 methylbutylsulphinyl, 2,2-dimethylpropylsulphinyl, 1-ethylpropylsulphinyl, hexylsulphinyl, 1,1-dimethylpropylsulphinyl, 1,2-dimethylpropylsulphinyl, 1-methylpentylsulphinyl, 2-methylpentylsulphinyl, 3-methylpentylsulphinyl, 4-methylpentylsulphinyl, 1,1-dimethylbutylsulphinyl, 1,2-dimethylbutylsulphinyl, 1,3-dimethylbutylsulphinyl, 2,2-dimethylbutylsulphinyl, 2,3-dimethylbutylsulphinyl, 3,3-dimethylbutylsulphinyl, 1-
20 ethylbutylsulphinyl, 2-ethylbutylsulphinyl, 1,1,2-trimethylpropylsulphinyl, 1,2,2-trimethylpropylsulphinyl, 1-ethyl-1-methylpropylsulphinyl and 1-ethyl-2-methylpropylsulphinyl and the different isomers. The term “arylsulfinyl” includes Ar-S(O), wherein Ar can be any carbocycle or heterocycle. This definition also applies to alkylsulphinyl as a part of a composite substituent, for example haloalkylsulphinyl etc., unless specifically defined elsewhere.

25 Non-limiting examples of “alkylsulfonyl” include methylsulphonyl, ethylsulphonyl, propylsulphonyl, 1-methylethylsulphonyl, butylsulphonyl, 1-methylpropylsulphonyl, 2-methylpropylsulphonyl, 1,1-dimethylethylsulphonyl, pentylsulphonyl, 1-methylbutylsulphonyl, 2-methylbutylsulphonyl, 3-methylbutylsulphonyl, 2,2-dimethylpropylsulphonyl, 1-ethylpropylsulphonyl, hexylsulphonyl, 1,1-dimethylpropylsulphonyl, 1,2-dimethylpropylsulphonyl, 1-methylpentylsulphonyl, 2-
30 methylpentylsulphonyl, 3-methylpentylsulphonyl, 4-methylpentylsulphonyl, 1,1-dimethylbutylsulphonyl, 1,2-dimethylbutylsulphonyl, 1,3-dimethylbutylsulphonyl, 2,2-dimethylbutylsulphonyl, 2,3-dimethylbutylsulphonyl, 3,3-dimethylbutylsulphonyl, 1-ethylbutylsulphonyl, 2-ethylbutylsulphonyl, 1,1,2-trimethylpropylsulphonyl, 1,2,2-trimethylpropylsulphonyl, 1-ethyl-1-methylpropylsulphonyl and 1-ethyl-2-methylpropylsulphonyl and
35 the different isomers. The term “arylsulfonyl” includes Ar-S(O)₂, wherein Ar can be any carbocycle or

heterocycle. This definition also applies to alkylsulphonyl as a part of a composite substituent, for example alkylsulphonylalkyl etc., unless defined elsewhere.

“Alkylamino”, “dialkylamino”, and the like, are defined analogously to the above examples.

The term “carbocycle or carbocyclic” includes “aromatic carbocyclic ring system” and “non-aromatic carbocyclic ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic (where aromatic indicates that the Huckel rule is satisfied and non-aromatic indicates that the Huckel rule is not satisfied).

The term “heterocycle or heterocyclic” includes “aromatic heterocycle or heteroaryl ring system” and “non-aromatic heterocycle ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(O)₀₋₂, and or C ring member of the heterocycle may be replaced by C(=O), C(=S), C(=CR*R*) and C=NR*, * indicates integers.

The term “non-aromatic heterocycle” or “non-aromatic heterocyclic” means three- to fifteen-membered, preferably three- to twelve- membered, saturated or partially unsaturated heterocycle containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur: mono, bi- or tricyclic heterocycles which contain, in addition to carbon ring members, one to three nitrogen atoms and/or one oxygen or sulphur atom or one or two oxygen and/or sulphur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; non-limiting examples oxetanyl, oxiranyl, aziridinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4-oxadiazolidin-3-yl, 1,2,4-oxadiazolidin-5-yl, 1,2,4-thiadiazolidin-3-yl, 1,2,4-thiadiazolidin-5-yl, 1,2,4-triazolidin-1-yl, 1,2,4-triazolidin-3-yl, 1,3,4-oxadiazolidin-2-yl, 1,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-1-yl, 1,3,4-triazolidin-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl, pyrrolinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-

yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyrazynyl, morpholinyl, thiomorphlinyl, 1,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, 1,3,5-hexahydrotriazin-2-yl, 1,2,4-hexahydrotriazin-3-yl, cycloserines, 2,3,4,5-tetrahydro[1H]azepin-1- or -2- or -3- or -4- or -5- or -6- or -7- yl, 3,4,5,6-tetrahydro[2H]azepin-2- or -3- or -4- or -5- or -6- or -7-yl, 2,3,4,7-tetrahydro[1H]azepin-1- or -2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,6,7-tetrahydro[1H]azepin-1- or -2- or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-1- or -2- or -3- or -4- yl, tetra- and hexahydrooxepinyl such as 2,3,4,5-tetrahydro[1H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,4,7-tetrahydro[1H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,6,7-tetrahydro[1H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-1- or -2- or -3- or -4- yl, tetra- and hexahydro-1,3-diazepinyl, tetra- and hexahydro-1,4-diazepinyl, tetra- and hexahydro-1,3-oxazepinyl, tetra- and hexahydro-1,4-oxazepinyl, tetra- and hexahydro-1,3-dioxepinyl, tetra- and hexahydro-1,4-dioxepinyl. This definition also applies to heterocyclyl as a part of a composite substituent, for example heterocyclylalkyl etc., unless specifically defined elsewhere.

The term "heteroaryl" or "aromatic heterocyclic" means 5 or 6-membered, fully unsaturated monocyclic ring system containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom; 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom as ring members, non-limiting examples furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,3,4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzofused nitrogen-bonded 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-1,3-diene-1,4-diyl group in which one or two carbon atoms may be replaced by nitrogen atoms, where these rings are attached to the skeleton via one of the nitrogen ring members, non-limiting examples 1-pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-1- yl, 1-imidazolyl, 1,2,3-triazol-1-yl and 1,3,4-triazol-1-yl.

6-membered heteroaryl which contains one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen atoms as ring members, non-limiting examples 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-

pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1,3,5-triazin-2-yl, 1,2,4-triazin-3-yl and 1,2,4,5-tetrazin-3-yl; benzofused 5-membered heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulphur atom: non-limiting examples indol-1-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-1-yl, benzimidazol-2-yl, 5 benzimidazol-4-yl, benzimidazol-5-yl, indazol-1-yl, indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl, indazol-2-yl, 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1-benzofuran-4-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, 1-benzofuran-7-yl, 1-benzothiophen-2-yl, 1-benzothiophen-3-yl, 1-benzothiophen-4-yl, 1-benzothiophen-5-yl, 1-benzothiophen-6-yl, 1-benzothiophen-7-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-10 benzothiazol-7-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-4-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl and 1,3-benzoxazol-7-yl; benzofused 6-membered heteroaryl which contains one to three nitrogen atoms: non-limiting examples quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl.

15 The term “trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom such as trimethylsilyl, triethylsilyl and t-butyl-dimethylsilyl. “Halotrialkylsilyl” denotes at least one of the three alkyl radicals is partially or fully substituted with halogen atoms which may be the same or different. The term “alkoxytrialkylsilyl” denotes at least one of the three alkyl radicals is substituted with one or more alkoxy radicals which may be the same or 20 different. The term “trialkylsilyloxy” denotes a trialkylsilyl moiety attached through oxygen.

Non-limiting examples of “alkylcarbonyl” include $C(=O)CH_3$, $C(=O)CH_2CH_2CH_3$ and $C(=O)CH(CH_3)_2$. Non-limiting examples of “alkoxycarbonyl” include $CH_3OC(=O)$, $CH_3CH_2OC(=O)$, $CH_3CH_2CH_2OC(=O)$, $(CH_3)_2CHOC(=O)$ and the different butoxy -or pentoxycarbonyl isomers. Non-limiting examples of “alkylaminocarbonyl” include $CH_3NHC(=O)$, $CH_3CH_2NHC(=O)$, 25 $CH_3CH_2CH_2NHC(=O)$, $(CH_3)_2CHNHC(=O)$ and the different butylamino -or pentylaminocarbonyl isomers. Non-limiting examples of “dialkylaminocarbonyl” include $(CH_3)_2NC(=O)$, $(CH_3CH_2)_2NC(=O)$, $CH_3CH_2(CH_3)NC(=O)$, $CH_3CH_2CH_2(CH_3)NC(=O)$ and $(CH_3)_2CHN(CH_3)C(=O)$. Non-limiting examples of “alkoxyalkylcarbonyl” include $CH_3OCH_2C(=O)$, $CH_3OCH_2CH_2C(=O)$, $CH_3CH_2OCH_2C(=O)$, $CH_3CH_2CH_2CH_2OCH_2C(=O)$ and $CH_3CH_2OCH_2CH_2C(=O)$. Non-limiting 30 examples of “alkylthioalkylcarbonyl” include $CH_3SCH_2C(=O)$, $CH_3SCH_2CH_2C(=O)$, $CH_3CH_2SCH_2C(=O)$, $CH_3CH_2CH_2CH_2SCH_2C(=O)$ and $CH_3CH_2SCH_2CH_2C(=O)$. The term haloalkylsulfonylaminocarbonyl, alkylsulfonylaminocarbonyl, alkylthioalkoxycarbonyl, alkoxycarbonylalkyl amino and the like are defined analogously

Non-limiting examples of “alkylaminoalkylcarbonyl” include $CH_3NHCH_2C(=O)$, 35 $CH_3NHCH_2CH_2C(=O)$, $CH_3CH_2NHCH_2C(=O)$, $CH_3CH_2CH_2CH_2NHCH_2C(=O)$ and $CH_3CH_2NHCH_2CH_2C(=O)$.

The term "amide" means $A-R'C=ONR''-B$, wherein R' and R'' indicates substituents and A and B indicate any group.

The term "thioamide" means $A-R'C=SNR''-B$, wherein R' and R'' indicates substituents and A and B indicate any group.

- 5 The total number of carbon atoms in a substituent group is indicated by the " C_i-C_j " prefix where i and j are numbers from 1 to 21. For example, C_1-C_3 alkylsulfonyl designates methylsulfonyl through propylsulfonyl; C_2 alkoxyalkyl designates CH_3OCH_2 ; C_3 alkoxyalkyl designates, for example, $CH_3CH(OCH_3)$, $CH_3OCH_2CH_2$ or $CH_3CH_2OCH_2$; and C_4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including $CH_3CH_2CH_2OCH_2$ and $CH_3CH_2OCH_2CH_2$. In the above recitations, when a compound of Formula I is comprised of one or more heterocyclic rings, all substituents are attached to these rings through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript m in $(R)_m$ indicates an integer ranging from for example 0 to 4 then the number of substituents may be selected from the integers between 0 and 4 inclusive.

When a group contains a substituent which can be hydrogen, then, when this substituent is taken as hydrogen, it is recognized that said group is being un-substituted.

- 20 The embodiments herein and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein.

The description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein.

Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application.

The numerical values mentioned in the description and the description/claims though might form a critical part of the present invention, any deviation from such numerical values shall still fall within the scope of the present invention if that deviation follows the same scientific principle as that of the present invention disclosed in the present invention.

10 The inventive compound of the present invention may, if appropriate, be present as mixtures of different possible isomeric forms, especially of stereoisomers, for example E and Z, threo and erythro, and also optical isomers, but if appropriate also of tautomers. Both the E and the Z isomers, and also the threo and erythro isomers, and the optical isomers, any desired mixtures of these isomers and the possible tautomeric forms are disclosed and claimed.

15 The term “pest” for the purpose of the present disclosure includes but is not limited to fungi, stramenopiles (oomycetes), bacteria, nematodes, mites, ticks, insects and rodents.

The term “plant” is understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by
20 biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non-protectable by plant breeders’ rights.

For the purpose of the present disclosure the term “plant” includes a living organism of the kind exemplified by trees, shrubs, herbs, grasses, ferns, and mosses, typically growing in a site, absorbing
25 water and required substances through its roots, and synthesizing nutrients in its leaves by photosynthesis.

Examples of “plant” for the purpose of the present invention include but are not limited to agricultural crops such as wheat, rye, barley, triticale, oats or rice; beet, e.g. sugar beet or fodder beet; fruits and fruit trees, such as pomes, stone fruits or soft fruits, e.g. apples, pears, plums, peaches, almonds,
30 cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit and citrus trees, such as oranges, lemons, grapefruits or mandarins; any horticultural plants, vegetables, such as spinach, lettuce,
35 asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such

as avocados, cinnamon or camphor; cucurbitaceae; oleaginous plants; energy and raw material plants, such as cereals, corn, soybean, other leguminous plants, rape, sugar cane or oil palm; tobacco; nuts; coffee; tea; cacao; bananas; peppers; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e.g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.

Preferably, the plant for the purpose of the present invention includes but is not limited to cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and vegetables, ornamentals, any floricultural plants and other plants for use of human and animals.


The term “plant parts” is understood to mean all parts and organs of plants above and below the ground. For the purpose of the present disclosure the term plant parts includes but is not limited to cuttings, leaves, twigs, tubers, flowers, seeds, branches, roots including taproots, lateral roots, root hairs, root apex, root cap, rhizomes, slips, shoots, fruits, fruit bodies, bark, stem, buds, auxillary buds, meristems, nodes and internodes.

The term “locus thereof” includes soil, surroundings of plant or plant parts and equipment or tools used before, during or after sowing/planting a plant or a plant part.

Application of the compounds of the present disclosure or the compound of the present disclosure in a composition optionally comprising other compatible compounds to a plant or a plant material or locus thereof include application by a technique known to a person skilled in the art which include but is not limited to spraying, coating, dipping, fumigating, impregnating, injecting and dusting.

The term “applied” means adhered to a plant or plant part either physically or chemically including impregnation.

In view of the above, the present invention provides a compound of formula (I),



Formula (I)

wherein,

R¹ is C₁-C₂-haloalkyl;


L¹ is a direct bond, -CR²R³-, -C(=W¹)-, -CR²R³C(=W¹)-, -O-, -S(=O)₀₋₂-, or -NR^{4a}-; wherein, the expression “-” at the start and the end of the group indicates the point of attachment to either oxadiazole ring or A;

W¹ is O or S;

5 A is a fused heterobicyclic ring having N at one or more bridgehead; wherein said ring is optionally substituted with one or more identical or different groups of R^A;

R^A is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, SF₅, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy-C₁-C₄-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-haloalkoxycarbonyl, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₁-C₆-haloalkylsulfinyl, C₁-C₆-haloalkylsulfonyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylamino, C₁-C₆-dialkylamino, C₃-C₈-cycloalkylamino, C₁-C₆-alkyl-C₃-C₈-cycloalkylamino, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylaminocarbonyl, C₁-C₆-dialkylaminocarbonyl, C₁-C₆-alkoxycarbonyloxy, C₁-C₆-alkylaminocarbonyloxy or C₁-C₆-dialkylaminocarbonyloxy, and 3- to 6- membered carbocyclic or heterocyclic ring, wherein, said 3- to 6- membered carbocyclic or heterocyclic ring may be optionally substituted with one or more identical or different substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxyalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₁-C₆-haloalkylsulfinyl, C₁-C₆-haloalkylsulfonyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₃-C₆-cycloalkylamino, C₁-C₆-alkyl-C₃-C₆-cycloalkylamino, C₁-C₆ alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylaminocarbonyl, di-C₁-C₆-alkylaminocarbonyl, C₁-C₆-alkoxycarbonyloxy, C₁-C₆-alkylaminocarbonyloxy and di-C₁-C₆-alkylaminocarbonyloxy;

L² is a direct bond or is selected from the group consisting of -C(=O)-, -C(=S)-, -O-, -S(=O)₀₋₂-, -



$\text{NR}^{10}\text{-NR}^{10}$ -, $\text{-NR}^{10}\text{-S(=O)}_{0-2}\text{-NR}^{10}\text{-NR}^{10}$ -, $\text{-NR}^{10}\text{-NR}^{10}\text{-(C=W}^2\text{)-NR}^{10}$ -, $\text{-NR}^{10}\text{-NR}^{10}\text{-S(=O)}_{0-2}\text{-NR}^{10}$ -, $\text{-O(C=W}^2\text{)-NR}^{10}$ -, and $\text{-NR}^{10}\text{-(C=W}^2\text{)-O-}$;

Y is a direct bond or -NR^{10} -, or -O- , or -S(O)_{0-2} - or $\text{-C(=NOR}^{11}\text{)-}$;

k is an integer ranging from 0 to 4; expressions “-”, “#” and “*” indicate point of attachments;

5 W^2 is O or S;

L^3 is a direct bond or is selected from the group consisting of $\text{-CR}^{8a}\text{R}^{9a}$ -, $\text{-CR}^{8a}\text{R}^{9a}\text{C(=O)-}$, -C(=O)- , -C(=S)- , -O- , -S(=O)_{0-2} -, $\text{-S(O)}_{0-1}\text{(=NR}^{10}\text{)-}$, -S(=N-CN)- , $\text{-S(=N-NO}_2\text{)-}$, $\text{-S(=N-COR}^{8a}\text{)-}$, $\text{-S(=N-COOR}^{11}\text{)-}$, $\text{-S(=N-(S(=O)}_2\text{R}^{12}\text{)-)}$ -, -NR^{10} -, $\text{-NR}^{10}\text{(C(=O))O-}$ and $\text{-CR}^{8a}\text{(=N)O-}$;

10 R^{10} is selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_2\text{-C}_6$ -alkenyl, $\text{C}_2\text{-C}_6$ -alkynyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_3\text{-C}_6$ -cycloalkyl, $\text{C}_3\text{-C}_6$ -cycloalkenyl, $\text{C}_3\text{-C}_6$ -cycloalkyl- $\text{C}_1\text{-C}_6$ -alkyl, phenyl- $\text{C}_1\text{-C}_6$ -alkyl, phenyl, pyridinyl, $\text{C(=O)-(C}_1\text{-C}_6\text{-alkyl)}$, $\text{C(=O)-(C}_1\text{-C}_6\text{-alkoxy)}$ and $\text{-N(R}^{10a}\text{)}_2$ -, wherein, R^{10a} is selected from the group consisting of hydrogen, hydroxyl, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_2\text{-C}_6$ -alkenyl, $\text{C}_2\text{-C}_6$ -alkynyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, $\text{C}_3\text{-C}_6$ -cycloalkenyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_1\text{-C}_6$ -alkoxy- $\text{C}_1\text{-C}_6$ -alkyl and $\text{C}_1\text{-C}_6$ -alkylthio; each

15 group of R^{10} is optionally substituted with identical or different radical selected from the group consisting of halogen, hydroxy, oxo, cyano, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_6$ -alkoxy and $\text{C}_3\text{-C}_6$ -cycloalkyl;

R^{11} is selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_6$ -haloalkyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_2\text{-C}_6$ -alkenyl, $\text{C}_2\text{-C}_6$ -alkynyl, $\text{C}_3\text{-C}_8$ -cycloalkyl, $\text{C}_1\text{-C}_6$ -alkylthio, $\text{C}_3\text{-C}_8$ -cycloalkenyl, phenyl- $\text{C}_1\text{-C}_6$ -alkyl, heteroaryl- $\text{C}_1\text{-C}_6$ -alkyl, phenyl and naphthyl;

20

R^{12} is selected from the group consisting of hydrogen, NR^gR^h ; wherein, R^g and R^h are independently selected from the group consisting of hydrogen, hydroxyl, cyano, $\text{C}_1\text{-C}_4$ -alkyl, $\text{C}_1\text{-C}_4$ -haloalkyl, $\text{C}_1\text{-C}_4$ -alkoxy and $\text{C}_3\text{-C}_8$ -cycloalkyl; (C=O)-R^i , wherein, R^i is selected from the group consisting of hydrogen, halogen, cyano, $\text{C}_1\text{-C}_4$ -alkyl, $\text{C}_2\text{-C}_4$ -alkenyl, $\text{C}_2\text{-C}_4$ -alkynyl, $\text{C}_1\text{-C}_4$ -haloalkyl, $\text{C}_2\text{-C}_4$ -haloalkenyl, $\text{C}_2\text{-C}_4$ -haloalkynyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, $\text{C}_3\text{-C}_6$ -halocycloalkyl, $\text{C}_1\text{-C}_4$ -alkoxy, $\text{C}_1\text{-C}_4$ -haloalkoxy and C_{1-8} -alkyl- $\text{S(O)}_{0-2}\text{R}^j$, wherein R^j is selected from the group consisting of hydrogen, halogen, cyano, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_6$ -haloalkyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_1\text{-C}_6$ -haloalkoxy, $\text{C}_3\text{-C}_8$ -cycloalkyl, $\text{C}_1\text{-C}_6$ -alkyl- (C=O)-R^i , $\text{CR}^i\text{=NR}^g$, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_2\text{-C}_6$ -alkenyl, $\text{C}_2\text{-C}_6$ -alkynyl, $\text{C}_1\text{-C}_6$ -haloalkyl, $\text{C}_2\text{-C}_6$ -haloalkenyl, $\text{C}_2\text{-C}_6$ -haloalkynyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_1\text{-C}_6$ -haloalkoxy, $\text{C}_3\text{-C}_8$ -cycloalkyl, $\text{C}_4\text{-C}_8$ -cycloalkenyl, $\text{C}_7\text{-C}_{19}$ -aralkyl, bicyclic $\text{C}_5\text{-C}_{12}$ -alkyl, $\text{C}_7\text{-C}_{12}$ -alkenyl and fused or non-fused or bicyclic $\text{C}_3\text{-C}_{18}$ -carbocyclic ring or ring system; wherein one or more C atoms of the carbocyclic ring or ring system may be

25

30

replaced by N, O, S(=O)₀₋₂, S(=O)₀₋₁(=NR¹⁰), C(=O), C(=S), C(=CR⁸R⁹) and C=NR¹⁰;

5 R¹² may optionally be substituted with one or more identical or different substituents selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy-C₁-C₄-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-haloalkoxycarbonyl, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₁-C₆-haloalkylsulfinyl, C₁-C₆-haloalkylsulfonyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₃-C₈-cycloalkylamino, C₁-C₆-alkyl-C₃-C₈-cycloalkylamino, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylaminocarbonyl, di-C₁-C₆-alkylaminocarbonyl, C₁-C₆-alkoxycarbonyloxy, C₁-C₆-alkylaminocarbonyloxy, di-C₁-C₆-alkylaminocarbonyloxy, 5- to 11-membered spirocyclic ring and 3- to 6- membered carbocyclic or heterocyclic ring;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₁-C₆-alkylthio, C₃-C₈-cycloalkenyl, phenyl-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, phenyl, naphthyl and a 3- to 10- membered saturated, partially unsaturated or aromatic mono- or bicyclic carbocyclic ring or heterocyclic ring, wherein the ring members of the heteroaryl of the heteroaryl-C₁-C₆-alkyl and the heterocyclic ring include C, N, O and S(O)₀₋₂ and the C ring members of the carbocyclic ring or the heterocyclic ring may be replaced by one or more C(=O) and C(=S); and wherein R⁸ and R⁹ are optionally substituted with one or more identical or different R^{8a} or R^{9a}; wherein R^{8a} and R^{9a} are selected from the group consisting of halogen, cyano, nitro, hydroxyl, sulfanyl, amino, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkyl, amino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino, NHSO₂-C₁-C₆-alkyl, -C(=O)-C₁-C₆-alkyl, C(=O)-C₁-C₆-alkoxy, C₁-C₆-alkylsulfonyl, hydroxy-C₁-C₆-alkyl, -C(=O)-NH₂, C(=O)-NH(C₁-C₆-alkyl), C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, aminocarbonyl-C₁-C₆-alkyl and C₁-C₆-alkoxy-C₁-C₆-alkyl; or

R⁸ and R⁹ together with the atoms to which they are bound form C(=O) or a vinyl group or a saturated, monocyclic 3- to 7-membered heterocyclic ring or carbocyclic ring, wherein the ring members of heterocyclic include C, N, O and S(O)₀₋₂; and wherein the vinyl group, the heterocyclic ring or the carbocyclic ring is unsubstituted or substituted with one or more identical or different R^{8b}, wherein R^{8b} is selected from the group consisting of halogen, cyano, nitro, hydroxyl, sulfanyl, amino, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-

alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkyl, SO₂-C₁-C₆-alkyl, NHSO₂-C₁-C₆-alkyl, -C(=O)-C₁-C₆-alkyl, C(=O)-C₁-C₆-alkoxy, C₁-C₆-alkylsulfonyl, SO₂-C₆H₄CH₃ and SO₂-aryl;

R⁵ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkyl-C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkenyl, C₃-C₈-halocycloalkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₈-cycloalkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkyl-C₁-C₆-thioalkyl, C₁-C₆-alkylsulfinyl-C₁-C₆-alkyl, C₁-C₆-alkylsulfonyl-C₁-C₆-alkyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-haloalkylamino-C₁-C₆-alkyl, C₃-C₈-cycloalkylamino, C₃-C₈-cycloalkylamino-C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxy-C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-hydroxyalkenyl, C₂-C₆-hydroxyalkynyl, C₃-C₈-halocycloalkoxy, C₃-C₈-cycloalkyl-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, C₂-C₆-haloalkenyloxy, C₂-C₆-alkynyloxy, C₂-C₆-haloalkynyloxy, C₁-C₆-alkoxy-C₁-C₆-alkoxy, C₁-C₆-alkylcarbonylalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkylthio, C₁-C₆-alkylsulfinyl, C₁-C₆-haloalkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-haloalkylsulfonyl, C₃-C₈-cycloalkylsulfonyl, C₃-C₈-cycloalkylsulfinyl, tri-C₁-C₆-alkylsilyl, C₁-C₆-alkylsulfonylamino, C₁-C₆-haloalkylsulfonylamino, C₁-C₆-alkylcarbonylthio, C₁-C₆-alkylsulfonyloxy, C₁-C₆-alkylsulfinyloxy, C₆-C₁₀-arylsulfonyloxy, C₆-C₁₀-arylsulfinyloxy, C₆-C₁₀-arylsulfonyl, C₆-C₁₀-arylsulfinyl, C₆-C₁₀-arylthio, C₁-C₆-cyanoalkyl, C₂-C₆-alkenylcarbonyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylthio, C₁-C₆-alkylthio-C₁-C₆-alkoxy, C₂-C₆-haloalkenylcarbonyloxy, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₂-C₆-alkynyl, C₂-C₆-alkynylthio, C₃-C₈-halocycloalkylcarbonyloxy, C₂-C₆-alkenylamino, C₂-C₆-alkynylamino, C₁-C₆-haloalkylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino, C₁-C₆-alkoxyamino, C₁-C₆-haloalkoxyamino, C₁-C₆-alkoxycarbonylamino, C₁-C₆-alkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-haloalkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkylamino, C₂-C₆-alkenylthio, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxycarbonylamino, di(C₁-C₆-haloalkyl)amino-C₁-C₆-alkyl, C₃-C₈-halocycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy(C₁-C₆-alkyl)aminocarbonyl, C₁-C₆-haloalkylsulfonylamino-C₁-C₆-alkyl, C₁-C₆-alkylthiocarbonyl, C₃-C₈-cycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxycarbonyl, di-C₁-C₆-alkylaminothiocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkoxy, C₁-C₆-alkoxy-C₁-C₆-haloalkoxy, C₃-C₈-halocycloalkoxy-C₁-C₆-alkyl, di-C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkoxy-C₂-C₆-alkenyl, C₁-C₆-alkylthiocarbonyloxy, C₁-C₆-haloalkoxy-C₁-C₆-alkoxy, C₁-C₆-haloalkylsulfonyloxy, C₁-C₆-alkoxy-C₁-C₆-haloalkyl, di(C₁-C₆-haloalkyl)amino, di-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkylaminocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₆-alkylamino, tri-C₁-C₆-alkylsilyl-

C₂-C₆-alkynyloxy, tri-C₁-C₆-alkylsilyloxy, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyl, cyano(C₁-C₆-alkoxy)-C₁-C₆-alkyl, di-C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkoxysulfonyl, C₃-C₈-halocycloalkoxycarbonyl, C₁-C₆-alkyl-C₃-C₈-cycloalkylcarbonyl, C₃-C₈-halocycloalkylcarbonyl, C₂-C₆-alkenyloxy, C₂-C₆-alkenyloxy, C₁-C₆-cyanoalkoxycarbonyl, C₁-C₆-alkylthio-C₁-C₆-alkoxycarbonyl, C₂-C₆-alkynylcarbonyloxy, C₂-C₆-haloalkynylcarbonyloxy, cyanocarbonyloxy, C₁-C₆-cyanoalkylcarbonyloxy, C₃-C₈-cycloalkylsulphonyloxy, C₃-C₈-cycloalkyl-C₁-C₆-alkylsulphonyloxy, C₃-C₈-halocycloalkylsulphonyloxy, C₂-C₆-alkenylsulphonyloxy, C₂-C₆-alkynylsulphonyloxy, C₁-C₆-cyanoalkylsulphonyloxy, C₂-C₆-haloalkenylsulphonyloxy, C₂-C₆-haloalkynylsulphonyloxy, C₂-C₆-alkynylcycloalkoxy, C₂-C₆-cyanoalkenyloxy, C₂-C₆-cyanoalkynyloxy, C₁-C₆-alkoxycarbonyloxy, C₂-C₆-alkenyloxy, C₂-C₆-alkenyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyloxy, sulfilimines, sulfoximines and SF₅ or Z¹Q¹; R⁵ may be optionally substituted with one or more R⁶;

Z¹ is a direct bond, CR^{2a}R^{3a}, N, O, C(O), C(S), C(=CR^{2a}R^{3a}) or S(O)₀₋₂;

Q¹ is selected from the group consisting of phenyl, benzyl, naphthalenyl, a 5- or 6-membered aromatic ring, an 8- to 11-membered aromatic multi-cyclic ring system, an 8- to 11-membered aromatic fused ring system, a 5- or 6-membered heteroaromatic ring, an 8- to 11-membered heteroaromatic multi-cyclic ring system and an 8- to 11-membered heteroaromatic fused ring system; wherein the heteroatom of the heteroaromatic rings is selected from N, O or S, and each ring or ring system may be optionally substituted with one or more substituents independently selected from R¹³; or

Q¹ is selected from the group consisting of a 3- to 7-membered non-aromatic carbocyclic ring, a 4-, 5-, 6- or 7-membered non-aromatic heterocyclic ring, an 8- to 15-membered non-aromatic multi-cyclic ring system, an 5- to 15 membered spirocyclic ring system, and an 8- to 15-membered non-aromatic fused ring system, wherein, the heteroatom of the non-aromatic rings is selected from N, O or S(O)₀₋₂, and C ring member of the non-aromatic carbocyclic or non-aromatic heterocyclic rings or ring systems may be replaced with C(O), C(S), C(=CR^{2b}R^{3b}) or C(=NR^{4b}), and each ring or ring system may be optionally substituted with one or more substituents independently selected from R¹³;

R², R³, R^{2a}, R^{3a}, R^{2b} and R^{3b} are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl, C₂-C₄-haloalkynyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;

R² and R³; R^{2a} and R^{3a}; and or R^{2b} and R^{3b} together with the atoms to which they are attached may form 3- to 5- membered non-aromatic carbocyclic ring

or heterocyclic ring which may be optionally substituted with halogen, C₁-C₂-alkyl, C₁-C₂-haloalkyl or C₁-C₂-alkoxy;

R^{4a} and R^{4b} are independently selected from the group consisting of hydrogen, cyano, hydroxy, NR^bR^c, (C=O)-R^d, S(O)₀₋₂R^e, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, tri-C₁-C₆-alkylamino and C₃-C₈-cycloalkyl;

R^b and R^c are selected from the group consisting of hydrogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₃-C₈-cycloalkyl and C₃-C₈-halocycloalkyl;

R^d is selected from the group consisting of hydrogen, hydroxy, halogen, NR^bR^c, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₃-C₈-cycloalkyl and C₃-C₈-halocycloalkyl;

R^e is selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy and C₃-C₈-cycloalkyl and C₃-C₈-halocycloalkyl;

R⁶ and R¹³ are independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkyl-C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkenyl, C₃-C₈-halocycloalkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₈-cycloalkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkyl-C₁-C₆-thioalkyl, C₁-C₆-alkylsulfinyl-C₁-C₆-alkyl, C₁-C₆-alkylsulfonyl-C₁-C₆-alkyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-haloalkylamino-C₁-C₆-alkyl, C₃-C₈-cycloalkylamino, C₃-C₈-cycloalkylamino-C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxy-C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-hydroxyalkenyl, C₂-C₆-hydroxyalkynyl, C₃-C₈-halocycloalkoxy, C₃-C₈-cycloalkyl-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, C₂-C₆-haloalkenyloxy, C₂-C₆-alkynyloxy, C₂-C₆-haloalkynyloxy, C₁-C₆-alkoxy-C₁-C₆-alkoxy, C₁-C₆-alkylcarbonylalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkylthio, C₁-C₆-alkylsulfinyl, C₁-C₆-haloalkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-haloalkylsulfonyl, C₃-C₈-cycloalkylsulfonyl, C₃-C₈-cycloalkylsulfinyl, tri-C₁-C₆-alkylsilyl, C₁-C₆-alkylsulfonylamino, C₁-C₆-haloalkylsulfonylamino, C₁-C₆-alkylcarbonylthio, C₁-C₆-alkylsulfonyloxy, C₁-C₆-alkylsulfinyloxy, C₆-C₁₀-arylsulfonyloxy, C₆-C₁₀-arylsulfinyloxy, C₆-C₁₀-arylsulfonyl, C₆-C₁₀-arylsulfinyl, C₆-C₁₀-arylthio, C₁-C₆-cyanoalkyl, C₂-C₆-alkenylcarbonyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylthio, C₁-C₆-alkylthio-C₁-C₆-alkoxy, C₂-C₆-

haloalkenylcarbonyloxy, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₂-C₆-alkynyl, C₂-C₆-alkynylthio, C₃-C₈-halocycloalkylcarbonyloxy, C₂-C₆-alkenylamino, C₂-C₆-alkynylamino, C₁-C₆-haloalkylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino, C₁-C₆-alkoxyamino, C₁-C₆-haloalkoxyamino, C₁-C₆-alkoxycarbonylamino, C₁-C₆-alkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-haloalkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkylamino, C₂-C₆-alkenylthio, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxycarbonylamino, di(C₁-C₆-haloalkyl)amino-C₁-C₆-alkyl, C₃-C₈-halocycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy(C₁-C₆-alkyl)aminocarbonyl, C₁-C₆-haloalkylsulfonylaminocarbonyl, C₁-C₆-alkylsulfonylaminocarbonyl, C₁-C₆-alkoxycarbonylalkoxy, C₁-C₆-alkylaminothiocabonylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-alkylthiocarbonyl, C₃-C₈-cycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxycarbonyl, di-C₁-C₆-alkylaminothiocabonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkoxy, C₁-C₆-alkoxy-C₁-C₆-haloalkoxy, C₃-C₈-halocycloalkoxy-C₁-C₆-alkyl, di-C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkoxy-C₂-C₆-alkenyl, C₁-C₆-alkylthiocarbonyloxy, C₁-C₆-haloalkoxy-C₁-C₆-alkoxy, C₁-C₆-haloalkylsulfonyloxy, C₁-C₆-alkoxy-C₁-C₆-haloalkyl, di(C₁-C₆-haloalkyl)amino, di-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkylaminocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₆-alkylamino, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyloxy, tri-C₁-C₆-alkylsilyloxy, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyl, cyano(C₁-C₆-alkoxy)-C₁-C₆-alkyl, di-C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkoxysulfonyl, C₃-C₈-halocycloalkoxycarbonyl, C₁-C₆-alkyl-C₃-C₈-cycloalkylcarbonyl, C₃-C₈-halocycloalkylcarbonyl, C₂-C₆-alkenyloxy carbonyl, C₂-C₆-alkynyloxy carbonyl, C₁-C₆-cyanoalkoxycarbonyl, C₁-C₆-alkylthio-C₁-C₆-alkoxycarbonyl, C₂-C₆-alkynylcarbonyloxy, C₂-C₆-haloalkynylcarbonyloxy, cyanocarbonyloxy, C₁-C₆-cyanoalkylcarbonyloxy, C₃-C₈-cycloalkylsulphonyloxy, C₃-C₈-cycloalkyl-C₁-C₆-alkylsulphonyloxy, C₃-C₈-halocycloalkylsulphonyloxy, C₂-C₆-alkenylsulphonyloxy, C₂-C₆-alkynylsulphonyloxy, C₁-C₆-cyanoalkylsulphonyloxy, C₂-C₆-haloalkenylsulphonyloxy, C₂-C₆-haloalkynylsulphonyloxy, C₂-C₆-alkynylcycloalkyloxy, C₂-C₆-cyanoalkenyloxy, C₂-C₆-cyanoalkynyloxy, C₁-C₆-alkoxycarbonyloxy, C₂-C₆-alkenyloxy carbonyloxy, C₂-C₆-alkynyloxy carbonyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyloxy, sulfilimines, sulfoximines and SF₅;

and/or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof; with the proviso that following compounds are excluded from the definition of compound of formula (I);

N-(2-methoxyethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide and ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate.

In one embodiment, the present invention provides a compound of formula (I), wherein

R^1 selected from the group consisting of CF_3 , CHF_2 , CF_2Cl , CF_2CF_3 , CH_2F , CH_2CF_3 , $CHClCF_3$ and CCl_2CF_3 ;

L^1 is a direct bond, $-CR^2R^3$;

- 5 A is a fused heterobicyclic ring having N at one or more bridgehead; wherein said ring is optionally substituted with one or more identical or different groups of R^A ,

R^A is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, SF_5 , C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_8 -cycloalkyl, C_3 - C_8 -cycloalkylalkyl and C_1 - C_6 -haloalkyl;


- 10 R^8 and R^9 are independently selected from the group consisting of hydrogen, halogen, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_8 -cycloalkyl and C_1 - C_6 -alkylthio; or

- R^8 and R^9 together with the atoms to which they are bound form $C(=O)$ or a vinyl group or a saturated, monocyclic 3- to 7-membered heterocyclic ring or carbocyclic ring, wherein the ring members of heterocyclic include C, N, O and $S(O)_{0-2}$; and wherein the vinyl group, the heterocyclic ring or the carbocyclic ring is unsubstituted or substituted with one or more identical or different R^{8b} , wherein R^{8b} is selected from the group consisting of halogen, cyano, nitro, hydroxyl, sulfanyl, amino, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -haloalkoxy, C_1 - C_6 -alkylthio, C_1 - C_6 -haloalkylthio and C_3 - C_8 -cycloalkyl.
- 15

- 20 In another embodiment, the present invention provides a compound of formula (I), wherein

R^1 selected from the group consisting of CF_3 , CHF_2 , CF_2Cl , $CHClCF_3$ and CCl_2CF_3 ;

L^1 is a direct bond;

- A is ; wherein “#” and “*” indicate point of attachments and said ring is optionally substituted with one or more identical or different groups of R^A ;

- 25 R^A is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, SF_5 , C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_8 -cycloalkyl, C_3 - C_8 -cycloalkylalkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -alkoxy- C_1 - C_4 -alkyl and C_1 - C_6 -hydroxyalkyl;

R^8 and R^9 are independently selected from the group consisting of hydrogen, halogen, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl and C_3 - C_8 -cycloalkyl; or

- 30 R^8 and R^9 together with the atoms to which they are bound form $C(=O)$ or a vinyl group.

In preferred embodiment, the compound of formula (I) is selected from N-(3-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(p-tolyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-fluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2,4-difluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-fluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-3-yl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-benzyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-4-yl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorophenyl)-N-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-methyl-N-(2-phenoxyethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-cyanophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2,4-difluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(p-tolyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-benzyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N,N-dimethyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chloro-2-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-cyanophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-3-yl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2,6-difluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-fluorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-4-yl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; azetidin-1-yl(7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone; N-(2-methoxyethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-

a]pyridine-2-carboxamide; N-isobutyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridine-2-carboxamide; N-neopentyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridine-2-carboxamide; N-isopentyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridine-2-carboxamide; N-(4-chlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
 5 yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-methoxybenzyl)-7-(5-(trifluoromethyl)-1,2,4-
 oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-chlorobenzyl)-7-(5-(trifluoromethyl)-
 1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-methoxybenzyl)-7-(5-
 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-fluorobenzyl)-7-
 (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-
 10 (dimethylamino)benzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-
 carboxamide; N-(3,4-dichlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridine-2-carboxamide; ethyl 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-
 2-carboxylate hydrobromide; 3-(2-(((3-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 (trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 15 (trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 (trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-7-
 yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 (trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 (trifluoromethyl)-1,2,4-oxadiazole; 5-(trifluoromethyl)-3-(2-(((4-
 20 (trifluoromethyl)phenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazole; 3-(2-(((4-
 methoxybenzyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-
 ((propylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-
 chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-
 (((4-methoxyphenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-
 25 oxadiazole; 3-(2-(((4-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-
 1,2,4-oxadiazole; 3-(2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-
 oxadiazole; 3-(2-(((2-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-
 1,2,4-oxadiazole; 3-(2-(((4-methoxybenzyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 (trifluoromethyl)-1,2,4-oxadiazole; 3-(2-((propylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-
 30 (trifluoromethyl)-1,2,4-oxadiazole; 5-(trifluoromethyl)-3-(2-(((4-
 (trifluoromethyl)phenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazole; 6-(5-
 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-2-
 carboxamide; morpholino(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
 yl)methanone; N-(2-methoxyethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 35 a]pyridine-2-carboxamide; N-isobutyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridine-2-carboxamide; N-cyclopentyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridine-2-carboxamide; (3-methoxypyrrolidin-1-yl)(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl)imidazo[1,2-a]pyridin-2-yl)methanone; azetidin-1-yl(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone; N-(cyclopropylmethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-benzyl-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(1-phenylethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(1-cyanocyclopropyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-methoxyethyl)-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-chlorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-methoxybenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-isobutyl-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate; 3-(2-(ethoxymethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 4-methoxy-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 4-chloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 2-(4-chlorophenyl)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)acetamide; 3-chloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 3,4-dichloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)picolinamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)propionamide; 4-(trifluoromethoxy)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 4-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 2-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)oxazole-4-carboxamide; 3-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 2-phenyl-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)acetamide; 4-(dimethylamino)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 3-methyl-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)butanamide; 4-(trifluoromethyl)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)nicotinamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)isonicotinamide; 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((phenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-

chlorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-chlorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-fluorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-
 5 fluorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((propylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((benzylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxybenzylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,4-dichlorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,5-dichlorophenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((isobutylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((cyclopentylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((cyclohexylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-ethylphenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,4-dichlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxybenzyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((cyclohexylsulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxyphenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,4-dichlorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-chlorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; N-
 20 (methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((dimethyl(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-
 25 30 35

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(1-oxidotetrahydro-2H-1 λ^6 -thiopyran-1-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-chlorophenyl)(2-methoxyethyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(isopropyl(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(methyl(oxo)(4-(trifluoromethyl)phenyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3,5-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(1-oxidotetrahydro-1 λ^6 -thiophen-1-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-bromophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3,4-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(4-oxido-1,4 λ^6 -oxathian-4-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((2-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-methoxypyridin-2-yl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(methyl(oxo)(o-tolyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; (3-fluorophenyl)(methyl)((2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; N-(((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)butyramide; imino(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)pivalamide; 4-methoxy-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 4-chloro-2-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 3-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 3-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 4-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 4-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide;

sulfaneylidene)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-4-(trifluoromethoxy)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-2-(trifluoromethyl)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-3-(trifluoromethyl)benzamide; 2-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; imino(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; imino(4-methoxyphenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (4-chlorophenyl)(imino)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (4-fluorophenyl)(imino)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(4-methoxybenzyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)((1-methyl-1H-pyrazol-4-yl)methyl)- λ^6 -sulfanone; (4-chlorobenzyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)((1-methyl-1H-1,2,4-triazol-3-yl)methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(phenyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(2,4-difluorophenyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(4-fluorophenyl)(methyl)- λ^6 -sulfanone; tert-butyl((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)((1-methyl-1H-imidazol-4-yl)methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)dimethyl- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(cyclopropylmethyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(2,6-dichlorophenyl)(methyl)- λ^6 -sulfanone; (2-chloro-4-fluorophenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; (2-chloro-4-(trifluoromethyl)phenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(4-methylbenzyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(4-

methoxyphenyl)(methyl)- λ^6 -sulfanone; benzyl((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(pyridin-3-yl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(isoxazol-4-ylmethyl)(methyl)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(oxazol-4-ylmethyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(thiazol-4-ylmethyl)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(pyrimidin-5-yl)- λ^6 -sulfanone; (3-chloro-4-(trifluoromethyl)phenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(isopropyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(ethyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(2-methoxyethyl)(methyl)- λ^6 -sulfanone; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((4-methoxybenzyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-((4-chlorobenzyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl((1-methyl-1H-1,2,4-triazol-3-yl)methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((2,4-difluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((4-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-(tert-butyl(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(3,3,3-trifluoropropyl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl((1-methyl-1H-imidazol-4-yl)methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(dimethyl(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((cyclopropylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((2,6-dichlorophenyl)(methyl)(oxo)- λ^6 -

sulfaneylidene)acetamide; N-((2-chloro-4-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((2-chloro-4-(trifluoromethyl)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(4-methylbenzyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-(benzyl(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(pyridin-3-yl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((isoxazol-4-ylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-(((1,2,4-oxadiazol-3-yl)methyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxazol-4-ylmethyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(thiazol-4-ylmethyl)- λ^6 -sulfaneylidene)acetamide; N-(((2-chloro-6-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(pyrimidin-5-yl)- λ^6 -sulfaneylidene)acetamide; N-((3-chloro-4-(trifluoromethyl)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(isopropyl(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(ethyl(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((2-methoxyethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl((1-methyl-1H-pyrazol-4-yl)methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(m-tolyl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-

3-yl)-N-((2,4-difluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide;
 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(((3-(dimethylamino)phenyl)(methyl)(oxo)- λ^6 -
 sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-
 3-yl)-N-(dimethyl(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-
 5 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(ethyl(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-
 a]pyridine-2-carboxamide; N-(tert-butyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((cyclopropylmethyl)(methyl)(oxo)- λ^6 -
 sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; N-(benzyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-
 10 (5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(pyrimidin-5-yl)- λ^6 -
 sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-
 3-yl)-N-(methyl(oxo)(pyridazin-4-yl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(pyrazin-2-yl)- λ^6 -
 15 sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-
 3-yl)-N-(methyl(oxo)(pyridin-4-yl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; (((7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(4-
 methoxybenzyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-
 20 yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)((1-methyl-1H-pyrazol-4-yl)methyl)- λ^6 -
 sulfanone; (4-chlorobenzyl)(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-
 yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)((1-methyl-1H-1,2,4-triazol-3-yl)methyl)- λ^6 -
 sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
 25 yl)methyl)imino)(methyl)(phenyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-
 yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(2,4-difluorophenyl)(methyl)- λ^6 -sulfanone; (((7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(4-
 fluorophenyl)(methyl)- λ^6 -sulfanone; tert-butyl((((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-
 30 yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-
 1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(3,3,3-trifluoropropyl)- λ^6 -
 sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
 yl)methyl)imino)(methyl)((1-methyl-1H-imidazol-4-yl)methyl)- λ^6 -sulfanone; (((7-(5-
 (chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)dimethyl- λ^6 -
 sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
 35 yl)methyl)imino)(cyclopropylmethyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-
 oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(2,6-dichlorophenyl)(methyl)- λ^6 -sulfanone;
 (2-chloro-4-fluorophenyl)(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-
 2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (2-chloro-4-(trifluoromethyl)phenyl)(((7-(5-

(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(4-methylbenzyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(4-methoxyphenyl)(methyl)- λ^6 -sulfanone; benzyl(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(pyridin-3-yl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(isoxazol-4-ylmethyl)(methyl)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(thiazol-4-ylmethyl)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(pyrimidin-5-yl)- λ^6 -sulfanone; (3-chloro-4-(trifluoromethyl)phenyl)(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(isopropyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(ethyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(2-methoxyethyl)(methyl)- λ^6 -sulfanone; (4-methoxybenzyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((1-methyl-1H-pyrazol-4-yl)methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (4-chlorobenzyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((1-methyl-1H-1,2,4-triazol-3-yl)methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(phenyl)- λ^6 -sulfanone; (2,4-difluorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (4-fluorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; methyl((1-methyl-1H-imidazol-4-yl)methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)-

λ^6 -sulfanone; dimethyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2,6-dichlorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone;

5 (2-chloro-4-fluorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2-chloro-4-(trifluoromethyl)phenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(4-methylbenzyl)- λ^6 -sulfanone; (4-methoxyphenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; benzyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(pyridin-3-yl)- λ^6 -sulfanone; (isoxazol-4-ylmethyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(oxazol-4-ylmethyl)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(thiazol-4-ylmethyl)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(pyrimidin-5-yl)- λ^6 -sulfanone; (3-chloro-4-(trifluoromethyl)phenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; isopropyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; ethyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2-methoxyethyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (isopropylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((cyclopropylmethyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((isoxazol-4-ylmethyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2-methoxyethyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(methylimino)- λ^6 -sulfanone; (ethylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(((1-methyl-1H-imidazol-4-yl)methyl)imino)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-

oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((3,3,3-trifluoropropyl)imino)- λ^6 -sulfanone; ((4-
 methoxybenzyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridin-3-yl)- λ^6 -sulfanone; methyl(((1-methyl-1H-pyrazol-4-yl)methyl)imino)(2-methyl-6-(5-
 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((4-
 5 chlorobenzyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridin-3-yl)- λ^6 -sulfanone; methyl(((1-methyl-1H-1,2,4-triazol-3-yl)methyl)imino)(2-methyl-6-(5-
 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-
 (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(phenylimino)- λ^6 -sulfanone;
 ((2,4-difluorophenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
 10 yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((4-fluorophenyl)imino)(methyl)(2-methyl-6-(5-
 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; (tert-
 butylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-
 yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-
 3-yl)(pyridin-3-ylimino)- λ^6 -sulfanone; (benzylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-
 15 oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone ; ((4-methoxyphenyl)imino)(methyl)(2-
 methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone;
 methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((4-
 methylbenzyl)imino)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
 yl)imidazo[1,2-a]pyridin-3-yl)((4-(trifluoromethoxy)phenyl)imino)- λ^6 -sulfanone; ((2-chloro-4-
 20 (trifluoromethyl)phenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
 yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2-chloro-4-fluorophenyl)imino)(methyl)(2-methyl-6-
 (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2,6-
 dichlorophenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
 a]pyridin-3-yl)- λ^6 -sulfanone; ((2-chloro-6-methoxyphenyl)imino)(methyl)(2-methyl-6-(5-
 25 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-
 (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((thiazol-4-ylmethyl)imino)- λ^6 -
 sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-
 yl)((oxazol-4-ylmethyl)imino)- λ^6 -sulfanone; (((1,2,4-oxadiazol-3-yl)methyl)imino)(methyl)(2-
 methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone ;
 30 methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(pyrimidin-
 5-ylimino)- λ^6 -sulfanone; ((3-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)(2-methyl-6-(5-
 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone;
 (isopropylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
 yl)methyl)- λ^6 -sulfanone; ((cyclopropylmethyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-
 35 oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((isoxazol-4-
 ylmethyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
 yl)methyl)- λ^6 -sulfanone; ((2-methoxyethyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(methylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (ethylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(((1-methyl-1H-imidazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)((3,3,3-trifluoropropyl)imino)- λ^6 -sulfanone; ((4-methoxybenzyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(((1-methyl-1H-pyrazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((4-chlorobenzyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(((1-methyl-1H-1,2,4-triazol-3-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(phenylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2,4-difluorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((4-fluorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (tert-butylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(pyridin-3-ylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (benzylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((4-methoxyphenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((4-(trifluoromethoxy)phenyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-chloro-4-fluorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2,6-dichlorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-chloro-6-methoxyphenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((thiazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((oxazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (((1,2,4-oxadiazol-3-yl)methyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(pyrimidin-5-ylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((3-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-

a]pyridin-2-yl)methyl)- λ^6 -sulfanone; N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(methyl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((2,4-difluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((3-(dimethylamino)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(dimethyl(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(ethyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(tert-butyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((cyclopropylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(benzyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyrimidin-5-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyridazin-4-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyrazin-2-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyridin-4-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; methyl(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (4-chlorophenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (4-methoxyphenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (2-fluorophenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (2,4-difluorophenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (3-(dimethylamino)phenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; dimethyl((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; ethyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; benzyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-

oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyrimidin-5-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyridazin-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyrazin-2-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyridin-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(3-methylbenzyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-4-ylmethyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyrimidin-4-ylmethyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-3-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-2-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(5-(trifluoromethyl)pyridin-2-yl)- λ^6 -sulfanone; (5-methoxypyridin-2-yl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (5-fluoropyridin-2-yl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyrimidin-5-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridazin-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(1-methyl-1H-pyrazol-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; isoxazol-4-yl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-methoxythiazol-4-yl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; dimethyl((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; ethyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; (2-methoxyethyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; benzyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (3-methoxybenzyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (3-fluorobenzyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; isopropyl(methyl)((6-(5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
(cyclopropylmethyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (isoxazol-4-ylmethyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-
5 methoxyethyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; dimethyl(((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; ethyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone methyl((1-methyl-1H-imidazol-4-yl)methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)-
10 λ^6 -sulfanone; methyl(((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; (4-methoxybenzyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl((1-methyl-1H-pyrazol-4-yl)methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (4-chlorobenzyl)(methyl)((6-(5-
15 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl((1-methyl-1H-1,2,4-triazol-3-yl)methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(phenyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2,4-difluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (4-fluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-3-yl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; benzyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (4-methoxyphenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(4-methylbenzyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(4-(trifluoromethoxy)phenyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-chloro-4-
20 (trifluoromethyl)phenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-chloro-4-fluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2,6-dichlorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(thiazol-4-ylmethyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(oxazol-4-ylmethyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
35

a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyrimidin-5-yl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone and (3-chloro-4-(trifluoromethyl)phenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone.

The compound of the present invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compound of the present invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form.

An anion part of the salt in case the compound of formula I is a cationic or capable of forming a cation can be inorganic or organic. Alternatively, a cation part of the salt in case the compound of formula (I) is an anionic or capable of forming anion can be inorganic or organic. Examples of inorganic anion part of the salt include but are not limited to chloride, bromide, iodide, fluoride, sulfate, phosphate, nitrate, nitrite, hydrogen carbonates and hydrogen sulfate. Examples of organic anion part of the salt include but are not limited to formate, alkanoates, carbonates, acetates, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate, lactate, succinate, malate, citrates, benzoates, cinnamates, oxalates, alkylsulphates, alkylsulphonates, arylsulphonates arylsulphonates, alkylphosphonates, arylphosphonates, aryldiphosphonates, p-toluenesulphonate, and salicylate. Examples of inorganic cation part of the salt include but are not limited to alkali and alkaline earth metals. Examples of organic cation part of the salt include but are not limited to pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene, tetramethyl ammonium, tetrabutylammonium, choline and trimethylamine.

Metal ions in metal complexes of the compound of formula (I) are especially the ions of the elements of the second main group, especially calcium and magnesium, of the third and fourth main group, especially aluminium, tin and lead, and also of the first to eighth transition groups, especially chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period and the first to eighth transition groups. Here, the metals can be present in the various valencies that they can assume.


The compound selected from formula (I), (including all stereoisomers, N-oxides, and salts thereof), typically may exist in more than one form. Formula I thus includes all crystalline and non-crystalline forms of the compound that formula (I) represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and

melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by formula (I) can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by formula (I). Preparation and isolation of a particular polymorph of a compound represented by formula (I) can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.


In an embodiment, the present invention provides a process for the preparation of compound of formula (I).

In one embodiment, the present invention provides a process for the preparation of the compound of formula (I) comprising the steps of:


- a) reacting a compound of formula i with an alpha-halo carbonyl compound of formula v to afford a compound of formula ii;




- b) reacting the compound of formula ii with a hydroxyl amine to afford a compound of formula iii;



- c) reacting a compound of formula iii with an acid anhydride of formula (d) or with an acid chloride compound of formula (e) to afford compound of formula iv;




d) reacting the compound of formula iv with sulfoximine compound of formula (a) to afford compound of formula (I);




5 wherein, L^1 is direct bond; A is ; R^1 , k, R^8 , R^9 , L^2 and R^5 are as defined in the above detailed description.

In another embodiment, the present invention provides a process for the preparation of the compound of formula (I) comprising the steps of:


10 a) reacting a compound of formula i with a compound of formula ix to afford a compound of formula vi;



b) reacting the compound of formula vi with a hydroxyl amine to afford a compound of formula vii;




15 c) reacting the compound of formula vii with an acid anhydride of formula (d) or with an acid chloride compound of formula (e) to afford compound of formula viii;





wherein, X= Br, Cl or I;

- d) reacting the compound of formula viii with a compound of formula (a) to afford compound of formula (I);




5


wherein, L¹ is direct bond; A is ; and L² is ; R¹, k, R⁸, R⁹ and R⁵ are as defined in the above detailed description.

In yet another embodiment, the present invention provides a process for the preparation of compound of formula (I) comprising the steps of:

- 10 a) reacting a compound of formula i with a compound of formula x to afford a compound of formula xi;




- b) reacting the compound of formula xi with a hydroxyl amine to afford a compound of formula xii;



15


wherein, X is Cl, Br, I;

- c) reacting the compound of formula xii with an acid anhydride of formula (d) or with an acid chloride compound of formula (e) to afford compound of formula xiii;





wherein, X is Cl, Br, I;

- d) reacting the compound of formula xiii with a compound of formula (f) to afford compound of formula xiv;




- e) oxidizing the compound of formula xiv with a suitable oxidizing agent to afford a compound of formula (I);




wherein, L¹ is direct bond; A is ; L² is -S(=O)₀₋₂-; R¹, k, R⁸, R⁹ and R⁵ are as defined in the above detailed description.

In yet another embodiment, the present invention provides a process for the preparation of compound of formula (I) comprising the steps of:


- a) reacting a compound of formula xii with a suitable alkali metal azide compound to afford a compound of formula xv;





- b) reacting the compound of formula xv with a suitable reducing agent to afford a compound of formula xvi;




- c) reacting the compound of formula xvi with a carboxylic acid of formula (b) or with a carboxylic acid chloride compound of formula (c) to afford compound of formula (I);




wherein, L^1 is direct bond; A is ; L^2 is  in which Y is $-NR^{10}$ and L^3 is $C(=O)-$; R^1 , k, R^8 , R^9 and R^5 are as defined in the above detailed description.

In still another embodiment, the present invention provides a process for the preparation of compound of formula (I) comprising the steps of:


- a) reacting a compound of formula iv with a suitable reducing reagent to afford a compound of formula xvii;





- b) reacting the compound of formula xvii with a suitable oxidizing reagent to afford a compound of formula xviii;



- c) reacting the compound of formula xviii with a sulfoximine compound of formula (a) to afford compound of formula (I);




wherein, L^1 is direct bond; A is ; L^2 is ; R^1 , k, R^8 , R^9 and R^5 are as defined in the above detailed description.

The compounds of the present invention as defined by general formula (I) and/or in tables 1 to 12 may be prepared, in known manner, in a variety of ways as described in the schemes 1-5.

The compounds of formula (I) can be prepared by using a process as depicted in scheme 1:

Scheme 1:-





5 wherein, L^1 is direct bond; A is ; L^2 is ; R^1 , k, R^8 , R^9 and R^5 are as defined

The compound of formula ii can be prepared by reacting 2-amino pyridine compound of formula i and alpha-halo carbonyl compound of formula v in the presence of polar protic solvents such as ethanol optionally in the presence of acid such as acetic acid at refluxing temperatures.

10 The compound of formula iii can be prepared by reacting compound of formula ii with hydroxyl amine in the presence of polar protic solvents such as ethanol, methanol etc. at ambient temperature to 60 °C. This reaction can also be done in solvents such as tetrahydrofuran, 1,4-dioxane etc.


15 The compound of formula iv can be prepared by reacting the compound of formula iii with acid anhydride of formula (d) optionally in the presence of organic bases such as triethylamine or *N,N*-diisopropylethylamine. Alternatively, the compound of formula iii can be reacted with acid chloride compound of formula (e) optionally in the presence of organic bases such as triethyl amine, *N,N*-diisopropylethyl amine etc. to obtain desired compound of formula iv. Typically this reaction is carried out in aprotic solvents such as tetrahydrofuran, 1,4-dioxane, dichloromethane, etc. at temperatures from 0-60 °C.





The compound of formula I wherein L² is  can be obtained by reacting the ester compound of formula iv and sulfoximine compound of formula (a) by using trimethyl aluminium as coupling reagent. This reaction can be carried out in solvents such as toluene, tetrahydrofuran or 1,4-dioxane at 0-110 °C.

- 5 Alternatively, the compounds of formula (I) can also be prepared by using a process as depicted in scheme 2:

Scheme: 2




10 wherein, L¹ is direct bond; A is  ; L² is  ; R¹, k, R⁸, R⁹ and R⁵ are as defined in the above detailed description.

The compound of formula vi can be obtained by reacting the compound of formula i and compound of formula ix optionally in the presence of organic acid such as acetic acid. This reaction can be carried out in solvents such as tetrahydrofuran or 1,4-dioxane at temperature 25 °C to refluxing temperature.

15 The compound of formula vii can be obtained by reacting compound of formula vi with hydroxylamine in aprotic solvents such as tetrahydrofuran, 1,4-dioxane, etc. at 0-60 °C.

The compound of formula viii can be prepared by reacting compound of formula vi and acid anhydride of formula (d) optionally in the presence of bases such as triethyl amine, diisopropyl ethyl amine etc. Alternatively, the compound of formula vii can be reacted with acid chloride compound of formula (e) optionally in the presence of organic bases such as triethyl amine, diisopropylethyl amine,


etc. to obtain desired compound of formula vii. Typically this reaction is carried out in aprotic solvents such as tetrahydrofuran, 1,4-dioxane, dichloromethane, etc. at temperatures from 0-60 °C.



The compound of formula I wherein L² is can be obtained by reacting acid compound of formula vii and sulfoximine compound of formula (a) by using amid coupling reagents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (in the presence of 4-dimethylaminopyridine), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), etc. in solvents such as dichloromethane, tetrahydrofuran, dimethyl formamide etc. This reaction can be carried out at 0-60 °C.

Alternatively, the compounds of formula (I) can also be prepared by using a process as depicted in scheme 3:

Scheme: 3



wherein, L¹ is direct bond; A is ; L² is -S(=O)₀₋₂; R¹, k, R⁸, R⁹ and R⁵ are as defined in the above detailed description.

15 The compound of formula xi can be obtained by reacting compound of formula i with compound of formula x in polar protic solvents such as ethanol, methanol, etc.

The compound of formula xii can be obtained by reacting compound of formula xi with hydroxyl amine in solvents such as ethanol, methanol etc. This reaction can be carried out at temperature 0-60 °C.

20 The compound of formula xiii can be obtained by cyclizing compound of formula xii with acid anhydride of formula (d) or acid chloride of formula (e) in solvents such as tetrahydrofuran,

dichloromethane or 1,4-dioxane. This reaction can be carried out at temperature 0-60 °C optionally in the presence of organic bases such as triethyl amine or diisopropyl ethyl amine.


The compound of formula xiv can be obtained by reacting compound of formula xiii and thiol compound of formula (f) in the presence of bases such as potassium carbonate, cesium carbonate.



- 5 This reaction can be carried out in solvents such as acetonitrile, *N,N*-dimethylformamide, dimethyl sulphoxide etc.

The compound of formula I wherein L^2 is $-S(=O)_{0-2}-$ can be obtained by oxidation of sulphide compound of formula xiv by using appropriate equivalents of oxidizing agent such as oxone, *m*-chloroperbenzoic acid. This reaction can be carried out in solvents such as dichloromethane at

10 temperature 0 °C to 35 °C.


In one embodiment, the compounds of formula (I) can be prepared by using a process as depicted in scheme 4:



- 15 wherein, L^1 is direct bond; A is ; L^2 is  in which Y is $-NR^{10}$ and L^3 is $-C(=O)-$; R^1 , k, R^8 , R^9 and R^5 are as defined in the above detailed description.

Azide compound of formula xv can be obtained by reacting compound of formula xii and alkali metal azides such as sodium azide, potassium azide, etc. in polar aprotic solvents such as *N,N*-dimethyl formamide, dimethyl sulphoxide, etc. This reaction can be carried out at temperatures 0-60 °C.


- 20 Amine compound of formula xvi can be synthesized by reacting azide compound of formula xv by staudinger reaction condition in the presence of triphenylphosphine and water. This reaction can be carried out in solvents such as tetrahydrofuran.





The compound of formula (I), wherein L^2 is L^{2c} in which Y is $-NR^{10}$ and L^3 is $-C(=O)-$, can be prepared by reacting the amine compound of formula xvi with carboxylic acid of formula (b) by conventional amide coupling reaction using a suitable coupling reagents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-hydroxybenzotriazole or 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate etc. in the presence of organic bases such as triethyl amine or diisopropyl ethyl amine. Alternatively, the compound of formula (I) can also be obtained by reacting amine compound of formula xvi with carboxylic acid chloride of formula c in the presence of organic bases such as triethylamine or diisopropylethyl amine or pyridine etc.

In another embodiment, the compounds of formula (I) can be prepared by using a process as depicted in scheme 5:


Scheme: 5



wherein, L^1 is direct bond; A is ; L^2 is ; R^1 , k, R^8 , R^9 and R^5 are as defined in the above detailed description.


The compound of formula xviii can be prepared by reducing the compound of formula iv with a suitable reducing reagent such as diisobutylaluminum hydride (DIBAL-H). This reaction can be carried out in solvents such as dichloromethane, tetrahydrofuran etc. at temperature $-78\text{ }^\circ\text{C}$ to $-50\text{ }^\circ\text{C}$.

The compound of formula xviii can be prepared by oxidation of dihydro-oxadiazole compound of formula xvii by using a suitable oxidizing reagent 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in solvents such as dichloromethane at $0\text{ }^\circ\text{C}$ to $35\text{ }^\circ\text{C}$.




The compound of formula I wherein L^2 is L^{2a} can be prepared by microwave assisted reductive amination of aldehyde compound of formula xviii and sulfoximine compound of formula (a) at temperature 125-135 °C.

In one embodiment, the present invention provides a compound of formula (B);




Formula (B)

wherein,



L^1 is direct bond;



A is

R^8 and R^9 are independently selected from the group consisting of hydrogen, halogen, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl and C_3 - C_8 -cycloalkyl;

k is an integer ranging from 0 and 1;

R is selected from the group consisting of hydrogen, azide, halogen, hydroxy, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -haloalkoxy, C_1 - C_6 -alkylthio, C_1 - C_6 -haloalkylthio, C_3 - C_8 -cycloalkyl, amino- C_1 - C_6 -alkyl, di- C_1 - C_6 -alkylamino, NHSO_2 - C_1 - C_6 -alkyl, $-\text{S}(=\text{O})(=\text{NH})$ - C_1 - C_6 -alkyl; $-\text{C}(=\text{O})$ - C_1 - C_6 -alkyl, $\text{C}(=\text{O})$ - C_1 - C_6 -alkoxy, C_1 - C_6 -alkylsulfonyl, hydroxy- C_1 - C_6 -alkyl, $-\text{C}(=\text{O})$ - NH_2 , $\text{C}(=\text{O})$ - $\text{NH}(\text{C}_1$ - C_6 -alkyl), C_1 - C_6 -alkylthio- C_1 - C_6 -alkyl, C_1 - C_6 -alkylamino- C_1 - C_6 -alkyl, di- C_1 - C_6 -alkylamino- C_1 - C_6 -alkyl, aminocarbonyl- C_1 - C_6 -alkyl and C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl;

with the proviso that the following compounds are excluded from the definition of compound of formula (I);

ethyl (Z)-2-(6-(N' -hydroxycarbamimidoyl)imidazo[1,2-a]pyridin-2-yl)acetate, 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid and ethyl (Z)-2-(7-(N' -hydroxycarbamimidoyl)imidazo[1,2-a]pyridin-2-yl)acetate.

In a preferred embodiment, the compound of formula (B) is selected from 7-(N' -hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylic acid, ethyl 2-(7-(5-(trifluoromethyl)-

1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetate, 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 7-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 7-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 2-(chloromethyl)-*N'*-hydroxyimidazo[1,2-a]pyridine-7-carboximidamide, 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(2-(azidomethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole, ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetate, 6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylic acid, ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetate, 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 6-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 2-(chloromethyl)-*N'*-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide, 3-(2-(azidomethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole and imino(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone.

In one embodiment, the present invention relates to a composition comprising the compound of formula (I), agriculturally acceptable salts, metal complexes, constitutional isomers, stereo-isomers, diastereoisomers, enantiomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, geometric isomers, or N-oxides thereof optionally with one or more additional active ingredient with the auxiliary such as inert carrier or any other essential ingredient such as surfactants, additives, solid diluents and liquid diluents.

The compound of Formula I and the composition according to the invention, respectively, are suitable as fungicides. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, which derive especially from the classes of the Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes (syn. Fungi imperfecti). Some are systemically effective and they can be used in crop protection as foliar fungicides, fungicides for seed dressing and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants.

The compound of Formula I and the composition according to the invention are particularly important in the control of a multitude of phytopathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats or rice; beet, e. g. sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, e. g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as

cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruits or mandarins; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; energy and raw material plants, such as corn, soybean, rape, sugar cane or oil palm; corn; tobacco; nuts; coffee; tea; bananas; vines
5 (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e. g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.

Particularly, the compound of Formula I and the composition according to the invention are important in the control of phytopathogenic fungi on soybeans and on the plant propagation material, such as
10 seeds, and the crop material of soybeans. Accordingly, the present invention also includes a composition comprising at least one compound of Formula I and seed. The amount of the compound of Formula I in the composition ranges from 0.1 gai (gram per active ingredient) to 10 kgai (kilogram per active ingredient) per 100 kg of seeds.

Preferably, the compound of formula (I) and composition thereof, respectively are used for controlling
15 a multitude of fungi on field crops, such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamentals; or vegetables, such as cucumbers, tomatoes, beans or squashes.

The term "plant propagation material" is to be understood to denote all the generative or reproductive parts of the plant such as seeds and vegetative plant material such as cuttings and tubers (e. g.
20 potatoes), which can be used for the multiplication of the plant. This includes seeds, roots, fruits, tubers, bulbs, rhizomes, shoots, sprouts, twigs, flowers, and other parts of plants, including seedlings and young plants, which are to be transplanted after germination or after emergence from soil.

These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring.

25 Preferably, treatment of plant propagation materials with the compound of Formula I, the combination and or the composition thereof, respectively, is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley and oats; rice, corn, cotton and soybeans.

The term "cultivated plants" is to be understood as including plants which have been modified by breeding, mutagenesis or genetic engineering including but not limiting to agricultural biotech
30 products on the market or in development (cf. <http://cera-gmc.org/>, see GM crop database therein). Genetically modified plants are plants, which genetic material has been so modified by the use of recombinant DNA techniques that under natural circumstances cannot readily be obtained by cross breeding, mutations or natural recombination. Typically, one or more genes have been integrated into the genetic material of a genetically modified plant in order to improve certain properties of the plant.
35 Such genetic modifications also include but are not limited to targeted post-translational modification

of protein(s), oligo- or polypeptides e. g. by glycosylation or polymer additions such as prenylated, acetylated or farnesylated moieties or PEG moieties. Plants that have been modified by breeding, mutagenesis or genetic engineering, e. g. have been rendered tolerant to applications of specific classes of herbicides, such as auxin herbicides such as dicamba or 2,4-D; bleacher herbicides such as hydroxylphenylpyruvate dioxygenase (HPPD) inhibitors or phytoene desaturase (PDS) inhibitors; acetolactate synthase (ALS) inhibitors such as sulfonyl ureas or imidazolinones; enolpyruvylshikimate-3-phosphate synthase (EPSPS) inhibitors, such as glyphosate; glutamine synthetase (GS) inhibitors such as glufosinate; protoporphyrinogen-IX oxidase inhibitors; lipid biosynthesis inhibitors such as acetyl CoA carboxylase (ACCase) inhibitors; or oxynil (i. e. bromoxynil or ioxynil) herbicides as a result of conventional methods of breeding or genetic engineering. Furthermore, plants have been made resistant to multiple classes of herbicides through multiple genetic modifications, such as resistance to both glyphosate and glufosinate or to both glyphosate and a herbicide from another class such as ALS inhibitors, HPPD inhibitors, auxin herbicides, or ACCase inhibitors. These herbicide resistance technologies are e. g. described in Pest Managem. Sci. 61, 2005, 246; 61, 2005, 258; 61, 2005, 277; 61, 2005, 269; 61, 2005, 286; 64, 2008, 326; 64, 2008, 332; Weed Sci. 57, 2009, 108; Austral. J. Agricult. Res. 58, 2007, 708; Science 316, 2007, 1 185; and references quoted therein. Several cultivated plants have been rendered tolerant to herbicides by conventional methods of breeding (mutagenesis), e. g. Clearfield[®] summer rape (Canola, BASF SE, Germany) being tolerant to imidazolinones, e. g. imazamox, or ExpressSun[®] sunflowers (DuPont, USA) being tolerant to sulfonyl ureas, e. g. tribenuron. Genetic engineering methods have been used to render cultivated plants such as soybean, cotton, corn, beets and rape, tolerant to herbicides such as glyphosate and glufosinate, some of which are commercially available under the trade names RoundupReady[®] (glyphosate-tolerant, Monsanto, U.S.A.), Cultivance[®] (imidazolinone tolerant, BASF SE, Germany) and LibertyLink[®] (glufosinate-tolerant, Bayer CropScience, Germany).

Furthermore, plants capable to synthesize one or more insecticidal proteins, especially those known from the bacterial genus (*Bacillus*), by the use of recombinant DNA techniques are within the scope of the present invention. The *Bacillus* are particularly from *Bacillus thuringiensis*, such as δ -endotoxins, e. g. CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c; vegetative insecticidal proteins (VIP), e. g. VIP1, VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, e. g. *Photorhabdus* spp. or *Xenorhabdus* spp.; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins; toxins produced by fungi, such as *Streptomyces* toxins, plant lectins, such as pea or barley lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroid oxidase,

ecdysteroid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase; ion channel blockers, such as blockers of sodium or calcium channels; juvenile hormone esterase; diuretic hormone receptors (helicokinin receptors); stilbene synthase, bibenzyl synthase, chitinases or glucanases. In the context of the present invention these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a new combination of protein domains, (see, e. g. WO02/015701). Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e. g., in EP374753, WO93/007278, WO95/34656, EP427 529, EP451 878, WO03/18810 und WO03/52073. The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. These insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of arthropods, especially to beetles (Coeloptera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda). Genetically modified plants capable to synthesize one or more insecticidal proteins are, e. g., described in the publications mentioned above, and some of which are commercially available such as YieldGard[®] (corn cultivars producing the CryIAb toxin), YieldGard[®] Plus (corn cultivars producing CryIAb and Cry3Bb1 toxins), Starlink[®] (corn cultivars producing the Cry9c toxin), Herculex[®] RW (corn cultivars producing Cry34Ab1, Cry35Ab1 and the enzyme phosphinothricin-N-acetyltransferase [PAT]); NuCOTN[®] 33B (cotton cultivars producing the CryIAc toxin), Bollgard[®] I (cotton cultivars producing the Cry1 Ac toxin), Bollgard[®] II (cotton cultivars producing CryIAc and Cry2Ab2 toxins); VIPCOT[®] (cotton cultivars producing a VIP-toxin); NewLeaf[®] (potato cultivars producing the Cry3A toxin); Bt-Xtra[®], NatureGard[®], KnockOut[®], BiteGard[®], Protecta[®], Bt1 1 (e. g. Agrisure[®] CB) and Bt176 from Syngenta Seeds SAS, France, (corn cultivars producing the CryIAb toxin and PAT enzyme), MIR604 from Syngenta Seeds SAS, France (corn cultivars producing a modified version of the Cry3A toxin, c.f. WO 03/018810), MON 863 from Monsanto Europe S.A., Belgium (corn cultivars producing the Cry3Bb1 toxin), IPC 531 from Monsanto Europe S.A., Belgium (cotton cultivars producing a modified version of the CryIAc toxin) and 1507 from Pioneer Overseas Corporation, Belgium (corn cultivars producing the Cry1 F toxin and PAT enzyme).

Furthermore, plants capable to synthesize one or more proteins to increase the resistance or tolerance of those plants to bacterial, viral or fungal pathogens by the use of recombinant DNA techniques are also within the scope of the present invention. Examples of such proteins are the so-called "pathogenesis-related proteins" (PR proteins, see, e. g. EP392225), plant disease resistance genes (e. g. potato cultivars, which express resistance genes acting against *Phytophthora infestans* derived from the Mexican wild potato *Solanum bulbocastanum*) or T4-lysozym (e. g. potato cultivars capable of synthesizing these proteins with increased resistance against bacteria such as *Erwinia amylovora*). The

methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above.

Furthermore, plants capable to synthesize one or more proteins, by the use of recombinant DNA techniques, to increase the productivity (e. g. bio mass production, grain yield, starch content, oil content or protein content), tolerance to drought, salinity or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral pathogens of those plants are within the scope of the present invention.

Furthermore, plants that contain a modified amount of substances of content or new substances of content, by the use of recombinant DNA techniques, to improve human or animal nutrition, e. g. oil crops that produce health-promoting long-chain omega-3 fatty acids or unsaturated omega-9 fatty acids (e. g. Nexera[®] rape, DOW Agro Sciences, Canada) are also within the scope of the present invention.

Furthermore, plants that contain a modified amount of substances of content or new substances of content, by the use of recombinant DNA techniques, to improve raw material production, e. g. potatoes that produce increased amounts of amylopectin (e. g. Amflora[®] potato, BASF SE, Germany) are also within the scope of the present invention.

The present invention also relates to a method for controlling or preventing infestation of plants by phytopathogenic micro-organisms in agricultural crops and or horticultural crops wherein an effective amount of at least one compound of Formula I or the combination of the present invention or the composition of the present invention, is applied to the seeds of plants. The compound, the combination and the composition of the present invention can be used for controlling or preventing plant diseases. The compound of Formula I, the combination and or the composition thereof, respectively, are particularly suitable for controlling the following plant diseases:

Albugo spp. (white rust) on ornamentals, vegetables (e. g. *A. Candida*) and sunflowers (e. g. *A. tragopogonis*); *Altemaria* spp. (Alternaria leaf spot) on vegetables, rape (*A. brassicola* or *brassicae*), sugar beets (*A. tenuis*), fruits, rice, soybeans, potatoes (e. g. *A. solani* or *A. alternata*), tomatoes (e. g. *A. solani* or *A. alternata*) and wheat; *Aphanomyces* spp. on sugar beets and vegetables; *Ascochyta* spp. on cereals and vegetables, e. g. *A. tritici* (anthracnose) on wheat and *A. hordei* on barley; *Bipolaris* and *Drechslera* spp. (teleomorph: *Cochliobolus* spp.), e. g. Southern leaf blight (*D. maydis*) or Northern leaf blight (*B. zeicola*) on corn, e. g. spot blotch (*C. sorokiniana*) on cereals and e. g. *B. oryzae* on rice and turfs; Blumeria (formerly Erysiphe) graminis (powdery mildew) on cereals (e. g. on wheat or barley); *Botrytis cinerea* (teleomorph: *Botryotinia fuckeliana*: grey mold) on fruits and berries (e. g. strawberries), vegetables (e. g. lettuce, carrots, celery and cabbages), rape, flowers, vines, forestry plants and wheat; *Bremia lactucae* (downy mildew) on lettuce; *Ceratocystis* (*syn. Ophiostoma*) spp. (rot or wilt) on broad-leaved trees and evergreens, e. g. *C. ulmi* (Dutch elm disease)

on elms; *Cercospora* spp. (*Cercospora* leaf spots) on corn (e. g. Gray leaf spot: *C. zea-maydis*), rice, sugar beets (e. g. *C. beticola*), sugar cane, vegetables, coffee, soybeans (e. g. *C. soja* or *C. kikuchii*) and rice; *Cladosporium* spp. on tomatoes (e. g. *C. fulvum*: leaf mold) and cereals, e. g. *C. herbarum* (black ear) on wheat; *Claviceps purpurea* (ergot) on cereals; *Cochliobolus* (anamorph: *Helminthosporium* of *Bipolaris*) spp. (leaf spots) on corn (*C. carbonum*), cereals (e. g. *C. sativus*, anamorph: *B. sorokiniana*) and rice (e. g. *C. miyabeanus*, anamorph: *H. oryzae*); *Colletotrichum* (teleomorph: *Glomerella*) spp. (anthracnose) on cotton (e. g. *C. gossypii*), corn (e. g. *C. graminicola*: Anthracnose stalk rot), soft fruits, potatoes (e. g. *C. coccodes*: black dot), beans (e. g. *C. lindemuthianum*) and soybeans (e. g. *C. truncatum* or *C. gloeosporioides*); *Corticium* spp., e. g. *C. sasakii* (sheath blight) on rice; *Corynespora cassicola* (leaf spots) on soybeans and ornamentals; *Cyloconium* spp., e. g. *C. oleaginum* on olive trees; *Cylindrocarpon* spp. (e. g. fruit tree canker or young vine decline, teleomorph: *Nectria* or *Neonectria* spp.) on fruit trees, vines (e. g. *C. liriodendri*, teleomorph: *Neonectria liriodendri*: Black Foot Disease) and ornamentals; *Dematophora* (teleomorph: *Rosellinia*) *necatrix* (root and stem rot) on soybeans; *Diaporthe* spp., e. g. *D. phaseolorum* (damping off) on soybeans; *Drechslera* (syn. *Helminthosporium*, teleomorph: *Pyrenophora*) spp. on corn, cereals, such as barley (e. g. *D. teres*, net blotch) and wheat (e. g. *D. tritici-repentis*: tan spot), rice and turf; Esca (dieback, apoplexy) on vines, caused by *Formitiporia* (syn. *Phellinus*) *punctata*, *F. mediterranea*, *Phaeomoniella chlamydospora* (earlier *Phaeoacremonium chlamydosporum*), *Phaeoacremonium aleophilum* and/or *Botryosphaeria obtusa*; *Elsinoe* spp. on pome fruits (*E. pyri*), soft fruits (*E. veneta*: anthracnose) and vines (*E. ampelina*: anthracnose); *Entyloma oryzae* (leaf smut) on rice; *Epicoccum* spp. (black mold) on wheat; *Erysiphe* spp. (powdery mildew) on sugar beets (*E. betae*), vegetables (e. g. *E. pisi*), such as cucurbits (e. g. *E. cichoracearum*), cabbages, rape (e. g. *E. cruciferarum*); *Eutypa lata* (*Eutypa* canker or dieback, anamorph: *Cytosporina lata*, syn. *Libertella blepharis*) on fruit trees, vines and ornamental woods; *Exserohilum* (syn. *Helminthosporium*) spp. on corn (e. g. *E. turcicum*); *Fusarium* (teleomorph: *Gibberella*) spp. (wilt, root or stem rot) on various plants, such as *F. graminearum* or *F. culmorum* (root rot, scab or head blight) on cereals (e. g. wheat or barley), *F. oxysporum* on tomatoes, *F. solani* (f. sp. *glycines* now syn. *F. virguliforme*) and *F. tucumaniae* and *F. brasiliense* each causing sudden death syndrome on soybeans, and *F. verticillioides* on corn; *Gaeumannomyces graminis* (take-all) on cereals (e. g. wheat or barley) and corn; *Gibberella* spp. on cereals (e. g. *G. zea*) and rice (e. g. *G. fujikuroi*: Bakanae disease); *Glomerella cingulata* on vines, pome fruits and other plants and *G. gossypii* on cotton; Grainstaining complex on rice; *Guignardia bidwellii* (black rot) on vines; *Gymnosporangium* spp. on rosaceous plants and junipers, e. g. *G. sabinae* (rust) on pears; *Helminthosporium* spp. (syn. *Drechslera*, teleomorph: *Cochliobolus*) on corn, cereals and rice; *Hemileia* spp., e. g. *H. vastatrix* (coffee leaf rust) on coffee; *Isariopsis clavispora* (syn. *Cladosporium vitis*) on vines; *Macrophomina phaseolina* (syn. *phaseoli*) (root and stem rot) on soybeans and cotton; *Microdochium* (syn. *Fusarium*) *nivale* (pink snow mold) on cereals (e. g. wheat or barley); *Microsphaera diffusa* (powdery mildew) on soybeans;

Monilinia spp., e. g. *M. laxa*, *M. fructicola* and *M. fructigena* (bloom and twig blight, brown rot) on stone fruits and other rosaceous plants; *Mycosphaerella* spp. on cereals, bananas, soft fruits and ground nuts, such as e. g. *M. graminicola* (anamorph: *Septoria tritici*, *Septoria blotch*) on wheat or *M. fijiensis* (black Sigatoka disease) on bananas; *Peronospora* spp. (downy mildew) on cabbage (e. g. *P. brassicae*), rape (e. g. *P. parasitica*), onions (e. g. *P. destructor*), tobacco (*P. tabacina*) and soybeans (e. g. *P. manshurica*); *Phakopsora pachyrhizi* and *P. meibomia* (soybean rust) on soybeans; *Phialophora* spp. e. g. on vines (e. g. *P. tracheiphila* and *P. tetraspora*) and soybeans (e. g. *P. gregata*: stem rot); *Phoma lingam* (root and stem rot) on rape and cabbage and *P. betae* (root rot, leaf spot and damping-off) on sugar beets; *Phomopsis* spp. on sunflowers, vines (e. g. *P. viticola*: can and leaf spot) and soybeans (e. g. stem rot: *P. phaseoli*, teleomorph: *Diaporthe phaseolorum*); *Physoderma maydis* (brown spots) on corn; *Phytophthora* spp. (wilt, root, leaf, fruit and stem rot) on various plants, such as paprika and cucurbits (e. g. *P. capsici*), soybeans (e. g. *P. megasperma*, syn. *P. sojae*), soybeans, potatoes and tomatoes (e. g. *P. infestans*: late blight) and broad-leaved trees (e. g. *P. ramorum*: sudden oak death); *Plasmodiophora brassicae* (club root) on cabbage, rape, radish and other plants; *Plasmopara* spp., e. g. *P. viticola* (grapevine downy mildew) on vines and *P. halstedii* on sunflowers; *Podosphaera* spp. (powdery mildew) on rosaceous plants, hop, pome and soft fruits, e. g. *P. leucotricha* on apples; *Polymyxa* spp., e. g. on cereals, such as barley and wheat (*P. graminis*) and sugar beets (*P. betae*) and thereby transmitted viral diseases; *Pseudocercospora herpotrichoides* (eyespot, teleomorph: *Tapesia yallundae*) on cereals, e. g. wheat or barley; *Pseudoperonospora* (downy mildew) on various plants, e. g. *P. cubensis* on cucurbits or *P. humili* on hop; *Pseudopezizicola tracheiphila* (red fire disease or 'rotbrenner', anamorph: *Phialophora*) on vines; *Puccinia* spp. (rusts) on various plants, e. g. *P. triticina* (brown or leaf rust), *P. striiformis* (stripe or yellow rust), *P. hordei* (dwarf rust), *P. graminis* (stem or black rust) or *P. recondita* (brown or leaf rust) on cereals, such as e. g. wheat, barley or rye, *P. kuehnii* (orange rust) on sugar cane and *P. asparagi* on asparagus; *Pyrenophora* (anamorph: *Drechslera*) *tritici-repentis* (tan spot) on wheat or *P. teres* (net blotch) on barley; *Pyricularia* spp., e. g. *P. oryzae* (teleomorph: *Magnaporthe grisea*, rice blast) on rice and *P. grisea* on turf and cereals; *Pythium* spp. (damping-off) on turf, rice, corn, wheat, cotton, rape, sunflowers, soybeans, sugar beets, vegetables and various other plants (e. g. *P. ultimum* or *P. aphanidermatum*); *Ramularia* spp., e. g. *R. collo-cygni* (*Ramularia* leaf spots, Physiological leaf spots) on barley and *R. beticola* on sugar beets; *Rhizoctonia* spp. on cotton, rice, potatoes, turf, corn, rape, potatoes, sugar beets, vegetables and various other plants, e. g. *R. solani* (root and stem rot) on soybeans, *R. solani* (sheath blight) on rice or *R. cerealis* (*Rhizoctonia* spring blight) on wheat or barley; *Rhizopus stolonifer* (black mold, soft rot) on strawberries, carrots, cabbage, vines and tomatoes; *Rhynchosporium secalis* (scald) on barley, rye and triticale; *Sarocladium oryzae* and *S. attenuatum* (sheath rot) on rice; *Sclerotinia* spp. (stem rot or white mold) on vegetables and field crops, such as rape, sunflowers (e. g. *S. sclerotiorum*) and soybeans (e. g. *S. rolfsii* or *S. sclerotiorum*); *Septoria* spp. on various plants, e. g. *S. glycines* (brown spot) on soybeans, *S. tritici* (*Septoria blotch*)

on wheat and *S.* (syn. *Stagonospora*) *nodorum* (*Stagonospora blotch*) on cereals; *Uncinula* (syn. *Erysiphe*) *necator* (powdery mildew, anamorph: *Oidium tuckeri*) on vines; *Setosphaeria* spp. (leaf blight) on corn (e. g. *S. turcicum*, syn. *Helminthosporium turcicum*) and turf; *Sphacelotheca* spp. (smut) on corn, (e. g. *S. reiliana*: head smut), sorghum and sugar cane; *Sphaerotheca fuliginea* (powdery mildew) on cucurbits; *Spongospora subterranea* (powdery scab) on potatoes and thereby transmitted viral diseases; *Stagonospora* spp. on cereals, e. g. *S. nodorum* (*Stagonospora blotch*, teleomorph: *Leptosphaeria* [syn. *Phaeosphaeria*] *nodorum*) on wheat; *Synchytrium endobioticum* on potatoes (potato wart disease); *Taphrina* spp., e. g. *T. deformans* (leaf curl disease) on peaches and *T. pruni* (plum pocket) on plums; *Thielaviopsis* spp. (black root rot) on tobacco, pome fruits, vegetables, soybeans and cotton, e. g. *T. basicola* (syn. *Chalara elegans*); *Tilletia* spp. (common bunt or stinking smut) on cereals, such as e. g. *T. tritici* (syn. *T. caries*, wheat bunt) and *T. controversa* (dwarf bunt) on wheat; *Typhula incarnata* (grey snow mold) on barley or wheat; *Urocystis* spp., e. g. *U. occulta* (stem smut) on rye; *Uromyces* spp. (rust) on vegetables, such as beans (e. g. *U. appendiculatus*, syn. *U. phaseoli*) and sugar beets (e. g. *U. betae*); *Ustilago* spp. (loose smut) on cereals (e. g. *U. nuda* and *U. avenae*), corn (e. g. *U. maydis*: corn smut) and sugar cane; *Venturia* spp. (scab) on apples (e. g. *V. inaequalis*) and pears; and *Verticillium* spp. (wilt) on various plants, such as fruits and ornamentals, vines, soft fruits, vegetables and field crops, e. g. *V. dahliae* on strawberries, rape, potatoes and tomatoes.

The compound of Formula I, the combination or the composition thereof may be used to treat several fungal pathogens. Non-limiting examples of pathogens of fungal diseases which can be treated in accordance with the invention include:

Ustilaginales such as *Ustilaginoidea virens*, *Ustilago nuda*, *Ustilago tritici*, *Ustilago zaeae*, rusts for example those caused by Pucciniales such as *Cerotelium fici*, *Chrysomyxa arctostaphyli*, *Coleosporium ipomoeae*, *Hemileia vastatrix*, *Puccinia arachidis*, *Puccinia cacabata*, *Puccinia graminis*, *Puccinia recondita*, *Puccinia sorghi*, *Puccinia hordei*, *Puccinia striiformis* f.sp. *Hordei*, *Puccinia striiformis* f.sp. *Secalis*, *Pucciniastrum coryli*, or Uredinales such as *Cronartium ribicola*, *Gymnosporangium juniperi-viginiana*, *Melampsora medusae*, *Phakopsora pachyrhizi*, *Phragmidium mucronatum*, *Physopella ampeloidis*, *Tranzschelia discolor* and *Uromyces viciae-fabae*; and other rots and diseases such as those caused by *Cryptococcus* spp., *Exobasidium vexans*, *Marasmiellus inoderma*, *Mycena* spp., *Sphacelotheca reiliana*, *Typhula ishikariensis*, *Urocystis agropyri*, *Itersonilia perplexans*, *Corticium invisum*, *Laetisaria fuciformis*, *Waitea circinata*, *Rhizoctonia solani*, *Thanetophorus cucurmeris*, *Entyloma dahliae*, *Entylomella microspora*, *Neovossia molinae* and *Tilletia caries*. Blastocladiomycetes, such as *Physoderma maydis*. Mucoromycetes, such as *Choanephora cucurbitarum*.; *Mucor* spp.; and *Rhizopus arrhizus*,

In another embodiment diseases caused by rust disease pathogens, for example *Gymnosporangium* species, for example *Gymnosporangium sabinae*; *Hemileia* species, for example *Hemileia vastatrix*;

Phakopsora species, for example *Phakopsora pachyrhizi* or *Phakopsora meibomia*; *Puccinia* species, for example *Puccinia recondita*, *Puccinia graminis* oder *Puccinia striiformis*; *Uromyces* species, for example *Uromyces appendiculatus*;

In particular, *Cronartium ribicola* (White pine blister rust); *Gymnosporangium juniperi-virginianae* (Cedar-apple rust); *Hemileia vastatrix* (Coffee rust); *Phakopsora meibomia* and *P. pachyrhizi* (Soybean rust); *Puccinia coronata* (Crown Rust of Oats and Ryegrass); *Puccinia graminis* (Stem rust of wheat and Kentucky bluegrass, or black rust of cereals); *Puccinia hemerocallidis* (Daylily rust); *Puccinia persistens subsp. triticina* (wheat rust or 'brown or red rust'); *Puccinia sorghi* (rust in corn); *Puccinia striiformis* ('Yellow rust' in cereals); *Uromyces appendiculatus* (rust of beans); *Uromyces phaseoli* (Bean rust); *Puccinia melanocephala* ('Brown rust' in sugarcane); *Puccinia kuehnii* ('Orange rust' in sugarcane).

Plants which can be treated in accordance with the invention include the following: cotton, flax, grapevine, fruits, vegetables, such as *Rosaceae sp* (for example pome fruits such as apples, pears, apricots, cherries, almonds and peaches), *Ribesioideae sp.*, *Juglandaceae sp.*, *Betulaceae sp.*, *Anacardiaceae sp.*, *Fagaceae sp.*, *Moraceae sp.*, *Oleaceae sp.*, *Actinidaceae sp.*, *Lauraceae sp.*, *Musaceae sp.* (for example banana trees and plantations), *Rubiaceae sp.* (for example coffee), *Theaceae sp.*, *Sterculiaceae sp.*, *Rutaceae sp.* (for example lemons, oranges and grapefruit); *Vitaceae sp.* (for example grapes); *Solanaceae sp.* (for example tomatoes, peppers), *Liliaceae sp.*, *Asteraceae sp.* (for example lettuce), *Umbelliferae sp.*, *Cruciferae sp.*, *Chenopodiaceae sp.*, *Cucurbitaceae sp.* (for example cucumber), *Alliaceae sp.* (for example leek, onion), *Papilionaceae sp.* (for example peas); major crop plants, such as *Poaceae/Gramineae sp.* (for example maize, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale), *Asteraceae sp.* (for example sunflower), *Brassicaceae sp.* (for example white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, and oilseed rape, mustard, horseradish and cress), *Fabaceae sp.* (for example bean, peanuts), *Papilionaceae sp.* (for example soya bean), *Solanaceae sp.* (for example potatoes), *Chenopodiaceae sp.* (for example sugar beet, fodder beet, swiss chard, beetroot); *Malvaceae* (for example cotton); useful plants and ornamental plants for gardens and wooded areas; and genetically modified varieties of each of these plants.

More preference is given to controlling the following diseases of soya beans: Fungal diseases on leaves, stems, pods and seeds caused, for example, by *Altemaria* leaf spot (*Altemaria spec. atrans tenuissima*), Anthracnose (*Colletotrichum gloeosporoides dematium var. truncatum*), brown spot (*Septoria glycines*), cercospora leaf spot and blight (*Cercospora kikuchii*), choanephora leaf blight (*Choanephora infundibulifera trisporea (Syn.)*), dactuliophora leaf spot (*Dactuliophora glycines*), downy mildew (*Peronospora manshurica*), drechslera blight (*Drechslera glycini*), frog-eye leaf spot (*Cercospora sojina*), leptosphaerulina leaf spot (*Leptosphaerulina trifolii*), phyllosticta leaf spot (*Phyllosticta sojaecola*), pod and stem blight (*Phomopsis sojiae*), powdery mildew (*Microsphaera*

diffusa), pyrenochaeta leaf spot (*Pyrenochaeta glycines*), rhizoctonia aerial, foliage, and web blight (*Rhizoctonia solani*), rust (*Phakopsora pachyrhizi*, *Phakopsora meibomiaie*), scab (*Sphaceloma glycines*), stemphylium leaf blight (*Stemphylium botryosum*), target spot (*Corynespora cassiicola*).

Fungal diseases on roots and the stem base caused, for example, by black root rot (*Calonectia crotalariae*), charcoal rot (*Macrophomina phaseolina*), fusarium blight or wilt, root rot, and pod and collar rot (*Fusarium oxysporum*, *Fusarium orthoceras*, *Fusarium semitectum*, *Fusarium equiseti*), mycoleptodiscus root rot (*Mycoleptodiscus terrestris*), neocosmospora (*Neocosmospora vasinfecta*), pod and stem blight (*Diaporthe phaseolorum*), stem canker (*Diaporthe phaseolorum* var. *caulivora*), phytophthora rot (*Phytophthora megasperma*), brown stem rot (*Phialophora gregata*), pythium rot (*Pythium aphanidennatum*, *Pythium irregulare*, *Pythium debaryanum*, *Pythium myriotylum*, *Pythium ultimum*), rhizoctonia root rot, stem decay, and damping-off (*Rhizoctonia solani*), sclerotinia stem decay (*Sclerotinia sclerotiorum*), sclerotinia southern blight (*Sclerotinia rolfsii*), thielaviopsis root rot (*Thielaviopsis basicola*).

The present invention also relates to the use of the compound of Formula I, the combination or the composition thereof for controlling or preventing the following plant diseases: *Puccinia* spp. (rusts) on various plants, for example, but not limited to *P. triticina* (brown or leaf rust), *P. striiformis* (stripe or yellow rust), *P. hordei* (dwarf rust), *P. graminis* (stem or black rust) or *P. recondita* (brown or leaf rust) on cereals, such as e. g. wheat, barley or rye and *Phakopsoraceae* spp. on various plants, in particular *Phakopsorapachyrhizi* and *P. meibomiaie* (soybean rust) on soybeans, *Hemileia vastatrix* (Coffee rust), *Uromyces appendiculatus*, *Uromyces fabae* and *Uromyces phaseoli* (rust of beans).

The present invention further relates to the use of the compound of Formula I, the combination or the composition thereof for controlling or preventing against phytopathogenic fungi such as *Phakopsora pachyrhizi*, *Phakopsora meibomiaie*, of agricultural crops and or horticultural crops.

The compound of formula (I), the combination and the composition thereof, respectively, are also suitable for controlling harmful fungi in the protection of stored products or harvest and in the protection of materials. The term "protection of materials" is to be understood to denote the protection of technical and non-living materials, such as adhesives, glues, wood, paper and paperboard, textiles, leather, paint dispersions, plastics, cooling lubricants, fiber or fabrics, against the infestation and destruction by harmful microorganisms, such as fungi and bacteria.

As to the protection of wood and other materials, the particular attention is paid to the following harmful fungi: Ascomycetes such as *Ophiostoma* spp., *Ceratocystis* spp., *Aureobasidium pullulans*, *Sclerophoma* spp., *Chaetomium* spp., *Humicola* spp., *Petriella* spp., *Trichurus* spp.; Basidiomycetes such as *Coniophora* spp., *Coriolus* spp., *Gloeophyllum* spp., *Lentinus* spp., *Pleurotus* spp., *Pora* spp., *Serpula* spp. and *Tyromyces* spp., Deuteromycetes such as *Aspergillus* spp., *Cladosporium* spp.,

Penicillium spp., *Trichoderma* spp., *Altemaria* spp., *Paecilomyces* spp. and Zygomycetes such as *Mucor* spp., and in addition in the protection of stored products and harvest the following yeast fungi are worthy of note: *Candida* spp. and *Saccharomyces cerevisiae*.

In one embodiment the compound of Formula (I), the combination and the composition thereof, respectively, are particularly suitable for controlling the following plant diseases: *Phakopsora pachyrhizi* and *P. meibomia* (soybean rust) on soybeans.

The present invention further relates to a method for controlling or preventing phytopathogenic fungi. The method comprises treating the fungi or the materials, plants, plant parts, locus thereof, soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula (I) or the combination or the composition comprising at least one compound of formula (I).

The method of treatment according to the invention can also be used in the field of protecting stored products or harvest against attack of fungi and microorganisms. According to the present invention, the term "stored products" is understood to denote natural substances of plant or animal origin and their processed forms, which have been taken from the natural life cycle and for which long-term protection is desired. Stored products of crop plant origin, such as plants or parts thereof, for example stalks, leafs, tubers, seeds, fruits or grains, can be protected in the freshly harvested state or in processed form, such as pre-dried, moistened, comminuted, ground, pressed or roasted, which process is also known as post-harvest treatment. Also falling under the definition of stored products is timber, whether in the form of crude timber, such as construction timber, electricity pylons and barriers, or in the form of finished articles, such as furniture or objects made from wood. Stored products of animal origin are hides, leather, furs, hairs and the like. The combination according the present invention can prevent disadvantageous effects such as decay, discoloration or mold. Preferably "stored products" is understood to denote natural substances of plant origin and their processed forms, more preferably fruits and their processed forms, such as pomes, stone fruits, soft fruits and citrus fruits and their processed forms.

The compound of formula (I), the combination and the composition thereof, respectively, may be used for improving the health of a plant. The invention also relates to a method for improving plant health by treating a plant, its propagation material and/or the locus where the plant is growing or is to grow with an effective amount of compound I and the composition thereof, respectively.

The term "plant health" is to be understood to denote a condition of the plant and/or its products which is determined by several indicators alone or in combination with each other such as yield (e. g. increased biomass and/or increased content of valuable ingredients), plant vigor (e. g. improved plant growth and/or greener leaves ("greening effect")), quality (e. g. improved content or composition of certain ingredients) and tolerance to abiotic and/or biotic stress. The above identified indicators for the health condition of a plant may be interdependent or may result from each other.

The compound of formula (I) can be present in different crystal modifications or polymorphs whose biological activity may differ. They are likewise subject matter of the present invention.

The compound of formula (I) are employed as such or in the form of composition for treating the fungi or the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to be
5 protected from fungal attack with a fungicidally effective amount of the active substances. The application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms by the fungi.

Plant propagation materials may be treated with the compound of formula (I), the combination and the composition thereof protectively either at or before planting or transplanting.

10 The invention also relates to agrochemical composition comprising an auxiliary and at least one compound of formula (I).

An agrochemical composition comprises a fungicidally effective amount of a compound of formula (I). The term "effective amount" denotes an amount of the composition or of the compound of formula (I), which is sufficient for controlling harmful fungi on cultivated plants or in the protection
15 of materials and which does not result in a substantial damage to the treated plants. Such an amount can vary in a broad range and is dependent on various factors, such as the fungal species to be controlled, the treated cultivated plant or material, the climatic conditions and the specific compound of formula (I) used.

The compound of formula (I), their -oxides, metal complexes, isomers, polymorphs or the
20 agriculturally acceptable salts thereof can be converted into customary types of agrochemical compositions, e. g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e. g. SC, OD, FS), emulsifiable concentrates (e. g. EC), emulsions (e. g. EW, EO, ES, ME), capsules (e. g. CS, ZC), pastes, pastilles, wettable powders or dusts (e. g. WP, SP, WS, DP, DS), pressings (e. g. BR, TB, DT),
25 granules (e. g. WG, SG, GR, FG, GG, MG), insecticidal articles (e. g. LN), as well as gel Formulations for the treatment of plant propagation materials such as seeds (e. g. GF). These and further compositions types are defined in the "Catalogue of pesticide Formulation types and international coding system", Technical Monograph No. 2, 6th Ed. May 2008, CropLife International.

The compositions are prepared in a known manner, such as described by Mollet and Grubemann,
30 Formulation technology, Wiley VCH, Weinheim, 2001; or Knowles, New developments in crop protection product Formulation, Agrow Reports DS243, T&F Informa, London, 2005.

Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion

agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders.

Suitable solvents and liquid carriers are water and organic solvents, such as mineral oil fractions of medium to high boiling point, e. g. kerosene, diesel oil; oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, e. g. toluene, paraffin, tetrahydronaphthalene, alkylated naphthalenes; alcohols, e. g. ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; glycols; DMSO; ketones, e. g. cyclohexanone; esters, e. g. lactates, carbonates, fatty acid esters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, e. g. N-methyl pyrrolidone, fatty acid dimethyl amides; and mixtures thereof. Suitable solid carriers or fillers are mineral earths, e. g. silicates, silica gels, talc, kaolins, limestone, lime, chalk, clays, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide; polysaccharides, e. g. cellulose, starch; fertilizers, e. g. ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas; products of vegetable origin, e. g. cereal meal, tree bark meal, wood meal, nutshell meal, and mixtures thereof.

Suitable surfactants are surface-active compounds, such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes, and mixtures thereof. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Examples of surfactants are listed in McCutcheon's, Vol.1: Emulsifiers & Detergents, McCutcheon's Directories, Glen Rock, USA, 2008 (International Ed. or North American Ed.).

Suitable anionic surfactants are alkali, alkaline earth or ammonium salts of sulfonates, sulfates, phosphates, carboxylates, and mixtures thereof. Examples of sulfonates are alkylaryl sulfonates, diphenyl sulfonates, alpha-olefin sulfonates, lignin sulfonates, sulfonates of fatty acids and oils, sulfonates of ethoxylated alkylphenols, sulfonates of alkoxyated arylphenols, sulfonates of condensed naphthalenes, sulfonates of dodecyl-and tridecylbenzenes, sulfonates of naphthalenes and alkyl naphthalenes, sulfosuccinates or sulfosuccinamates. Examples of sulfates are sulfates of fatty acids and oils, of ethoxylated alkylphenols, of alcohols, of ethoxylated alcohols, or of fatty acid esters. Examples of phosphates are phosphate esters. Examples of carboxylates are alkyl carboxylates, and carboxylated alcohol or alkylphenol ethoxylates.

Suitable nonionic surfactants are alkoxyates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxyates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters which have been alkoxyated with 1 to 50 equivalents. Ethylene oxide and/or propylene oxide may be employed for the alkoxylation, preferably ethylene oxide.

Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerol esters or monoglycerides. Examples of sugar-based surfactants are sorbitans, ethoxylated sorbitans, sucrose and glucose esters or alkylpolyglucosides.

Examples of polymeric surfactants are homo- or copolymers of vinyl pyrrolidone, vinyl alcohols, or vinyl acetate.

Suitable cationic surfactants are quaternary surfactants, for example quaternary ammonium compounds with one or two hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkylbetains and imidazolines. Suitable block polymers are block polymers of the A-B or A-B-A type comprising blocks of polyethylene oxide and polypropylene oxide, or of the A-B-C type comprising alkanol, polyethylene oxide and polypropylene oxide. Suitable polyelectrolytes are polyacids or polybases. Examples of polyacids are alkali salts of polyacrylic acid or polyacid comb polymers. Examples of polybases are polyvinyl amines or polyethylene amines.

5 Suitable adjuvants are compounds, which have a negligible or even no pesticidal activity themselves, and which improve the biological performance of the compound of formula (I) on the target. Examples are surfactants, mineral or vegetable oils, and other auxiliaries. Further examples are listed by Knowles, Adjuvants and additives, Agrow Reports DS256, T&F Informa UK, 2006, chapter 5.

10 Suitable thickeners are polysaccharides (e. g. xanthan gum, carboxymethyl cellulose), inorganic clays (organically modified or unmodified), polycarboxylates, and silicates.

Suitable bactericides are bronopol and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones.

Suitable anti-freezing agents are ethylene glycol, propylene glycol, urea and glycerin.

Suitable anti-foaming agents are silicones, long chain alcohols, and salts of fatty acids.

20 Suitable colorants (e. g. in red, blue, or green) are pigments of low water solubility and water-soluble dyes. Examples are inorganic colorants (e. g. iron oxide, titan oxide, iron hexacyanoferrate) and organic colorants (e. g. alizarin-, azo- and phthalocyanine colorants).

Suitable tackifiers or binders are polyvinyl pyrrolidones, polyvinyl acetates, polyvinyl alcohols, polyacrylates, biological or synthetic waxes, and cellulose ethers.

25 Examples for composition types and their preparation are:

i) Water-soluble concentrates (SL, LS)

10-60 wt% of a compound of formula (I) and 5-15 wt% wetting agent (e. g. alcohol alkoxyates) are dissolved in water and/or in a water-soluble solvent (e. g. alcohols) ad 100 wt%. The active substance dissolves upon dilution with water.

30 ii) Dispersible concentrates (DC)

5-25 wt% of a compound of formula (I) and 1-10 wt% dispersant (e. g. polyvinyl pyrrolidone) are dissolved in organic solvent (e. g. cyclohexanone) ad 100 wt%. Dilution with water gives a dispersion.

iii) Emulsifiable concentrates (EC)

15-70 wt% of a compound of formula (I) and 5-10 wt% emulsifiers (e. g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in water-insoluble organic solvent (e. g. aromatic hydrocarbon) ad 100 wt%. Dilution with water gives an emulsion.

5 iv) Emulsions (EW, EO, ES)

5-40 wt% of a compound of formula (I) and 1-10 wt% emulsifiers (e. g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in 20-40 wt% water-insoluble organic solvent (e. g. aromatic hydrocarbon). This mixture is introduced into water ad 100 wt% by means of an emulsifying machine and made into a homogeneous emulsion. Dilution with water gives
10 an emulsion.

v) Suspensions (SC, OD, FS)

In an agitated ball mill, 20-60 wt% of a compound of formula (I) are comminuted with addition of 2-10 wt% dispersants and wetting agents (e. g. sodium lignosulfonate and alcohol ethoxylate), 0.1-2 wt% thickener (e. g. xanthan gum) and water ad 100 wt% to give a fine active substance suspension.
15 Dilution with water gives a stable suspension of the active substance. For FS type composition up to 40 wt% binder (e. g. polyvinyl alcohol) is added.

vi) Water-dispersible granules and water-soluble granules (WG, SG)

50-80 wt% of a compound of formula (I) are ground finely with addition of dispersants and wetting agents (e. g. sodium lignosulfonate and alcohol ethoxylate) ad 100 wt% and prepared as water-
20 dispersible or water-soluble granules by means of technical appliances (e. g. extrusion, spray tower, fluidized bed). Dilution with water gives a stable dispersion or solution of the active substance.

Water-dispersible powders and water-soluble powders (WP, SP, WS) 50-80 wt% of a compound of formula (I) are ground in a rotor-stator mill with addition of 1-5 wt% dispersants (e. g. sodium lignosulfonate), 1-3 wt% wetting agents (e. g. alcohol ethoxylate) and solid carrier (e. g. silica gel) ad
25 100 wt%. Dilution with water gives a stable dispersion or solution of the active substance.

viii) Gel (GW, GF)

In an agitated ball mill, 5-25 wt% of a compound of formula (I) are comminuted with addition of 3-10 wt% dispersants (e. g. sodium lignosulfonate), 1-5 wt% thickener (e. g. carboxymethyl cellulose) and water ad 100 wt% to give a fine suspension of the active substance. Dilution with water gives a stable
30 suspension of the active substance.

ix) Microemulsion (ME)

5-20 wt% of a compound of formula (I) are added to 5-30 wt% organic solvent blend (e. g. fatty acid dimethyl amide and cyclohexanone), 10-25 wt% surfactant blend (e. g. alcohol ethoxylate and

arylphenol ethoxylate), and water ad 100 %. This mixture is stirred for 1 h to produce spontaneously a thermodynamically stable microemulsion.

x) Microcapsules (CS)

5 An oil phase comprising 5-50 wt% of a compound of formula (I), 0-40 wt% water insoluble organic solvent

(e. g. aromatic hydrocarbon), 2-15 wt% acrylic monomers (e. g. methylmethacrylate, methacrylic acid and a di- or triacrylate) are dispersed into an aqueous solution of a protective colloid (e. g. polyvinyl alcohol). Radical polymerization results in the formation of poly(meth)acrylate microcapsules. Alternatively, an oil phase comprising 5-50 wt% of a compound of formula (I) according to the
10 invention, 0-40 wt% water insoluble organic solvent (e. g. aromatic hydrocarbon), and an isocyanate monomer (e. g. diphenylmethene-4,4'-diisocyanatae) are dispersed into an aqueous solution of a protective colloid (e. g. polyvinyl alcohol). The addition of a polyamine (e. g. hexamethylenediamine) results in the formation of polyurea microcapsules. The monomers amount to 1-10 wt%. The wt% relate to the total CS composition.

15 xi) Dustable powders (DP, DS)

1-10 wt% of a compound of formula (I) are ground finely and mixed intimately with solid carrier (e. g. finely divided kaolin) ad 100 wt%.

xii) Granules (GR, FG)

0.5-30 wt% of a compound of formula (I) are ground finely and associated with solid carrier (e. g. silicate) ad 100 wt%. Granulation is achieved by extrusion, spray-drying or fluidized bed.
20

xiii) Ultra-low volume liquids (UL)

1-50 wt% of a compound of formula (I) are dissolved in organic solvent (e. g. aromatic hydrocarbon) ad 100 wt%.

The compositions types i) to xiii) may optionally comprise further auxiliaries, such as 0.1-1 wt%
25 bactericides, 5-15 wt% anti-freezing agents, 0.1-1 wt% anti-foaming agents, and 0.1-1 wt% colorants.

The agrochemical compositions generally comprise between 0.01 and 95%, preferably between 0.1 and 90%, and in particular between 0.5 and 75%, by weight of active ingredient (ai). The active ingredients (ai) are employed in a purity of from 90% to 100%, preferably from 95% to 100% (according to NMR spectrum).

30 For the purposes of treatment of plant propagation materials, particularly seeds, solutions for seed treatment (LS), Suspoemulsions (SE), flowable concentrates (FS), powders for dry treatment (DS), water-dispersible powders for slurry treatment (WS), water-soluble powders (SS), emulsions (ES), emulsifiable concentrates (EC), and gels (GF) are usually employed. The compositions in question

give, after two-to-tenfold dilution, active substance concentrations of from 0.01 to 60% by weight, preferably from 0.1 to 40%, in the ready-to-use preparations.

Application can be carried out before or during sowing. Methods for applying the compound of formula (I), the combination and the composition thereof, respectively, onto plant propagation material, especially seeds, include dressing, coating, pelleting, dusting, and soaking as well as in-furrow application methods. Preferably, the compound of formula (I), the combination and the composition thereof, respectively, are applied on to the plant propagation material by a method such that germination is not induced, e. g. by seed dressing, pelleting, coating and dusting.

When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more preferably from 0.05 to 1.0 kg per ha, and in particular from 0.1 to 1.0 kg per ha.

In the treatment of plant propagation materials such as seeds, e. g. by dusting, coating or drenching seeds, amounts of active substance from 0.1 to 1000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g and most preferably from 5 to 100 g, per 100 kg of plant propagation material (preferably seeds) are generally required.

When used in the protection of materials or stored products, the amount of active substance applied depends on the kind of application area and on the desired effect. Amounts customarily applied in the protection of materials are 0.001 g to 2 kg, preferably 0.005 g to 1 kg, of active substance per cubic meter of treated material.

Various types of oils, wetters, adjuvants, fertilizer, or micronutrients, and further pesticides (e. g. herbicides, insecticides, fungicides, growth regulators, safeners, biopesticides) may be added to the active substances or the compositions comprising them as premix or, if appropriate not until immediately prior to use (tank mix). These agents can be mixed with the composition according to the invention in a weight ratio of 1:100 to 100:1, preferably 1:20 to 20:1.

A pesticide is generally a chemical or biological agent (such as pesticidally active ingredient, compound, composition, virus, bacterium, antimicrobial or disinfectant) that through its effect deters, incapacitates, kills or otherwise discourages pests. Target pests can include insects, plant pathogens, weeds, mollusks, birds, mammals, fish, nematodes (roundworms), and microbes that destroy property, cause nuisance, spread disease or are vectors for disease. The term "pesticide" includes also plant growth regulators that alter the expected growth, flowering, or reproduction rate of plants; defoliant that cause leaves or other foliage to drop from a plant, usually to facilitate harvest; desiccants that promote drying of living tissues, such as unwanted plant tops; plant activators that activate plant physiology for defense of/against certain pests; safeners that reduce unwanted herbicidal action of pesticides on crop plants; and plant growth promoters that affect plant physiology e.g. to increase plant growth, biomass, yield or any other quality parameter of the harvestable goods of a crop plant.

The user applies the composition according to the invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and/or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters, preferably 50 to 400 liters, of the ready-to-use spray liquor are applied per hectare of agricultural useful area.

According to one embodiment, individual components of the composition according to the invention such as parts of a kit or parts of a binary or ternary mixture may be mixed by the user himself in a spray tank or any other kind of vessel used for applications (e. g. seed treater drums, seed pelleting machinery, knapsack sprayer) and further auxiliaries may be added, if appropriate.

Consequently, one embodiment of the invention is a kit for preparing a usable pesticidal composition, the kit comprising a) a composition comprising component 1) as defined herein and at least one auxiliary; and b) a composition comprising component 2) as defined herein and at least one auxiliary; and optionally c) a composition comprising at least one auxiliary and optionally a further active component 3) as defined herein.

The compound of formula (I), the combination and the composition thereof comprising them in the use as fungicides with other fungicides may result in an expansion of the fungicidal spectrum of activity being obtained or in a prevention of fungicide resistance development. Furthermore, in many cases, extraordinary effects are obtained.

In one embodiment, the present invention provides a combination comprising at least one compound of formula (I) and at least one further pesticidally active substance selected from the group of fungicides, insecticides, nematocides, acaricides, biopesticides, herbicides, safeners, plant growth regulators, antibiotics, fertilizers and nutrients. The pesticidally active substances reported in WO2015185485 pages 36-43 and WO2017093019 pages 42-56 can be used in conjunction with which the compound of formula (I).

The active substances referred to as component 2, their preparation and their activity e. g. against harmful fungi is known (cf.: <http://www.alanwood.net/pesticides/>); these substances are commercially available. The compounds described by IUPAC nomenclature, their preparation and their pesticidal activity are also known (cf. Can. J. Plant Sci. 48(6), 587-94, 1968; EP141317; EP152031; EP226917; EP243970; EP256503; EP428941 ; EP532022; EP1028125; EP1035122; EP1201648; EP1122244, JP2002316902; DE19650197; DE10021412; DE102005009458; US3296272; US3325503; WO9846608; WO9914187; WO9924413; WO9927783; WO0029404; WO0046148; WO0065913; WO0154501 ; WO 0156358; WO0222583; WO0240431; WO0310149; WO0311853; WO0314103; WO0316286; WO0353145; WO0361388; WO0366609; WO0374491; WO0449804; WO0483193; WO05120234; WO05123689; WO05123690; WO0563721; WO0587772; WO0587773;

WO0615866; WO0687325; WO0687343; WO0782098; WO0790624; WO11028657; WO2012168188; WO2007006670; WO201177514; WO13047749; WO10069882; WO13047441; WO0316303; WO0990181; WO13007767; WO1310862; WO13127704; WO13024009; WO13024010; WO13047441; WO13162072; WO13092224 and WO11135833.

- 5 The present invention furthermore relates to agrochemical mixtures comprising at least one compound of formula (I) (component 1) and at least one further active substance useful for plant protection.

By applying the compound of formula (I) together with at least one pesticidally active compound an additional effect can be obtained.

- 10 This can be obtained by applying the compound of formula (I) and at least one further pesticidally active substance simultaneously, either jointly (e. g. as tank-mix) or separately, or in succession, wherein the time interval between the individual applications is selected to ensure that the active substance applied first still occurs at the site of action in a sufficient amount at the time of application of the further pesticidally active substance(s). The order of application is not essential for working of the present invention.

- 15 When applying the compound of formula (I) and a pesticidally active substance sequentially the time between both applications may vary e. g. between 2 hours to 7 days. Also a broader range is possible ranging from 0.25 hour to 30 days, preferably from 0.5 hour to 14 days, particularly from 1 hour to 7 days or from 1.5 hours to 5 days, even more preferred from 2 hours to 1 day. In the binary mixtures and the composition according to the invention the weight ratio of the component 1) and the
20 component 2) generally depends from the properties of the active components used, usually it is in the range of 1:1000 to 1000:1, often in the range of 1:100 to 100:1, regularly in the range of 1:50 to 50:1, preferably in the range of 1:20 to 20:1, more preferably in the range of 1:10 to 10:1, even more preferably in the range of 1:4 to 4:1 and in particular in the range of 1:2 to 2:1.

- 25 According to a further embodiment of the binary mixtures and the composition thereof, the weight ratio of the component 1) and the component 2) usually is in the range of 1000:1 to 1:1000, often in the range of 100:1 to 1:100, regularly in the range of 50:1 to 1:50, preferably in the range of 20:1 to 1:20, more preferably in the range of 10:1 to 1:10, even more preferably in the range of 4:1 to 1:4 and in particular in the range of 2:1 to 1:2.

- 30 In the ternary mixtures, i.e. the composition according to the invention comprising the component 1) and component 2) and a compound III (component 3), the weight ratio of component 1) and component 2) depends from the properties of the active substances used, usually it is in the range of 1:100 to 100:1, regularly in the range of 1:50 to 50:1, preferably in the range of 1:20 to 20:1, more preferably in the range of 1:10 to 10:1 and in particular in the range of 1:4 to 4:1, and the weight ratio of component 1) and component 3) usually it is in the range of 1:100 to 100:1, regularly in the range

of 1:50 to 50:1, preferably in the range of 1:20 to 20:1, more preferably in the range of 1:10 to 10:1 and in particular in the range of 1:4 to 4:1.

Any further active components are, if desired, added in a ratio of 20:1 to 1:20 to the component 1).

These ratios are also suitable for inventive mixtures applied by seed treatment.

- 5 The present invention also relates to a process for preparing the compound of the present invention. The process for preparing the compound of the present invention is described in the experimental section in more detail.

The invention disclosed in the present disclosure shall now be elaborated with the help of non-limiting schemes and examples.

10 CHEMISTRY EXAMPLES:

Example 1:- Preparation of N-(3-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (compound no. 1)

Step 1:- Ethyl 7-cyanoimidazo[1,2-a]pyridine-2-carboxylate

- 15 To a stirred solution of 2-aminoisonicotinonitrile (0.5 g, 4.2 mmol) in tetrahydrofuran (0.5 mL), ethyl bromopyruvate (0.77 mL, 6.1 mmol) was added and stirred for 24 h at 25 °C. Further, to this reaction mixture, acetic acid (1 mL, 17.5 mmol) was added and refluxed for 16 h. The volatiles were removed under reduced pressure, hexane (10 mL) was added to the obtained residue and stirred for 30 min. The precipitate was filtered, washed with hexane (5 mL) and dried under reduced pressure to obtain ethyl 7-cyanoimidazo[1,2-a]pyridine-2-carboxylate (1 g, 58% yield).

- 20 **Step 2:- Ethyl 7-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylate**

To a stirred suspension of ethyl 7-cyanoimidazo[1,2-a]pyridine-2-carboxylate (6.2 g, 29 mmol) in ethanol (100 mL), hydroxylamine (3.64 mL, 58 mmol) was added at 25 °C and the resulting reaction mixture was stirred at 40 °C for 16 h. The volatiles were removed under reduced pressure to obtain crude ethyl 7-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylate (7 g).

- 25 **Step 3:- Ethyl 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate**

- To a stirred suspension of ethyl 7-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylate (6 g, 24.2 mmol) in tetrahydrofuran (60 mL), trifluoroacetic anhydride (13.7 mL, 97 mmol) was added at 0 °C. The resulting reaction mixture was stirred at 25 °C for 24 h. The reaction mixture was quenched by pouring into saturated aqueous sodium bicarbonate solution (100 mL) at 0-5 °C. The product was extracted into ethyl acetate (150 mL). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain a crude product. Hexane (60 mL) was added to this crude product and the mixture was stirred for 30 min. The obtained slurry was filtered, washed with hexane (30 mL) and dried under reduced pressure to obtain
- 30

ethyl 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate (6.5 g, 82% yield).

Step 4:- N-(3-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide

5 To a stirred solution of ethyl 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate (0.3 g, 0.9 mmol) in toluene (3 mL), *m*-anisidine (0.2 mL, 1.8 mmol) and trimethylaluminium (2M in toluene) (1.0 mL, 2.0 mmol) were added at 0-5 °C and stirred at 25 °C till effervescence ceases. The resulting reaction mixture was stirred at 65 °C for 16 h. The reaction mixture was cooled to 25 °C and poured into 10% aqueous acetic acid solution (10 mL). The product
10 was extracted with ethyl acetate (30 mL). The ethyl acetate layer was washed with aqueous sodium bicarbonate solution (10 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel to obtain N-(3-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (180 mg, 49% yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 10.35 (s, 1H), 8.84
15 (dd, 1H), 8.73 (d, 1H), 8.27-8.26 (m, 1H), 7.62-7.59(m, 2H), 7.52-7.49 (m, 1H), 7.25 (t, 1H), 6.68 (dd, 1H), 3.76 (s, 3H); LCMS (M+H): 404.15.

Table 1: The following compounds were prepared by the procedure analogous to that of the compound no. 1

Compd no.	IUPAC name	Analytical data
2	N-(4-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.30 (s, 1H), 8.83 (dd, 1H), 8.70 (d, 1H), 8.26 (t, 1H), 7.81-7.78(m, 2H), 7.60 (dd, 1H), 6.94-6.91(m, 2H), 3.74 (s, 3H); LCMS (M+H): 404.1
3	N-(<i>p</i> -tolyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.29 (s, 1H), 8.83 (dd, 1H), 8.71 (d, 1H), 8.27-8.26(m, 1H), 7.79-7.76(m, 2H), 7.61 (dd, 1H), 7.15 (d., 2H), 2.28 (s, 3H); LCMS (M+H): 388.1
4	N-(3-fluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.059 (s, 1H), 8.88 (dd, 1H), 8.74 (d, 1H), 8.305 (t, 1H), 7.876 (dt, 1H), 7.62-7.59 (dd, 1H), 7.41-7.35 (m, 1H), 7.41-7.35 (m, 1H), 7.15-7.17 (td, 1H); LCMS (M+H): 392.05
5	N-(2,4-difluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.059 (s, 1H), 8.84 (dd, 1H), 8.744, 1H), 8.30(t, 1H), 7.86 (td, 1H), 7.62 (dd, 1H), 7.43-7.37 (m, 1H), 7.17-

	carboxamide	7.15(m, 1H); LCMS (M+H): 410.05
6	N-(4-chlorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.60 (s, 1H), 8.83 (dd, 1H), 8.75(d, 1H), 8.26 (t, 1H), 7.96-7.94(m, 2H), 7.61 (dd, 1H), 7.42-7.39(m, 2H); LCMS (M+H): 408.05
7	N-(2-fluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.95 (s, 1H), 8.83 (dd, 1H), 8.76 (d, 1H), 8.33 (t, 1H), 8.02-7.96 (m, 1H), 7.61 (dd, 1H), 7.35-7.30 (m, 1H), 7.25-7.201 (m, 2H); LCMS (M+H): 392.05
8	7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.23 (t, 1H), 8.80 (dd, 1H), 8.60 (d, 1H), 8.22 (t, 1H), 7.68 (d, 2H), 7.58-7.53 (m, 3H), 4.56 (d, 2H); LCMS (M+H): 456.15
9	N-(pyridin-3-yl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.73 (s, 1H), 9.07-9.06 (m, 1H), 8.84 (dd, 1H), 8.77 (d, 1H), 8.32-8.27 (m, 3H), 7.62 (dd, 1H), 7.41-7.37 (m, 1H); LCMS (M+H): 375.1
10	N-benzyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.06 (t, 1H), 8.79 (d, 1H), 8.59 (s, 1H), 8.22 (s, 1H), 7.57 (dd, 1H), 7.35-7.29 (m, 4H), 7.24-7.21 (m, 1H), 4.48 (d, 2H); LCMS (M+H): 388.15
11	N-(pyridin-4-yl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.85 (s, 1H), 8.84 (dd, 1H), 8.80 (d, 1H), 8.47 (dd, 2H), 8.27 (t, 1H), 7.94-7.92 (m, 2H), 7.62 (dd, 1H); LCMS (M+H): 375.1
12	N-(4-chlorophenyl)-N-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.70 (d, 1H), 8.23 (s, 1H), 8.05 (s, 1H), 7.48 (dd, 1H), 7.39-7.37(m, 2H), 7.295-7.273 (m, 2H), 3.46 (s, 3H); LCMS (M+H): 422.1
13	N-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.78 (dd, 1H), 8.55 (d, 1H), 8.46 (q, 1H), 8.19 (t, 1H), 7.55 (dd, 1H), 2.80 (d, 3H); LCMS (M+H): 312.05
14	N-methyl-N-(2-phenoxyethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) @ 80 degree celcius δ 8.74 (dd, 1H), 8.45 (s, 1H), 8.23 (s, 1H), 7.50 (dd, 1H), 7.23 (t, 2H), 6.93-6.89 (m, 3H), 4.27 (t, 2H); LCMS (M+H): 432.1

15	N-(4-cyanophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 9.48 (s, 1H), 8.47 (s, 1H), 8.36 (s, 1H), 8.33 (dd, 1H), 7.93-7.91(m, 2H), 7.70-7.68 (m, 2H), 7.63 (dd, 1H); LCMS (M+H): 399.05
33	azetidin-1-yl(7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 8.76 (dd, 1H), 8.56 (d, 1H), 8.24 (t, 1H), 7.55 (dd, 1H), 4.65 (t, 2H), 4.07 (t, 2H), 2.35-2.27 (m, 2H); LCMS (M+H): 338.15.
34	N-(2-methoxyethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 8.79 (d, 1H), 8.57 (s, 1H), 8.36 (s, 1H), 8.23 (s, 1H), 7.56 (dd, 1H), 3.47-3.44 (m, 4H), 3.27 (s, 3H); LCMS (M+H): 355.70.
35	N-isobutyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 8.78 (dd, 1H), 8.56 (s, 1H), 8.46 (t, 1H), 8.22 (d, 1H), 7.56 (dd, 1H), 3.11 (t, 2H), 1.91-1.84 (m, 1H), 0.87 (d, 6H); LCMS (M+H): 353.70.
36	N-neopentyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 8.79 (dd, 1H), 8.57 (s, 1H), 8.25-8.22 (m, 2H), 7.56 (dd, 1H), 3.14 (d, 2H), 0.88 (d, 9H); LCMS (M+H): 368.30.
37	N-isopentyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 8.79-8.76 (m, 1H), 8.54 (d, 1H), 8.44 (t, 1H), 8.20 (t, 1H), 7.59-7.54 (m, 1H), 3.33-3.28 (m, 2H), 1.59 (td, 1H), 1.43 (q, 2H), 0.90 (d, 6H); LCMS (M+H): 368.05
38	N-(4-chlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.13 (s, 1H), 8.79 (dd, 1H), 8.59 (s, 1H), 8.21 (s, 1H), 7.57 (dd, 1H), 7.36 (dd, 4H), 4.46 (d, 2H); LCMS (M+H): 421.85.
39	N-(4-methoxybenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 8.95 (t, 1H), 8.79 (dd, 1H), 8.58 (d, 1H), 8.21 (t, 1H), 7.56 (dd, 1H), 7.26 (d, 2H), 6.87 (dd, 2H), 4.40 (d, 2H), 3.71 (s, 3H); LCMS (M+H): 418.05.
40	N-(3-chlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.17 (t, 1H), 8.79 (dd, 1H), 8.60 (d, 1H), 8.22 (t, 1H), 7.58-7.48 (m, 1H), 7.38-7.28 (m, 4H), 4.47 (d, 2H); LCMS (M+H): 421.85.
41	N-(3-methoxybenzyl)-7-(5-	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.03 (t, 1H),

	(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	8.79 (dd, 1H), 8.59 (d, 1H), 8.22 (t, 1H), 7.56 (dd, 1H), 7.24-7.20 (m, 1H), 6.91-6.78 (m, 3H), 4.45 (d, 2H), 3.72 (s, 3H); LCMS (M+H): 417.95.
42	N-(2-fluorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.03 (t, 1H), 8.79 (dd, 1H), 8.60 (d, 1H), 8.23 (t, 1H), 7.57 (dd, 1H), 7.38-7.13 (m, 4H), 4.54 (d, 2H); LCMS (M+H): 406.15.
43	N-(4-(dimethylamino)benzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.82-8.78 (m, 2H), 8.57 (d, 1H), 8.20 (s, 1H), 7.55 (dd, 1H), 7.17 (d, 2H), 6.67 (d, 2H), 4.35 (d, 2H), 2.84 (s, 6H); LCMS (M+H): 430.95.
44	N-(3,4-dichlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.21 (t, 1H), 8.79 (dd, 1H), 8.60 (d, 1H), 8.22 (t, 1H), 7.59-7.56 (m, 3H), 7.33 (dd, 1H), 4.46 (d, 2H); LCMS (M+H): 455.85.

Example 2: Preparation of N-(3-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (compound no. 16)

Step 1:- Ethyl 6-cyanoimidazo[1,2-a]pyridine-3-carboxylate

- 5 To a stirred solution of 6-aminonicotinonitrile (6 g, 50.4 mmol) in tetrahydrofuran (80 mL), ethyl bromopyruvate (7.0 mL, 55.4 mmol) was added drop wise at 0-5 °C. The resulting reaction mixture was stirred at 25 °C for 24 h. The volatiles were removed under reduced pressure. To the obtained residue, ethanol (80 mL) and acetic acid (23 mL, 403 mmol) were added at 25 °C and the resulting reaction mixture was stirred at 80 °C for 18 h. The reaction mixture was cooled to 0-5 °C and diluted
- 10 with 150 mL of ethyl acetate. The aqueous saturated sodium bicarbonate solution was added to the reaction mixture until the pH became basic. The ethyl acetate layer was isolated, washed with water (50 mL), brine solution (50 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain ethyl 6-cyanoimidazo[1,2-a]pyridine-3-carboxylate (9 g, 83% yield).

Step 2:- Methyl-6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylate

- 15 To a stirred solution of ethyl 6-cyanoimidazo[1,2-a]pyridine-2-carboxylate hydrobromide (1 g, 3.38 mmol) in a mixture of methanol (7 mL) and water (3 mL), hydroxylamine hydrochloride (0.35 g, 5.0 mmol) and sodium bicarbonate (0.9 g, 10.1 mmol) were added at 15 °C. The resulting reaction mixture was stirred for 24 h at 25 °C. The volatiles were removed under reduced pressure to obtain crude product. Water (30 mL) was added to the crude product and stirred for 1h at 0-5 °C. The
- 20 resulting slurry was filtered, washed with water (10 mL) and dried under vacuum. The solid

compound obtained was stirred with 10 mL of acetone at 0-5 °C for 15 min, filtered, washed with hexane (10 mL) and dried under vacuum to obtain ethyl 6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylate (0.75 g, 89% yield).

Step 3:- Ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate

5 To a stirred suspension of ethyl-6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylate (1.3 g, 5.2 mmol) in tetrahydrofuran (20 mL), trifluoroacetic anhydride (2.2 mL, 15.7 mmol) was added at 0-5 °C. The resulting reaction mixture was stirred at 25 °C for 24 h. The reaction mixture was diluted with hexanes (20 mL), filtered and dried under vacuum to obtain the solid. The solid was diluted with dichloromethane (30 mL), cooled to 0-5 °C and basified with aqueous saturated sodium
10 bicarbonate solution. The dichloromethane layer was isolated, washed with water (10 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate (1.5g, 88% yield).

Step 4:- N-(3-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide

15 To a stirred solution of ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate (250 mg, 0.7 mmol) in toluene (2.5 mL), *m*-anisidine (94 mg, 0.7 mmol) and trimethylaluminium (0.8 mL, 1.5 mmol) were added at 0-5 °C. The resulting reaction mixture was stirred at 70 °C for 24 h. The reaction mixture was cooled to 25 °C and poured into 10 % aqueous acetic acid solution (10 mL) at 0-5 °C. The product was extracted with ethyl acetate (30 mL). The
20 ethyl acetate layer was washed with aqueous sodium bicarbonate solution (10 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel to obtain N-(3-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide (184 mg, 55% yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 9.59 (q, 1H), 8.71 (d, 1H), 7.91 (dd, 1H), 7.85-
25 7.87 (m, 1H), 7.60 (t, 1H), 7.52-7.50 (m, 1H), 7.24 (t, 1H), 6.69 (dd, 1H), 3.75 (s, 3H); LCMS (M+H): 404.15.

Table 2: The following compounds were prepared by the procedure analogous to that of the compound no. 16

Compd no.	IUPAC name	Analytical Data
17	N-(2,4-difluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.04 (s, 1H), 9.57 (t, 1H), 8.72 (s, 1H), 7.93-7.82 (m, 3H), 7.41-7.35(m, 1H), 7.16-7.10(m, 1H); LCMS (M+H): 410.15
18	N-(4-chlorophenyl)-6-(5-	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.59 (s, 1H), 9.58 (q,

	(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H), 8.72 (d, 1H), 7.97-7.93(m, 2H), 7.92-7.89 (m,1H), 7.87-7.85(m, 1H), 7.42-7.38 (m, 2H); LCMS (M+H): 408.15
19	N-(p-tolyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.28 (s, 1H), 9.58 (s, 1H), 8.69 (s, 1H), 7.91-7.86 (m, 2H), 7.77 (d, 2H), 7.14 (d, 2H), 2.27 (s, 3H); LCMS (M+H): 388.15
20	N-(2-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.93 (s, 1H), 9.58 (t, 1H), 8.73 (s, 1H),8.03-7.98 (m, 1H), 7.92 (d, 2H), 7.35-7.30(m, 1H), 7.26-7.21(m, 2H); LCMS (M+H): 391.95
21	N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (q, 1H), 8.53 (d, 1H), 8.48-8.44(m, 1H), 7.85 (dd, 1H), 7.79-7.76 (m, 1H), 2.79 (d, 3H); LCMS (M+H): 312.15
22	N-(4-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.27 (s, 1H), 9.58 (s, 1H), 8.68 (s, 1H), 7.91-7.88(m, 1H), 7.86-7.84 (m,1H), 7.81-7.82(m,2H), 6.92 (d, 2H), 3.74 (s, 3H); LCMS (M+H): 403.8
23	N-benzyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (q, 1H), 9.05 (t, 1H), 8.57 (s, 1H), 7.87 (dd, 1H), 7.81-7.78 (m, 1H), 7.34-7.28(m, 4H), 7.24-7.20(m, 1H), 4.47 (d, 2H); LCMS (M+H): 388.15
24	N-(3-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.64 (s, 1H), 9.58 (q, 1H), 8.73 (s, 1H), 7.93-7.85 (m, 3H), 7.76-7.74 (m, 1H), 7.41-7.34 (m, 1H), 6.92 (td, 1H); LCMS (M+H): 392
25	N,N-dimethyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.52 (t, 1H), 8.49 (s, 1H), 7.85-7.80(m, 2H), 3.41 (s, 3H), 3.01 (s, 3H); LCMS (M+H): 326.15
26	N-(4-chloro-2-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.03 (s, 1H), 9.57 (t, 1H), 8.74 (s, 1H), 7.98-7.88 (m, 3H), 7.56 (dd, 1H), 7.35-7.32 (m, 1H); LCMS (M+H): 425.95
27	N-(4-cyanophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.90 (s, 1H), 9.59 (t, 1H), 8.77 (s, 1H), 8.15-8.13(m, 2H), 7.92 (dd, 1H), 7.88-

	3-yl)imidazo[1,2-a]pyridine-2-carboxamide	7.86(m,1H), 7.83-7.81 (m 2H); LCMS (M+H): 399
28	N-(2-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.76 (s,1H), 9.57 (t, 1H), 8.71 (d, 1H), 8.40-8.38 (m, 1H), 7.94-7.81 (m, 2H), 7.15-7.09 (m, 2H),7.01-6.94 (m, 1H), 3.95 (s, 3H); LCMS (M+H): 404.1
29	N-(pyridin-3-yl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.70 (s, 1H), 9.59 (t, 1H), 9.07 (d, 1H), 8.74 (d, 1H), 8.31-8.28 (m, 2H), 7.92 (dd, 1H), 7.87 (d, 1H), 7.38 (dd, 1H); LCMS (M+H): 374.8
30	N-(2,6-difluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.21(s, 1H), 9.57 (q, 1H), 8.70 (d, 1H), 7.92 (dd, 1H), 7.87-7.85 (m,1H), 7.44-7.36 (m, 1H), 7.22-7.16 (m, 2H); LCMS (M+H): 410.15
31	N-(3-fluorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.55 (q, 1H), 9.15 (t, 1H), 8.58 (s, 1H), 7.87 (dd, 1H), 7.80 (d, 1H), 7.38-7.32 (m, 1H), 7.17-7.11 (m, 2H), 7.07-7.03 (m, 1H), 4.48 (d, 2H); LCMS (M+H): 405.8
32	N-(pyridin-4-yl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 9.35 (s, 1H), 9.07 (q, 1H), 8.58 (dd, 2H), 8.37 (d, 1H), 7.98 (dd, 1H), 7.77 (d, 1H), 7.70 (dd, 2H); LCMS (M+H): 374.75
63	6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.55 (q, 1H), 9.23 (t, 1H), 8.58 (s, 1H), 7.88 (dd, 1H), 7.81 (d, 1H), 7.68 (d, 2H), 7.53 (d, 2H), 4.55 (d, 2H); LCMS (M+H): 456.05.
64	morpholino(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (s, 1H), 8.55 (s, 1H), 7.86-7.81 (m, 2H), 4.20 (s, 2H), 3.65 (s, 6H); LCMS (M+H): 367.70.
65	N-(2-methoxyethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (s, 1H), 8.55 (s, 1H), 8.36 (d, 1H), 7.86 (dd, 1H), 7.80 (d, 1H), 3.45 (d, 4H), 3.26 (s, 3H); LCMS (M+H): 355.80.
66	N-isobutyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (d, 1H), 8.54 (s, 1H), 8.45 (t, 1H), 7.86 (dd, 1H), 7.79 (d, 1H), 3.10 (t,

	a]pyridine-2-carboxamide	2H), 1.90-1.83 (m, 1H), 0.87 (d, 6H); LCMS (M+H): 353.80.
67	N-cyclopentyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (s, 1H), 8.53 (s, 1H), 8.24 (d, 1H), 7.86 (dd, 1H), 7.78 (d, 1H), 4.24 (q, 1H), 1.91-1.82 (m, 2H), 1.70-1.68 (m, 2H), 1.60-1.52 (m, 4H); LCMS (M+H): 365.80.
68	(3-methoxypyrrolidin-1-yl)(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (s, 1H), 8.58 (s, 1H), 7.84-7.81 (m, 2H), 4.23-4.17 (m, 1H), 4.05-3.88 (m, 2H), 3.65-3.48 (m, 2H), 3.24 (d, 3H), 2.11-1.89 (m, 2H); LCMS (M+H): 381.75.
69	azetidin-1-yl(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.52 (s, 1H), 8.56 (s, 1H), 7.85-7.79 (m, 2H), 4.64 (t, 2H), 4.06 (t, 2H), 2.34-2.26 (m, 2H); LCMS (M+H): 338.00.
70	N-(cyclopropylmethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (t, 1H), 8.54 (s, 1H), 8.51 (t, 1H), 7.86 (dd, 1H), 7.79 (d, 1H), 3.15 (t, 2H), 1.09-1.02 (m, 1H), 0.43-0.39 (m, 2H), 0.26-0.22 (m, 2H); LCMS (M+H): 351.75.
71	N-benzyl-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (s, 1H), 8.58 (d, 1H), 7.82 (d, 2H), 7.37-7.27 (m, 5H), 5.31 (s, 1H), 4.71 (s, 1H), 3.35 (s, 2H), 2.89 (s, 2H); LCMS (M+H): 401.80.
72	N-(1-phenylethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (s, 1H), 8.78 (d, 1H), 8.54 (s, 1H), 7.87 (dd, 1H), 7.81 (d, 1H), 7.42 (d, 2H), 7.31 (t, 2H), 7.21 (t, 1H), 5.21-5.14 (m, 1H), 1.51 (d, 3H); LCMS (M+H): 401.75.
73	N-(1-cyanocyclopropyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.55 (t, 2H), 8.64 (s, 1H), 7.88 (dd, 1H), 7.79 (d, 1H), 1.55-1.48 (m, 2H), 1.37-1.25 (m, 2H); LCMS (M+H): 362.65.
74	N-(methoxymethyl)-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.51 (d, 1H), 8.50 (d, 1H), 7.85-7.80 (m, 2H), 4.11 (t, 1H), 3.63-3.43 (m, 4H), 3.28 (s, 1H), 3.19 (s, 2H), 3.02 (s, 2H); LCMS (M+H): 370.30.
75	N-(3-chlorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (q, 1H), 9.17 (t, 1H), 8.58 (s, 1H), 7.89-7.79 (m, 2H), 7.37-7.27 (m, 4H),

	3-yl)imidazo[1,2-a]pyridine-2-carboxamide	4.47 (d, 2H); LCMS (M+H): 421.95.
76	N-(3-methoxybenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (d, 1H), 9.03 (s, 1H), 8.57 (d, 1H), 7.88-7.81 (m, 2H), 7.22 (t, 1H), 6.90 (s, 2H), 6.81 (s, 1H), 4.44 (d, 2H), 3.72 (s, 3H); LCMS (M+H): 418.20.
77	N-(4-chlorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.54 (q, 1H), 9.13 (t, 1H), 8.57 (d, 1H), 7.88-7.78 (m, 2H), 7.38-7.33 (m, 4H), 4.45 (d, 2H); LCMS (M+H): 421.90.
78	N-isobutyl-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.53 (t, 1H), 8.50 (d, 1H), 7.85 (d, 2H), 3.85 (d, 1H), 3.36 (d, 3H), 3.01 (s, 1H), 2.03 (dt, 1H), 0.92 (d, 3H), 0.80 (d, 3H); LCMS (M+H): 368.30.

Example 3:- Preparation of 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound no.50)

Step 1:- 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile

To a stirred solution of 2-aminoisonicotinonitrile (20 g, 168 mmol) in ethanol (100 mL), 1,3-dichloropropan-2-one (38.4 g, 302 mmol) was added and stirred for 16 h at 50 °C. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution (500 mL), and the resulting precipitate was filtered *via* a Buchner funnel, obtained solids were washed with ethanol (50 mL). The obtained residue was dried under reduced pressure to obtain 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (21 g, 110 mmol, 65% yield).

Step 2:- 2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-7-carboximidamide

To a stirred solution of 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (10.25 g, 53.5 mmol) in ethanol (50 mL), hydroxylamine solution 50 wt.% in water (6.56 mL, 107 mmol) was added at 25 °C. The resulting reaction mixture was stirred at 60 °C for 3 h and concentrated under reduced pressure to obtain 2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-7-carboximidamide (11.54 g, 53.5 mmol, 96% yield).

Step 3:- 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

To a stirred solution of 2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-7-carboximidamide (12.0 g, 53.4 mmol) in tetrahydrofuran (50 mL), trifluoroacetic anhydride (13.58 mL, 96 mmol) was added slowly at 0-5 °C under nitrogen atmosphere and stirred for 18 h at 25 °C. The resulting reaction mixture was concentrated under reduced pressure and obtained residue was dissolved in

dichloromethane (100 mL). The dichloromethane layer was washed with aqueous sodium bicarbonate solution (50 mL), followed by brine (50 mL) dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel using eluent 60% of ethyl acetate in hexane to obtain 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (12.56 g, 41.5 mmol, 78% yield).

Step 4:- 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

To a stirred solution of benzenethiol (0.473 g, 4.30 mmol) in acetonitrile (8 mL) under nitrogen atmosphere, potassium carbonate (0.91 g, 6.6 mmol) was added and the reaction mixture was stirred at 0 °C for 10 min. To the resulting reaction mixture, a solution of 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (1.0 g, 3.30 mmol) in *N,N*-dimethylformamide was added and the resulting reaction mixture was stirred for 3 h at 60 °C. After completion of the reaction, the reaction mixture was diluted with ethyl acetate (15 mL) and washed with water (15 mL). The ethyl acetate layer was separated and dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude product. The crude product was purified by flash column chromatography on silica gel using eluent 10% of ethyl acetate in hexane to obtain 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (1.03 g, 2.73 mmol, 83% yield). ¹H-NMR (400 MHz, CHLOROFORM-D) δ 8.39 (t, 1H), 8.20-8.12 (m, 1H), 7.49-7.45 (m, 1H), 7.38-7.35 (m, 2H), 7.29-7.24 (m, 3H), 7.19-7.15 (m, 1H), 4.36 (s, 2H); LCMS (M+H): 377.35.

Table 3: The following compounds were prepared by the procedure analogous to that of the compound no. 50

Compd no.	IUPAC name	Analytical Data
46	3-(2-(((3-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.56-8.41 (m, 1H), 8.19-8.14 (m, 1H), 7.61 (d, 1H), 7.52-7.48 (m, 1H), 7.22-7.17 (m, 1H), 7.01-6.93 (m, 2H), 6.78-6.71 (m, 1H), 4.38-4.34 (s, 2H), 3.77 (s, 3H); LCMS (M+H): 407.35.
47	3-(2-(((4-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.08-8.06 (m, 1H), 7.83 (dd, 1.0 Hz, 1H), 7.26 (d, 1H), 7.18-7.11 (m, 1H), 7.04-6.88 (m, 4H), 4.01 (s, 2H); LCMS (M+H): 410.85.
48	3-(2-(((4-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.42 (t, 1H), 8.21-8.17 (m, 1H), 7.57-7.54 (m, 1H), 7.51 (dd, 1H), 7.42-7.37 (m, 2H), 7.03-6.97 (m, 2H), 4.30 (s,

	1,2,4-oxadiazole	2H); LCMS (M+H): 395.15.
49	3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.40 (d, 1H), 8.14 (dd, 1H), 7.52-7.45 (m, 2H), 7.37-7.33 (m, 2H), 6.84-6.80 (m, 2H), 4.25-4.23 (m, 2H), 3.78 (s, 3H); LCMS (M+H): 407.25.
51	3-(2-(((2-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.38 (s, 1H), 8.14 (dd, 1H), 7.60 (d, 1H), 7.48-7.37 (m, 2H), 7.24-7.18 (m, 1H), 7.09-7.02 (m, 2H), 4.35 (s, 2H); LCMS (M+H): 395.0.
52	5-(trifluoromethyl)-3-(2-(((4-(trifluoromethyl)phenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.40 (s, 1H), 8.16 (dd, 1.0 Hz, 1H), 7.65 (d, 1H), 7.51-7.42 (m, 5H), 4.41 (s, 2H); LCMS (M+H): 445.00.
53	3-(2-(((4-methoxybenzyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.39 (s, 1H), 8.22-8.16 (m, 1H), 7.59 (s, 1H), 7.48 (dd, 1.7 Hz, 1H), 7.31-7.20 (m, 2H), 6.92-6.81 (m, 2H), 4.00-3.53 (m, 7H); LCMS (M+H): 421.05.
54	3-(2-(((propylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.39 (d, 1H), 8.19 (dd, 1H), 7.68 (s, 1H), 7.52-7.47 (m, 1H), 3.92 (d, 2H), 2.60-2.57 (m, 2H), 1.66 (td, 7.3 Hz, 2H), 1.08-0.97 (m, 3H); LCMS (M+H): 343.00.

Example 4: Preparation of 3-(2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound no. 58)

To a stirred solution of 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (0.250 g, 0.664 mmol) in dichloromethane (10 mL), *meta*-chloroperoxybenzoic acid (0.573 g, 1.993 mmol) was added portion wise at 0 °C and stirred for 1 h and then at 25 °C for 8h. The reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated aqueous sodium bicarbonate solution (20 mL). The organic layer was separated and dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude product. The crude product was purified by flash column chromatography on silica gel using eluent 30% of ethyl acetate in hexane to obtain 3-(2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (0.156 g, 0.382 mmol, 58% yield). ¹H-NMR (400 MHz, CHLOROFORM-D) δ 8.31 (t, 1H), 8.24 (dd, 1H), 7.89 (s, 1H), 7.83-7.80 (m, 2H), 7.66-7.62 (m, 1H), 7.57-7.49 (m, 3H), 4.65 (s, 2H); LCMS (M+H): 409.05.

Table 4: The following compounds were prepared by the procedure analogous to that of the compound no. 58

Compd no.	IUPAC name	Analytical Data
55	3-(2-(((4-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.32-8.24 (m, 2H), 8.05-7.89 (m, 1H), 7.72 (dt, 2H), 7.57-7.42 (m, 3H), 4.65 (s, 2H); LCMS (M+H): 442.95.
56	3-(2-(((4-methoxyphenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.33-8.23 (m, 2H), 7.89 (s, 1H), 7.73-7.70 (m, 2H), 7.53 (dd, 1H), 7.00-6.93 (m, 2H), 4.62 (s, 2H), 3.88 (s, 3H); LCMS (M+H): 438.95.
57	3-(2-(((4-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.31 (t, 1H), 8.25 (dd, 1H), 7.90 (s, 1H), 7.82-7.77 (m, 2H), 7.58-7.40 (m, 1H), 7.19-7.14 (m, 2H), 4.65 (s, 2H); LCMS (M+H): 427.20.
59	3-(2-(((2-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.30 (t, 1H), 8.21 (dd, 1.0 Hz, 1H), 7.88 (s, 1H), 7.79-7.75 (m, 1H), 7.66-7.60 (m, 1H), 7.52-7.49 (m, 1H), 7.28-7.21 (m, 2H), 4.85 (s, 2H); LCMS (M+H): 427.50.
60	3-(2-(((4-methoxybenzyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.48 (s, 1H), 8.31-8.23 (m, 1H), 7.87 (s, 1H), 7.59-7.52 (m, 3H), 7.00-6.92 (m, 2H), 4.37 (s, 2H), 4.32 (s, 2H), 3.82 (s, 3H); LCMS (M+H): 453.50.
61	3-(2-(((propylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.42 (t, 1H), 8.25 (dd, 1H), 7.89 (s, 1H), 7.56-7.52 (m, 1H), 4.52-4.47 (m, 2H), 3.13-3.04 (m, 2H), 2.03-1.89 (m, 2H), 1.14-1.06 (m, 3H); LCMS (M+H): 375.50.
62	5-(trifluoromethyl)-3-(2-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.32 (s, 1H), 8.26 (dd, 1H), 7.97-7.92 (m, 3H), 7.77 (d, 2H), 7.57-7.52 (m, 1H), 4.70 (s, 2H); LCMS (M+H): 477.50.

Example 5: N-(((5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide (Compound no. 81)

Step 1:- 3-(2-(azidomethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

To a stirred solution of 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (2.70 g, 8.92 mmol) in *N,N*-dimethylformamide (25 mL), sodium azide (0.638 g, 9.81 mmol) was added under nitrogen atmosphere. The resulting reaction mixture was stirred for 16h at 25 °C. The reaction mixture was poured into crushed ice (50 g) and extracted twice with ethyl acetate (50 mL). The ethyl acetate layer was washed twice by water (50 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain 3-(2-(azidomethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (2.72 g, 8.8 mmol, 99 % yield).

Step 2:- (6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanamine

To a stirred solution of 3-(2-(azidomethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (3.43 g, 11.09 mmol) in tetrahydrofuran (30 mL), triphenylphosphine (2.91 g, 11.1 mmol) was added at 0 °C then water (6mL) was added and the resulting reaction mixture was stirred at 70 °C for 16 h. The reaction mixture was concentrated and under reduced pressure and crude was coevaporated thrice with acetonitrile (25 mL). Dichloromethane (20mL) and hydrochloric acid in 1,4-dioxane (4 Mol.) (13.87 mL, 55.5 mmol) was added at 0 °C and stirred for 1 h. The volatiles were removed under reduced pressure to obtain the crude product. The crude product was stirred with 60% ethyl acetate in hexane (50 mL) at 25 °C and filtered to obtain (6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanamine (3.12 g, 11.02 mmol, 99 % yield).

Step 3:- N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide

To a stirred solution of (6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanamine (300 mg, 1.06 mmol) in dichloromethane (10 mL), triethylamine (0.517 mL, 3.71 mmol) was added at 0 °C under nitrogen atmosphere and then the reaction mixture was stirred for 10 min. Benzoic acid (194 mg, 1.589 mmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (1007 mg, 2.65 mmol) were added and the resulting reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was extracted with dichloromethane (25 mL) and washed with water (25 mL). The dichloromethane layer dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude product. The crude product was purified by column chromatography on silica gel using eluent 0-50 % ethyl acetate in hexane to obtain N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide (101 mg, 0.26 mmol, 25 % yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 9.45-9.46 (m, 1H), 9.09 (t, 1H), 8.04 (d, 1H), 7.89-7.92 (m, 2H), 7.75 (dd, 1H), 7.70 (d, 1H), 7.52-7.56 (m, 1H), 7.45-7.49 (m, 2H), 4.61 (d, 2H), 1.22 (s, 2H); LCMS (M); 387.90.

Table 5: The following compounds were prepared by the procedure analogous to that of the compound no. 81

Compd	IUPAC name	Analytical Data
-------	------------	-----------------

no.		
82	4-methoxy-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 8.94 (t, 1H), 8.01 (s, 1H), 7.89 (dd, 2H), 7.74 (dd, 1H), 7.69 (d, 1H), 6.98-7.01 (m, 2H), 4.58 (d, 2H), 3.80 (s, 3H), 1.22 (s, 3H); LCMS(M+1) = 418.05
83	4-chloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 9.18 (t, 1H), 8.04 (s, 1H), 7.92 (dd, 2H), 7.74 (dd, 1H), 7.69 (d, 1H), 7.54-7.57 (m, 2H), 4.60 (d, 2H); LCMS(M) = 421.85
84	2-(4-chlorophenyl)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.47 (q, 1H), 8.65 (t, 1H), 7.97 (s, 1H), 7.76 (dd, 1H), 7.70 (d, 1H), 7.34-7.36 (m, 2H), 7.30 (dd, 2H), 4.39 (d, 2H), 3.49 (s, 2H); LCMS(M+1) = 436.05
85	3-chloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, 1H), 9.23 (t, 1H), 8.05 (d, 1H), 7.95 (t, 1H), 7.85-7.88 (m, 1H), 7.75 (dd, 1H), 7.70 (dd, 1H), 7.62 (dq, 1H), 7.52 (t, 1H), 4.61 (d, 2H); LCMS(M+1) = 422.05
86	3,4-dichloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 9.30 (t, 1H), 8.14 (d, 1H), 8.05 (s, 1H), 7.88 (dd, 1H), 7.74-7.79 (m, 2H), 7.70 (d, 1H), 4.60 (d, 2H); LCMS(M) = 456.00
87	N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)picolinamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.46 (q, 1H), 9.27 (t, 1H), 8.67 (dq, 1H), 8.07 (dt, 1H), 7.99-8.03 (m, 2H), 7.78 (dd, 1H), 7.72 (d, 1H), 7.62 (ddd, 1H), 4.66 (d, 2H); LCMS(M+1) = 389.40
88	N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)propionamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.46 (q, 1H), 8.33 (t, 1H), 7.75 (dd, 1H), 7.68 (d, 1H), 4.37 (d, 2H), 2.14 (q, 2H), 1.03 (t, 3H); LCMS(M+1) = 340.10
90	4-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 9.13 (t, 1H), 8.03 (s, 1H), 7.96-7.99 (m, 2H), 7.74 (dd, 1H), 7.69 (d, 1H), 7.28-7.34 (m, 2H), 4.60 (d, 2H); LCMS(M) = 405.95
91	2-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.49 (q, 1H), 8.89-8.91 (m, 1H), 8.04 (d, 1H), 7.65-7.76 (m, 3H), 7.51-7.57 (m, 1H), 7.27-7.33 (m, 2H), 4.60 (d, 2H);

		LCMS(M+1) = 406.10
92	N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)oxazole-4-carboxamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, 1H), 8.79 (t, 1H), 8.66 (d, 1H), 8.53 (d, 1H), 7.99 (s, 1H), 7.74 (dd, , 1.7 Hz, 1H), 7.68-7.70 (m, 1H), 4.57 (d, 2H); LCMS(M) = 378.95
93	3-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 9.20 (t, 1H), 8.05 (s, 1H), 7.73-7.77 (m, 2H), 7.68-7.72 (m, 2H), 7.54 (td, 1H), 7.37-7.42 (m, 1H), 4.61 (d, 2H); LCMS(M+1) = 406.15
94	2-phenyl-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.47 (q, 1H), 8.62 (t, 1H), 7.97 (s, 1H), 7.75 (dd, 1H), 7.69 (d, 1H), 7.27-7.30 (m, 4H), 7.19-7.24 (m, 1H), 4.39 (d, 2H), 3.48 (s, 2H); LCMS(M+1) = 402.15
95	4-(dimethylamino)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, 1H), 8.71 (t, 1H), 7.99 (s, 1H), 7.78 (d, 2H), 7.73 (dd, 1H), 7.68 (d, 1H), 6.71 (d, 2H), 4.56 (d, 2H), 2.96 (s, 6H); LCMS(M+1) = 431.20
96	3-methyl-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)butanamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.51 (q, 1H), 8.37 (t, 1H), 7.97 (s, 1H), 7.76 (dd, 1H), 7.69 (d, 1H), 4.40 (d, 2H), 1.98-2.04 (m, 3H), 0.88-0.91 (m, 6H); LCMS(M+1) = 368.10
97	4-(trifluoromethyl)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, 1H), 9.34 (t, 1H), 8.10 (d, 2H), 8.06 (s, 1H), 7.87 (d, 2H), 7.75 (dd, 1H), 7.70 (d, 1H), 4.63 (d, 2H); LCMS(M) = 455.75
98	N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)nicotinamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 9.31 (t, 1H), 9.06 (q, 1H), 8.71 (dd, 1H), 8.23 (dt, 1H), 8.07 (s, 1H), 7.75 (dd, 1H), 7.70 (d, 1H), 7.52 (ddd, 1H), 4.63 (d, 2H); LCMS(M) = 388.75
99	N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)isonicotinamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, 1H), 9.41 (t, 1H), 8.74 (dd, 2H), 8.06 (s, 1H), 7.80 (dd, 2H), 7.75 (dd, 1H), 7.69-7.71 (m, 1H), 4.62 (d, 2H); LCMS(M) = 388.75

Example 6:- Preparation of 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (compound no. 100)

Step 1:- 2-(chloromethyl)imidazo[1,2-a]pyridine-6-carbonitrile

To a stirred solution of 6-aminonicotinonitrile (15 g, 126 mmol) in ethanol (40 mL), 1,3-dichloropropan-2-one (63.9 g, 504 mmol) was added under nitrogen atmosphere and stirred for 16 h at 60 °C. After completion of the reaction, the reaction mixture was poured into ice cold saturated solution of sodium bicarbonate (160 mL), then filtered to obtain a crude product 2-(chloromethyl)imidazo[1,2-a]pyridine-6-carbonitrile (20 g, 104 mmol, 83 % yield).

Step 2:- (Z)-2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide

To a stirred solution of 2-(chloromethyl)imidazo[1,2-a]pyridine-6-carbonitrile (8.64 g, 45.1 mmol) in ethanol (10 mL), hydroxylamine (4.47 mL, 67.6 mmol) was added and stirred for 4 h at 25 °C. The volatiles were removed under reduced pressure to obtain a mixture of (Z)-2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide (9.9 g, 44.1 mmol, 98 % yield) and 2-(ethoxymethyl)-N'-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide.

Step 3:- 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

To a stirred solution of (Z)-2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide (2.3 g, 10.24 mmol) and 2-(ethoxymethyl)-N'-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide in tetrahydrofuran (12 mL), trifluoroacetic anhydride (1.848 mL, 13.09 mmol) was added at 0 °C under nitrogen atmosphere. The resulting reaction mixture was stirred for 16h at 25 °C. The reaction mixture was quenched by pouring into saturated aqueous sodium bicarbonate solution (100 mL) at 0-5 °C. The product was extracted into ethyl acetate (150 mL). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography on silica gel using eluent 0-50% ethyl acetate in hexane to obtain 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (3 g, 9.91 mmol, 97 % yield) and 2-(ethoxymethyl)-N'-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide. ¹H-NMR (400 MHz, DMSO-*d*₆) δ 9.45 (q, 1H), 8.07 (d, 1H), 7.75 (dd, 1H), 7.68-7.70 (m, 1H), 4.58 (d, 2H), 3.56 (q, 2H), 1.15 (t, 3H); LCMS (M+1): 313.15.

Step 4:- 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

To a stirred solution of 4-methoxybenzenethiol (0.264 mL, 2.148 mmol) in acetonitrile (8 mL), potassium carbonate (457 mg, 3.30 mmol) was added and stirred for 10 min at 0 °C. Then solution of 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (500 mg, 1.652 mmol) in *N,N*-dimethylformamide was added. The resulting reaction mixture was stirred for 3 h at 60 °C. The reaction mixture was diluted with ethyl acetate (15 mL) and washed with water (15 mL). The ethyl acetate layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude product. The crude product was purified by flash column chromatography on silica gel using eluent 20% ethyl acetate in hexane to obtain 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (244

mg, 0.6 mmol, 37 % yield). ¹H-NMR (400 MHz, CHLOROFORM-D) δ 8.88-8.94 (m, 1H), 7.85 (dd, 1H), 7.74 (d, 1H), 7.47 (d, 1H), 7.33-7.37 (m, 2H), 6.82 (dt, 2H), 4.21-4.23 (m, 2H), 3.78 (s, 3H); LCMS (M+1): 407.35.

Table 6: The following compounds were prepared by the procedure analogous to that of the compound 100

5

Compd no.	IUPAC Name	Analytical Data
101	3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.43 (q, 1H), 8.05 (s, 1H), 7.74 (dd, 1H), 7.67-7.70 (m, 1H), 7.37-7.40 (m, 2H), 7.27-7.32 (m, 2H), 7.14-7.19 (m, 1H), 4.37 (s, 2H) ; LCMS (M+1) = 377.40
102	3-(2-(((4-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.42 (q, 1H), 8.05 (d, 1H), 7.74 (dd, 1H), 7.68 (d, 1H), 7.41 (dt, 2H), 7.35 (dt, 2H), 4.38 (s, 2H) ; LCMS (M+1) = 411.20
103	3-(2-(((3-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.43-9.45 (m, 1H), 8.07 (s, 1H), 7.74 (dd, 1H), 7.69 (dd, 1H), 7.48 (t, 1H), 7.34 (dt, 1H), 7.28-7.32 (m, 1H), 7.20-7.25 (m, 1H), 4.43 (s, 2H) ; LCMS (M) = 410.95
104	3-(2-(((3-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (q, 1H), 8.07 (s, 1H), 7.75 (dd, 1H), 7.68-7.70 (m, 1H), 7.29-7.35 (m, 2H), 7.20 (dq, 1H), 6.95-7.00 (m, 1H), 4.43 (s, 2H) ; LCMS (M+1) = 395.35
105	3-(2-(((4-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.42 (q, 1H), 7.99 (s, 1H), 7.74 (dd, 1H), 7.67-7.69 (m, 1H), 7.42-7.47 (m, 2H), 7.12-7.18 (m, 2H), 4.33 (s, 2H) ; LCMS (M+1) = 395.35
106	3-(2-(((2-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.45 (q, 1H), 8.07 (s, 1H), 7.76 (dd, 1H), 7.70 (d, 1H), 7.56 (td, 1H), 7.16-7.30 (m, 3H), 4.40 (s, 2H) ; LCMS (M+1) = 395.35
107	3-(2-((propylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (q, 1H), 8.05 (s, 1H), 7.74 (dd, 1H), 7.68 (d, 1H), 3.81 (d, 2H), 2.52 (t, 2H), 1.56 (td, 2H), 0.91 (q, 3H) ; LCMS (M+1) = 343.35
108	3-(2-	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.43 (q, 1H), 8.06

	((benzylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	(s, 1H), 7.74 (dd, 1H), 7.69 (dd, 1H), 7.30-7.37 (m, 4H), 7.21-7.26 (m, 1H), 3.80 (s, 2H), 3.74 (s, 2H) ; LCMS (M+1) = 391.40
109	3-(2-(((4-methoxybenzyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.43 (q, 1H), 8.05 (s, 1H), 7.68-7.76 (m, 2H), 7.24-7.28 (m, 2H), 6.85-6.89 (m, 2H), 3.72-3.75 (m, 7H) ; LCMS (M+1) = 421.35
110	3-(2-(((3,4-dichlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (q, 1H), 8.06 (s, 1H), 7.75 (dd, 1H), 7.68-7.70 (m, 2H), 7.53 (d, 1H), 7.37 (dd, 1H), 4.45 (s, 2H) ; LCMS (M+1) = 444.90
111	3-(2-(((3,5-dichlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.46 (q, 1H), 8.09 (d, 1H), 7.68-7.77 (m, 2H), 7.47-7.48 (m, 2H), 7.37 (t, 1H), 4.50 (s, 2H) ; LCMS (M+1) = 446.80
112	3-(2-(((isobutylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (q, 1H), 8.05 (s, 1H), 7.74 (dd, 1H), 7.68 (d, 1H), 3.82 (s, 2H), 2.44 (d, 2H), 1.74-1.81 (m, 1H), 0.93 (t, 6H) ; LCMS (M+1) = 357.50
113	3-(2-(((cyclopentylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.42-9.50 (m, 1H), 8.09 (d, 1H), 7.66-7.80 (m, 2H), 3.88 (d, 2H), 3.12-3.19 (m, 1H), 1.90-1.98 (m, 2H), 1.58-1.71 (m, 2H), 1.40-1.56 (m, 4H) ; LCMS (M+1) = 369.40
114	3-(2-(((cyclohexylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.43 (q, 1H), 8.04 (s, 1H), 7.73 (dd, 1H), 7.67 (d, 1H), 3.87 (s, 2H), 2.71-2.77 (m, 1H), 1.92-1.96 (m, 2H), 1.68 (d, 2H), 1.54 (d, 1H), 1.21-1.29 (m, 5H) ; LCMS (M+1) = 383.40
115	3-(2-(((2-ethylphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.43 (q, 1H), 8.04 (s, 1H), 7.68-7.76 (m, 2H), 7.44-7.46 (m, 1H), 7.10-7.20 (m, 3H), 4.34 (s, 2H), 2.64 (q, 2H), 1.08-1.13 (m, 3H) ; LCMS (M+1) = 406.00

Example 7:- Preparation of 3-(2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound no. 116)

To a stirred solution of 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (250 mg, 0.664 mmol) in dichloromethane (5 mL), *m*-chloroperoxybenzoic acid (252 mg, 1.461 mmol) was added at 0 °C and stirred for 16 h at 25 °C. After completion of the reaction, the reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated solution of sodium bicarbonate (20 mL). The dichloromethane layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude product. The crude product was purified by flash column chromatography on silica gel using eluent 30% ethyl acetate in hexane to obtain 3-(2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (135 mg, 0.331 mmol, 50 % yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 9.49 (q, 1H), 8.04 (s, 1H), 7.75-7.78 (m, 2H), 7.66-7.73 (m, 2H), 7.63 (d, 1H), 7.54-7.58 (m, 2H), 4.80-4.90 (m, 2H): LCMS (M+1): 409.05.

Table 7: The following compounds were prepared by the procedure analogous to that of the compound 116

Compd no.	IUPAC name	Analytical Data
117	3-(2-(((3,4-dichlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.52 (q, 1H), 8.09 (s, 1H), 8.04 (d, 1H), 7.85-7.88 (m, 1H), 7.75-7.79 (m, 1H), 7.66-7.71 (m, 2H), 5.01 (s, 2H); LCMS (M+1) = 476.80
118	3-(2-(((3-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.52 (q, 1H), 8.09 (s, 1H), 7.84 (t, 1H), 7.80 (dq, 1H), 7.76 (dd, 1H), 7.71-7.74 (m, 1H), 7.69-7.69 (OH), 7.66 (d, 1H), 7.61 (t, 1H), 4.97 (s, 2H); LCMS (M+1) = 443.00
119	3-(2-(((4-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.52 (q, 1H), 8.07 (s, 1H), 7.74-7.80 (m, 3H), 7.66-7.69 (m, 3H), 4.92 (s, 2H); LCMS (M+1) = 444.00
120	3-(2-(((3-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.52 (q, 1H), 8.08 (s, 1H), 7.74-7.78 (m, 1H), 7.57-7.69 (m, 5H), 4.96 (s, 2H); LCMS (M+1) = 427.30
121	3-(2-(((4-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.51 (q, 1H), 8.04 (s, 1H), 7.82-7.86 (m, 2H), 7.75 (dd, 1H), 7.66 (d, 1H), 7.40-7.46 (m, 2H), 4.89 (s, 2H); LCMS (M+1) = 427.20
122	3-(2-(((4-methoxybenzyl)sulfonyl)methyl)imi	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.56 (t, 1H), 8.23 (s, 1H), 7.82 (dd, 2H), 7.40 (dt, 2H), 6.96 (dt, 2H),

	dazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	4.57 (s, 2H), 4.52 (s, 2H), 3.75 (s, 3H); LCMS (M+1) = 453.25
123	3-(2-((cyclohexylsulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.55 (t, 1H), 8.22 (s, 1H), 7.75-7.81 (m, 2H), 4.63 (s, 2H), 3.16 (tt, 1H), 2.14 (d, 2H), 1.82 (d, 2H), 1.64 (d, 1H), 1.41 (qd, 2H), 1.14-1.31 (m, 3H); LCMS (M+1) = 415.50
124	3-(2-(((2-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.57 (q, 1H), 8.21 (s, 1H), 7.87 (dd, 1H), 7.77-7.83 (m, 1H), 7.72 (d, 1H), 7.68 (td, 1H), 7.53 (ddd, 1H), 7.37 (td, 1H), 5.03 (s, 2H); LCMS (M+1) = 426.90
126	3-(2-(((3,4-dichlorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.52 (d, 1H), 8.02 (s, 1H), 7.75-7.81 (m, 3H), 7.68 (d, 1H), 7.55 (dd, 1H), 4.50 (d, 1H), 4.36 (d, 1H); LCMS (M+1) = 460.75
127	3-(2-(((3-chlorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.51 (q, 1H), 8.02 (s, 1H), 7.77 (dd, 1H), 7.69 (d, 1H), 7.64 (q, 1H), 7.54-7.61 (m, 3H), 4.46 (d, 1H), 4.33 (d, 1H); LCMS (M) = 426.85
128	3-(2-(((2-fluorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole	¹ H-NMR (400 MHz, DMSO- <i>d</i> 6) δ 9.50 (q, 1H), 8.06 (s, 1H), 7.76 (dd, 1H), 7.67 (d, 1H), 7.58-7.62 (m, 2H), 7.33-7.42 (m, 2H), 4.46 (d, 1H), 4.34 (d, 1H); LCMS (M+1) = 411.25

Example 8:- Preparation of N-(methyl(oxo)(phenyl)-λ⁶-sulfanylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide (Compound no. 129)

Step 1:- ethyl 2-(6-cyanoimidazo[1,2-a]pyridin-2-yl)acetate

- 5 To a stirred solution of 6-aminonicotinonitrile (7 g, 58.8 mmol) in ethanol (70 mL), ethyl 4-chloro-3-oxobutanoate (19.98 mL, 147 mmol) was added and stirred for 48 h at 60 °C. The reaction mixture was stirred at 25 °C for 1h then filtered it to get pure product. The product was stirred with saturated solution of sodium bicarbonate (50 mL), then filtered to obtain ethyl 2-(6-cyanoimidazo[1,2-a]pyridin-2-yl)acetate (11 g, 41.4 mmol, 71 % yield).

10 **Step 2:- ethyl 2-(6-(N'-hydroxycarbamimidoyl)imidazo[1,2-a]pyridin-2-yl)acetate**

To a stirred solution of ethyl 2-(6-cyanoimidazo[1,2-a]pyridin-2-yl)acetate (9.1 g, 39.7 mmol) in ethanol (100 mL), hydroxylamine (6.50 mL, 119 mmol) was added at 25 °C and the resulting reaction mixture was stirred at 25 °C for 4 h. The volatiles were removed under reduced pressure to obtain

crude ethyl 2-(6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-*a*]pyridin-2-yl)acetate (10.1 g, 38.5 mmol, 97 % yield).

Step 3:- ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)acetate

To a stirred solution of ethyl 2-(6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-*a*]pyridin-2-yl)acetate (10.1 g, 38.5 mmol) and tetrahydrofuran (100 mL), trifluoroacetic anhydride (7.62 mL, 53.9 mmol) was added at 0 °C under nitrogen atmosphere and reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched by pouring into saturated aqueous sodium bicarbonate solution (100 mL) at 0-5 °C. The product was extracted into ethyl acetate (150 mL). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)acetate (10.52 g, 30.9 mmol, 80 % yield).

Step 4:- N-(methyl(oxo)(phenyl)- λ^6 -sulfanylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)acetamide

To a stirred solution of imino(methyl)(phenyl)- λ^6 -sulfanone (205 mg, 1.323 mmol) in toluene (7 mL), trimethylaluminium 25% in hexane (0.636 mL, 2.204 mmol) was added at 0-5 °C and stirred at 25 °C for 30 min. Then ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)acetate (300 mg, 0.882 mmol) was added under nitrogen atmosphere. The resulting reaction mixture was stirred at 65 °C for 16 h. The reaction mixture was cooled to 25 °C and poured into ice cold solution of 10 % aqueous acetic acid solution (10 mL). The product was extracted with ethyl acetate (30 mL). The ethyl acetate layer was washed with aqueous sodium bicarbonate solution (10 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative HPLC to obtain N-(methyl(oxo)(phenyl)- λ^6 -sulfanylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)acetamide (112 mg, 0.25 mmol, 28% yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 9.45 (q, 1H), 8.03 (s, 1H), 7.95-7.97 (m, 2H), 7.71-7.75 (m, 2H), 7.63-7.68 (m, 3H), 3.77 (s, 2H), 3.43 (d, 3H); LCMS (M+1): 450.40.

Table 8: The following compounds were prepared by using analogous procedure to that of the compound 129

Comp no.	IUPAC name	Analytical Data
130	N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2- <i>a</i>]pyridin-2-yl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q 1H), 8.01 (s, 1H), 7.94 (td, 1H), 7.78-7.83 (m, 1H), 7.72 (dd 1H), 7.66 (d, 1H), 7.47-7.53 (m, 2H), 3.75 (d, 2H), 3.52 (s, 3H); LCMS (M+1): 468.40
131	N-((3-fluorophenyl)(methyl)(oxo)- λ^6 -	¹ H-NMR - (400 MHz, DMSO- <i>d</i> ₆) δ 9.47 (q,

	sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H), 8.05 (s, 1H), 7.81-7.85 (m, 2H), 7.71-7.77 (m, 2H), 7.68 (d, 1H), 7.60-7.65 (m, 1H), 3.75-3.88 (m, 2H), 3.51 (s, 3H) ; LCMS (M+1): 468.40
132	N-((4-fluorophenyl)(methyl)(oxo)-λ ⁶ -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, J = 1.0 Hz, 1H), 8.03-8.06 (m, 3H), 7.73 (dd, J = 9.4, 1.8 Hz, 1H), 7.68 (d, J = 9.3 Hz, 1H), 7.48-7.54 (m, 2H), 3.77 (dd, J = 18.0, 16.5 Hz, 2H), 3.48 (s, 3H); LCMS(M+1):468.00
133	N-((3-methoxyphenyl)(methyl)(oxo)-λ ⁶ -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR - (400 MHz, DMSO- <i>d</i> ₆) δ 9.47 (q, 1H), 8.06 (s, 1H), 7.75 (dd, 1.8 Hz, 1H), 7.68 (d, 1H), 7.58 (t, 1H), 7.54 (dt, 1H), 7.42 (t,1H), 7.29 (dq, 1H), 3.83 (t, 3H), 3.78 (d, 2H), 3.47 (s, 3H) ; LCMS (M+1): 480
134	N-(dimethyl(oxo)-λ ⁶ -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR - (400 MHz, DMSO- <i>d</i> ₆) δ 9.46 (q, 1H), 8.06 (s, 1H), 7.74 (dd, 1H), 7.66-7.69 (m, 1H), 3.71 (s, 2H), 3.35 (s, 6H) ; LCMS (M+1): 388
135	N-(1-oxidotetrahydro-2H-1λ ⁶ -thiopyran-1-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR - (400 MHz, DMSO- <i>d</i> ₆) δ 9.46 (q, 1H), 8.04 (s, 1H), 7.72 (dd, 1H), 7.66 (d, 1H), 3.72 (s, 2H), 3.54-3.59 (m, 2H), 3.34-3.38 (m, 2H), 1.90-1.97 (m, 2H), 1.78-1.87 (m, 2H), 1.50-1.59 (m, 2H) ; LCMS (M+1): 428.05
136	N-((4-chlorophenyl)(2-methoxyethyl)(oxo)-λ ⁶ -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR - (400 MHz, DMSO- <i>d</i> ₆) δ 9.46 (q, 1H), 8.03 (s, 1H), 7.91-7.96 (m, 2H), 7.68-7.74 (m, 4H), 3.85-3.96 (m, 2H), 3.79 (dd, 2H), 3.55-3.67 (m, 2H), 2.99 (s, 3H) ; LCMS (M+1): 528
137	N-(isopropyl(methyl)(oxo)-λ ⁶ -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.48 (q, 1H), 8.05 (s, 1H), 7.73 (dd, 1H), 7.67 (d, 1H), 3.72 (s, 2H), 3.64 (td, 1H), 3.30 (d, 3H), 1.24-1.44 (m, 6H) ; LCMS (M+1):415.75
138	N-((4-methoxyphenyl)(methyl)(oxo)-λ ⁶ -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR- (400 MHz, DMSO- <i>d</i> ₆) δ 9.45-9.47 (m, 1H), 8.03 (s, 1H), 7.87-7.90 (m, 2H), 7.66-7.74 (m, 2H), 7.14-7.18 (m, 2H), 3.84 (d, 3H), 3.76 (t, 2H), 3.43 (s, 3H) ; LCMS (M+1): 480.05

139	N-(methyl(oxo)(4-(trifluoromethyl)phenyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (t, 1H), 8.19 (d, 2H), 8.04 (t, 3H), 7.73 (dd, 1H), 7.68 (d, 1H), 3.78 (d, 2H), 3.52 (s, 3H) ; LCMS (M+1): 518.00
140	N-((3,5-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (q, 1H), 8.03 (t, 2H), 7.95 (d, 2H), 7.74 (dd, 1H), 7.68 (d, 1H), 3.76 (dd, Hz, 2H), 3.53 (s, 3H) ; LCMS (M-1): 517.70
141	N-(1-oxidotetrahydro-1 λ^6 -thiophen-1-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.46 (s, 1H), 8.04 (s, 1H), 7.72 (dd, 1H), 7.66 (d, 1H), 3.71 (d, 2H), 3.47-3.54 (m, 2H), 3.16 (d, 2H), 2.15-2.24 (m, 2H), 2.06-2.11 (m, 2H) ; LCMS (M+1): 413.95
142	N-((4-bromophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.46 (q, 1H), 8.06 (d, 1H), 7.88-7.93 (m, 4H), 7.75 (dd, 1H), 7.70 (d, 1H), 3.78 (dd, 16.6 Hz, 2H), 3.49 (s, 3H) ; LCMS (M-1): 527.70
143	N-((3,4-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.46 (q, 1H), 8.17 (d, 1H), 8.04 (s, 1H), 7.95-7.96 (m, 2H), 7.75 (dd, 1H), 7.70 (d, 1H), 3.81 (d, 1H), 3.74 (d, 1H), 3.53 (s, 3H) - LCMS (M-1): 517.70
144	N-(4-oxido-1,4 λ^6 -oxathian-4-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.46 (q, 1H), 8.06 (s, 1H), 7.73 (dd, 1H), 7.66 (d, 1H), 4.08 (td, 2H), 3.81-3.87 (m, 2H), 3.76 (s, 2H), 3.70 (dt, 2H), 3.45-3.52 (m, 2H) ; LCMS (M+1): 429.95
145	N-((2-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.45 (q, 1H), 8.00 (s, 1H), 7.86 (dd, 1H), 7.64-7.73 (m, 3H), 7.28 (d, 1H), 7.16-7.20 (m, 1H), 3.87 (d, 3H), 3.69 (s, 2H), 3.45 (s, 3H) ; LCMS (M+1) : 480
146	N-((4-methoxypyridin-2-yl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-	$^1\text{H-NMR}$ - (400 MHz, DMSO- <i>d</i> 6) δ 9.44 (q, 1H), 8.58 (d, 1H), 8.00 (s, 1H), 7.72 (dd, 1H), 7.65 (d, 1H), 7.60 (d, 1H), 7.30 (q, 1H), 3.92 (s, 3H), 3.74 (d, 2H), 3.44 (s, 3H) ; LCMS (M+1):

	yl)acetamide	481.05
147	N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.45 (q, 1H), 8.02 (s, 1H), 7.98 (dt, 2H), 7.71-7.76 (m, 3H), 7.68 (d, 1H), 3.76 (dd, 2H), 3.48 (s, 3H) ; LCMS(M+1): 483.95
148	N-(methyl(oxo)(<i>o</i> -tolyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 8.02 (s, 1H), 7.94 (dd, 1.2 Hz, 1H), 7.72 (dd, 1.7 Hz, 1H), 7.66 (d, 1H), 7.59 (td, 1H), 7.45 (q, 2H), 3.76 (s, 2H), 3.43 (s, 3H), 2.54 (s, 3H) ; LCMS(M+1) : 464.45
149	N-((3-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.44 (q, 1H), 8.03 (s, 1H), 7.97 (t, 1H), 7.92 (dq, 1H), 7.80 (dq, 1H), 7.72-7.74 (m, 1H), 7.66-7.70 (m, 2H), 3.70-3.83 (m, 2H), 3.50 (s, 3H) ; LCMS(M+1):484.05

Example 9:- Preparation of N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide (Compound no. 155)

Step 1:- 2-(Chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile

5 To a stirred solution of 2-aminoisonicotinonitrile (20 g, 168 mmol) in ethanol (100 mL), 1,3-dichloropropan-2-one (38.4 g, 302 mmol) was added and stirred for 16 h at 50 °C. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution, and the resulting precipitate was filtered *via* a Buchner funnel and washed with minimum amount of ethanol to remove unreacted starting materials. The obtained residue is 2-(chloromethyl)imidazo[1,2-a]pyridine-7-
10 carbonitrile (21 g, 110 mmol, 65% yield).

Step 2:- 2-((Methylthio)methyl)imidazo[1,2-a]pyridine-7-carbonitrile

To a stirred solution of 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (1.0 g, 5.22 mmol) in tetrahydrofuran (20 mL), sodium methanethiolate (0.439 g, 6.26 mmol) was added portion wise slowly at 0 °C and further stirred at 25 °C for 8 h. The resulting reaction mixture was quenched with
15 water and extracted twice with ethyl acetate (20 mL), and washed twice with brine (20 mL), dried over sodium sulphate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel using eluent 20% of ethyl acetate in hexane to obtain 2-((methylthio)methyl)imidazo[1,2-a]pyridine-7-carbonitrile (0.98 g, 4.82 mmol, 92% yield).

Step 3:- N'-Hydroxy-2-((methylthio)methyl)imidazo[1,2-a]pyridine-7-carboximidamide

20 Experimental procedure for the synthesis of N'-Hydroxy-2-((methylthio)methyl)imidazo[1,2-a]pyridine-7-carboximidamide is similar to step-2 of example 8 (7.8 g, 33.0 mmol, 96% yield).

Step 4:- 3-(2-((methylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

Experimental procedure for the synthesis of 3-(2-((methylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole is similar to step-3 of example 8 (8.25 g, 26.2 mmol, 86% yield).

5 Step 5:- Imino(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ⁶-sulfanone

To a stirred solution of 3-(2-((methylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (8.5 g, 27.0 mmol) and ammonium carbamate (5.28 g, 67.6 mmol) in methanol (50 mL), iodobenzene diacetate (21.78 g, 67.6 mmol) was added slowly portion wise at 0 °C and allowed to stirred at 25 °C for 12 h. The resulting reaction mixture was concentrated under reduced pressure. The obtained crude residue was diluted with ethyl acetate (50 mL) and the solution was neutralized with sodium bicarbonate (80 mL) solution. The ethyl acetate layer was collected and aqueous layer was extracted thrice with ethyl acetate (50 mL). The combined ethyl acetate layers were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude residue was purified by flash column chromatography on silica gel using eluent 10 % of methanol in dichloromethane to obtain imino(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ⁶-sulfanone (4.8 g, 13.90 mmol, 51% yield).

Step 6:- N-(Methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ⁶-sulfanylidene)benzamide

To a stirred solution of imino(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ⁶-sulfanone (0.2 g, 0.579 mmol) and 4-dimethylaminopyridine (0.014 g, 0.116 mmol), trimethylamine (0.109 mL, 1.158 mmol) and dichloromethane (10 mL) was added at 0°C followed by benzoyl chloride (0.122 g, 0.869 mmol) was added and stirred at 25 °C for 3 h. The resulting reaction mixture was diluted with water, extracted twice with ethyl acetate (20 mL), washed twice with brine (20 mL), dried over sodium sulphate and concentrated under reduced pressure. The obtained crude product was purified by flash column chromatography on silica gel using eluent 80% of ethyl acetate in hexane to obtain N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ⁶-sulfanylidene)benzamide (0.124 g, 0.276 mmol, 48 % yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 8.83-8.30 (m, 1H), 8.32 (s, 1H), 8.27-8.25 (m, 1H), 8.00-7.98 (m, 2H), 7.57-7.51 (m, 2H), 7.46-7.42 (m, 2H), 5.29-5.11 (m, 2H), 3.51 (s, 3H); ¹⁹F-NMR (377 MHz, CHLOROFORM-D) δ -64.67; LCMS (M+H): 449.95.

Table 9: The following compounds were prepared by the procedure analogous to that of the compound 155

Compd no.	IUPAC name	Analytical Data

152	imino(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.78 (dd, 1H), 8.20 (q 2H), 7.49 (dd, 1H), 4.57 (dd, 2H), 3.73 (s, 1H), 2.96 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -64.68; LCMS (M+H): 345.95.
153	N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)pivalamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.82 (dd, 1H), 8.22-8.19 (m, 2H), 7.51 (dd, 1H), 5.08 (s, 2H), 3.32 (s, 3H), 0.98 (s, 9H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -64.58; LCMS (M+H): 430.05.
154	4-methoxy-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.82-8.78 (m, 1H), 8.28 (s, 1H), 8.25-8.23 (m, 1H), 7.93 (dt, 2H), 7.50 (dd, 1H), 6.95 (dt, 2H), 5.21 (t, 2H), 3.79 (s, 3H), 3.46 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -64.58; LCMS (M+H): 479.80.
156	4-chloro-2-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.80 (dd, 1H), 8.28 (s, 1H), 8.23 (t, 1H), 7.82 (t, 1H), 7.51 (dd, 1H), 7.45 (dd, 1H), 7.33-7.30 (m, 1H), 5.24 (s, 2H), 3.48 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -64.58, -109.05; LCMS (M+H): 501.95.
157	3-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.80 (dd, 1H), 8.30 (s, 1H), 8.23 (t, 1H), 7.80 (dt, 1H), 7.66 (dq, 1H), 7.52-7.46 (m, 2H), 7.41-7.36 (m, 1H), 5.25 (dd, 2H), 3.51 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -64.58, -113.12; LCMS (M+H): 467.95.
158	3-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.79 (dd, 1H), 8.30 (s, 1H), 8.23 (s, 1H), 7.92-7.89 (m, 2H), 7.61 (dt, 1H), 7.52-7.45 (m, 2H), 5.26 (dd, 2H), 3.51 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -64.58; LCMS (M+H): 483.95.
159	4-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.82-8.78 (m, 1H), 8.29 (s, 1H), 8.24 (d, 1H), 7.98-7.95 (m, 2H), 7.53-7.48 (m, 3H), 5.25 (dd, 2H), 3.50 (s, 3H); $^{19}\text{F-NMR}$

	yl)methyl)- λ^6 -sulfanylidene)benzamide	NMR (377 MHz, CHLOROFORM-D) δ -64.58; LCMS (M+H): 484.00.
160	N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)-4-(trifluoromethoxy)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.81 (dd, 1H), 8.32 (s, 1H), 8.24 (t, 1H), 8.11-8.08 (m, 2H), 7.52 (dd, 1H), 7.43 (dd, 2H), 5.27 (s, 2H), 3.52 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -56.60, -64.68; LCMS (M+H): 534.
161	N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanylidene)-2-(trifluoromethyl)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.82 (dd, 1H), 8.29 (s, 1H), 8.25 (d, 1H), 7.74-7.72 (m, 1H), 7.69-7.58 (m, 3H), 7.52 (dd, 1H), 5.25 (dd, 2H), 3.48 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, CHLOROFORM-D) δ -57.31, -64.58; LCMS (M+H): 517.95
162	N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-3-(trifluoromethyl)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.79 (dd, 1H), 8.30 (s, 1H), 8.22-8.24 (m, 3H), 7.91 (d, 1H), 7.70 (t, 1H), 7.51 (dd, 1H), 5.28 (dd, 2H), 3.54 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, DMSO- <i>d</i> 6) δ -61.22, -64.68; LCMS (M-H): 516
163	2-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide	$^1\text{H-NMR}$ (400 MHz, DMSO- <i>d</i> 6) δ 8.80 (dd, 1H), 8.29 (s, 1H), 8.23 (t, 1H), 7.77 (td, 1H), 7.48-7.54 (m, 2H), 7.18-7.22 (m, 2H), 5.22 (d, 2H), 3.48 (s, 3H); $^{19}\text{F-NMR}$ (377 MHz, DMSO- <i>d</i> 6) δ -64.67, -112.36; LCMS (M+H): 468.00

Example 10:- Preparation of imino(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone (compound no. 164)

Step 1:- 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile

- 5 To a stirred solution of 2-aminoisonicotinonitrile (20 g, 168 mmol) in ethanol (100 mL), 1,3-dichloropropan-2-one (38.4 g, 302 mmol) was added and stirred for 16 h at 50 °C. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution (500 mL) and the resulting precipitate was filtered *via* a Buchner funnel, obtained solids were washed with ethanol (50 mL). The obtained residue was dried under reduced pressure to obtain 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (21 g, 110 mmol, 65% yield).
- 10

Step 2:- 2-(chloromethyl)-*N'*-hydroxyimidazo[1,2-a]pyridine-7-carboximidamide

To a stirred solution of 2-(chloromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (10.25 g, 53.5 mmol) in ethanol (50 mL), hydroxylamine solution 50 wt.% in water(6.56 mL, 107 mmol) was added at 25

°C. The resulting reaction mixture was stirred at 60 °C for 3 h and concentrated under reduced pressure to obtain 2-(chloromethyl)-*N'*-hydroxyimidazo[1,2-*a*]pyridine-7-carboximidamide (11.54 g, 53.5 mmol, 96% yield).

Step 3:- 3-(2-(chloromethyl)imidazo[1,2-*a*]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

5 To a stirred solution of 2-(chloromethyl)-*N'*-hydroxyimidazo[1,2-*a*]pyridine-7-carboximidamide (12.0 g, 53.4 mmol) in tetrahydrofuran (50 mL), trifluoroacetic anhydride (13.58 mL, 96 mmol) was added slowly at 0-5 °C under nitrogen atmosphere and stirred for 18 h at 25 °C. The resulting mixture was concentrated under reduced pressure and obtained residue was dissolved in dichloromethane (100 mL). The dichloromethane layer was washed with aqueous sodium bicarbonate solution (50 mL),
10 followed by brine (50 mL) dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel using eluent 60% of ethyl acetate in hexane to obtain 3-(2-(chloromethyl)imidazo[1,2-*a*]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (12.56 g, 41.5 mmol, 78% yield).

Step 4:- 3-(2-((phenylthio)methyl)imidazo[1,2-*a*]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole

To a stirred solution of benzenethiol (0.473 g, 4.30 mmol) in acetonitrile (8 mL) under nitrogen atmosphere, potassium carbonate (0.91 g, 6.6 mmol) was added and the reaction mixture was stirred at 0 °C for 10 min. To the resulting reaction mixture, a solution of 3-(2-(chloromethyl)imidazo[1,2-*a*]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (1.0 g, 3.30 mmol) in *N,N*-dimethylformamide
20 was added and the resulting reaction mixture was stirred for 3 h at 60 °C. After completion of the reaction, the reaction mixture was diluted with ethyl acetate (15 mL) and washed with water (15 mL). The ethyl acetate layer was separated and dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude. The crude was purified by flash column chromatography on silica gel using eluent 10% of ethyl acetate in hexane to obtain 3-(2-((phenylthio)methyl)imidazo[1,2-*a*]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole (1.03 g, 2.73 mmol, 83% yield).¹H-NMR (400 MHz, CHLOROFORM-D) δ 8.39 (t, 1H), 8.20-8.12 (m, 1H), 7.49-7.45 (m, 1H), 7.38-7.35 (m, 2H), 7.29-7.24 (m, 3H), 7.19-7.15 (m, 1H), 4.36 (s, 2H); LCMS (M+H): 377.35.

Step 5:- Imino(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)methyl)-λ⁶-sulfanone

30 Experimental procedure for the synthesis of Imino(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-*a*]pyridin-2-yl)methyl)-λ⁶-sulfanone is similar to step-5 of example 9 (0.132 g, 31%).¹H-NMR (400 MHz, DMSO-*d*₆) δ 8.76 (dd, 1H), 8.08-8.06 (m, 2H), 7.80-7.77 (m, 2H), 7.65-7.61 (m, 1H), 7.53 (td, 2H), 7.46 (dd, 1H), 4.68 (dd, 2H), 4.41 (s, 1H); ¹⁹F-NMR (377 MHz, CHLOROFORM-D) δ -64.68; LCMS (M+H): 407.85.

Table 10:- Following compounds were prepared by the procedure analogous to that of the compound 164

Compd no.	IUPAC name	Analytical Data
165	imino(4-methoxyphenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ ⁶ -sulfanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.76 (dd, 1H), 8.10 (t, 1H), 8.05 (d, 1H), 7.71-7.67 (m, 2H), 7.46 (dd, 1H), 7.06-7.02 (m, 2H), 4.63 (dd, 2H), 4.26 (s, 1H), 3.81 (s, 3H); ¹⁹ F-NMR (377 MHz, CHLOROFORM-D) δ -64.68; LCMS (M+H): 438.05
166	(4-chlorophenyl)(imino)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ ⁶ -sulfanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.76 (dd, 1H), 8.09-8.07 (m, 2H), 7.76 (dt, 2H), 7.60 (dt, 2H), 7.46 (dd, 1H), 4.71 (dd, 2H), 4.54 (s, 1H); ¹⁹ F-NMR (377 MHz, CHLOROFORM-D) δ -64.67; LCMS (M+H): 441.70
167	(4-fluorophenyl)(imino)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-λ ⁶ -sulfanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.78-8.76 (m, 1H), 8.07 (d, 2H), 7.82-7.78 (m, 2H), 7.46 (dd, 1H), 7.38-7.33 (m, 2H), 4.70 (dd, 2H), 4.50 (s, 1H); ¹⁹ F-NMR (377 MHz, CHLOROFORM-D) δ -64.58, -107.05; LCMS (M+H): 425.85

Example 11:- Preparation of (3-fluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)-λ⁶-sulfanone (Compound no. 168)

Step-1:- 6-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde

To a stirred solution of ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate (3.5 g, 10.73 mmol) in dichloromethane (150 mL), DIBAL-H (37.5 mL, 37.5 mmol) was added dropwise at -78 °C and further stirred at same temperature for another 30 min. The reaction mixture was quenched with 10 % acetic acid (250 mL) and extracted thrice with dichloromethane (150 mL). The combined organic layers were further washed twice with brine (100 mL), dried over sodium sulfate and evaporated to dryness under reduced pressure to obtain 6-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde (3.0 g, 10.56 mmol, 98 % yield). This crude was carried forward as such in next step.

Step-2:- 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde

To a stirred solution of 6-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde (3 g, 10.56 mmol) in dichloromethane (15 mL), 2,3-Dichloro-5,6-dicyano-

1,4-benzoquinone(1.198 g, 5.28 mmol) was added at 0 °C and further stirred at 25 °C for 30 min. After completion of the reaction, the reaction mixture was quenched with saturated sodium bicarbonate (100 mL) and extracted thrice with ethyl acetate (100 mL). The combined organic layers were washed twice with brine (50 mL), dried over sodium sulphate and evaporated to dryness. The obtained crude was purified by combiflash, eluted desired compound in 20 % ethyl acetate in hexane to afford 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde (1.5 g, 5.32 mmol, 50 % yield over two step) as a white solid.

Step 3: (3-fluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)-λ⁶-sulfanone

To a stirred solution of 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde (0.3 g, 1.063 mmol) in formic acid (3 mL), (3-fluorophenyl)(imino)(methyl)-λ⁶-sulfanone (0.331 g, 1.914 mmol) was added. The resulted mixture was irradiated in microwave at 130 °C for 1h. After completion of the reaction, the reaction mixture was poured over cold saturated sodium bicarbonate (200 mL) and extracted thrice with ethyl acetate (100 mL). Combined organic layer was washed twice with brine (100 mL), dried over sodium sulfate and evaporated to dryness under vacuum. Crude compound was purified by prep HPLC to obtain (3-fluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)-λ⁶-sulfanone (0.017 g, 0.039 mmol, 3.6 % yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 9.42 (q, 1H), 8.02 (s, 1H), 7.76 (dt, 1H), 7.65-7.72 (m, 3H), 7.62 (d, 1H), 7.51-7.56 (m, 1H), 4.17 (d, 1H), 4.02 (d, 1H), 3.28 (s, 3H); LCMS (M+1): 440.5.

Table 11: The following compounds were prepared by the procedure analogous to that of the compound no. 168

Compd no.	IUPAC name	Analytical data
169	ethyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)-λ ⁶ -sulfanone	¹ H-NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.42 (s, 1H), 7.99 (s, 1H), 7.71 (dd, 1H), 7.64 (d, 1H), 4.27 (s, 2H), 3.16-3.22 (m, 2H), 2.96 (s, 3H), 1.22-1.27 (m, 3H); LCMS (M+1): 374.00

Example 12:- Preparation of (3-fluorophenyl)(methyl)((2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)-λ⁶-sulfanone (Compound no.170)

Step-1:-3-(((3-fluorophenyl)(methyl)(oxo)-λ⁶-sulfaneylidene)amino)-2-methylimidazo[1,2-a]pyridine-6-carbonitrile

To a solution of (3-fluorophenyl)(imino)(methyl)-λ⁶-sulfanone (0.3 g, 1.732 mmol) in dimethyl sulphoxide (2 mL), potassium hydroxide (0.097 g, 1.732 mmol) was added at 0 °C under nitrogen atmosphere and stirred at 25 °C for 15 min. A solution of 2-(chloromethyl)imidazo[1,2-a]pyridine-6-

carbonitrile (0.266 g, 1.386 mmol) in 1 mL of dimethyl sulphoxide was added and the resulting reaction mixture was stirred at 25 °C for 10 min. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (20 mL) and extracted twice with dichloromethane (100 mL). The combined dichloromethane layers were washed twice with brine (25 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain 3-(((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)amino)-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (0.09 g, 0.274 mmol, 16 % yield).

Step-2:- 3-(((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)amino)-N'-hydroxy-2-methylimidazo[1,2-a]pyridine-6-carboximidamide

To stirred solution of 3-(((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)amino)-2-methylimidazo[1,2-a]pyridine-6-carbonitrile (0.22 g, 0.670 mmol) in methanol (5 mL), hydroxylamine (0.111 mL, 2.010 mmol) was added under nitrogen atmosphere at 0 °C. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was concentrated under reduced pressure and co-distilled with ethyl acetate twice to obtain 3-(((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)amino)-N'-hydroxy-2-methylimidazo[1,2-a]pyridine-6-carboximidamide (0.22 g, 0.610 mmol, 91 % yield). Crude was carried forward as such in next step.

Step-3: (3-fluorophenyl)(methyl)((2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone

To a stirred solution of 3-(((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)amino)-N'-hydroxy-2-methylimidazo[1,2-a]pyridine-6-carboximidamide (0.22 g, 0.610 mmol) in tetrahydrofuran (5 mL), trifluoroacetic anhydride (0.172 mL, 1.221 mmol) was added at 0 °C under nitrogen atmosphere. The resulting reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into ice cold saturated solution of sodium bicarbonate (25 mL) and extract twice with ethyl acetate (50 mL). The organic layer was dried over anhydrous sodium sulphate and concentrate to obtain crude (150 mg). The crude was purified by combiflash to obtain 120 mg desired compound containing trapped acetic acid. Then material was dissolved in tetrahydrofuran and added potassium carbonate (50 mg) and stirred at 25 °C for 1 h, filtered and evaporated to dryness to obtain (3-fluorophenyl)(methyl)((2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone (0.061 g, 0.139 mmol, 23 % yield). ¹H-NMR (400 MHz, CHLOROFORM-D) δ 8.98 (q, 1H), 7.79 (dq, 1H), 7.72 (dt, 1H), 7.66 (dd, 1H), 7.56 (td, 1H), 7.48 (dd, 1H), 7.33-7.37 (m, 1H), 3.41 (s, 3H), 2.31-2.33 (m, 3H); LCMS (M+1): 440.05.

Example 13: Preparation (2-fluorophenyl)(methyl)((2-(trifluoromethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone (compound no. 171)

Step a: 2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile

To a stirred solution of 2-aminoisonicotinonitrile (10 g, 84 mmol) in ethanol (50 mL), 3-bromo-1,1,1-trifluoropropan-2-one (13.1 mL, 126 mmol) was added and stirred for 24 h at 100 °C. The reaction was quenched with saturated aqueous sodium hydrogen carbonate solution (70 mL); the resulting precipitate was filtered *via* a Buchner funnel and washed with ethanol (10 mL) to remove unreacted starting materials. The obtained residue was dried under air suction to obtain 2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (9.1 g, 43 mmol, 51 % yield).

Step b:- 3-bromo-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile

To a stirred solution of 2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (3 g, 14.21 mmol) in dichloromethane (20 mL), *N*-bromosuccinimide (2.78 g, 15.63 mmol) was added at 0 °C and further stirred at 25 °C for 15 min. After completion of the reaction, the reaction was quenched with saturated aqueous sodium hydrogen carbonate solution (70 mL) and extracted twice into ethyl acetate (50 mL). The ethyl acetate layer was washed twice with brine solution (25 mL), dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain 3-bromo-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (4g, 13.8 mmol, 97 % yield).

Step c: 3-(((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfanylidene)amino)-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile

To a stirred solution 3-bromo-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (0.2 g, 0.7 mmol) and (2-fluorophenyl)(imino)(methyl)- λ^6 -sulfanone (0.13 g, 0.76 mmol) in toluene (8 mL), cesium carbonate (0.52 g, 1.59 mmol) was added followed by (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) (0.021 g, 0.034 mmol) and palladium(II) acetate (1.55 mg, 6.9 μ mol) at 25 °C. The resulting reaction mixture was purged with nitrogen for 2 min and stirred at 110 °C for 16 h. The reaction mixture was cooled to 25 °C and filtered through a pad of celite. The filter cake was washed with ethyl acetate (20 mL). The filtrate was washed with water (5 mL) and brine solution (5mL). The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by flash chromatography to obtain 3-(((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfanylidene)amino)-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (0.16 g, 0.42 mmol, 61 % yield).

Step d:- 3-(((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfanylidene)amino)-*N'*-hydroxy-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carboximidamide

To a stirred solution of 3-(((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfanylidene)amino)-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carbonitrile (0.3 g, 0.78 mmol) in ethanol (15 mL), aqueous hydroxylamine solution (50 %) (0.24 mL, 3.92 mmol) was added. The resulting reaction mixture was stirred at 60 °C for 4h. The volatiles were removed under reduced pressure and obtained residue was co evaporated with toluene (10 mL) to obtain 3-(((2-fluorophenyl)(methyl)(oxo)- λ^6 -

sulfanylidene)amino)-*N'*-hydroxy-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carboximidamide (0.2 g, 0.48 mmol, 61 % yield).

Step e:- (2-fluorophenyl)(methyl)((2-(trifluoromethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone

To a stirred solution of 3-(((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfanylidene)amino)-*N'*-hydroxy-2-(trifluoromethyl)imidazo[1,2-a]pyridine-7-carboximidamide (0.2 g, 0.48 mmol) in tetrahydrofuran (2 mL), trifluoroacetic anhydride (0.1 mL, 0.72 mmol) was added dropwise at 5 °C for 30 min. The resulting reaction mixture was allowed to warm to 25 °C and stirred for 16h. The reaction mixture was quenched by sodium bicarbonate solution (2 mL), extracted in dichloromethane (20 mL) and washed with water (5 mL) and brine solution (5 mL). The dichloromethane layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. Crude was purified by flash chromatography eluent 35% ethyl acetate in hexane to obtain (2-fluorophenyl)(methyl)((2-(trifluoromethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone (0.14 g, 0.28 mmol, 58 % yield). ¹H-NMR (400 MHz, DMSO-*d*₆) δ 8.64 (dd, 1H), 8.16 (q, 1H), 7.76-7.84 (m, 2H), 7.50-7.55 (m, 2H), 7.40 (td, 1H), 3.83 (s, 3H) LCMS.

Table 12: The following compounds were prepared by the procedure analogous to that of the compound No. 171

Compd no.	IUPAC name	Analytical Data
172	methyl(phenyl)((2-(trifluoromethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone	¹ H-NMR (400 MHz, DMSO-D ₆) δ 8.74-8.65 (m, 1H), 8.24-8.13 (m, 1H), 8.10-7.99 (m, 2H), 7.80-7.60 (m, 3H), 7.57-7.41 (m, 1H), 3.70-3.57 (m, 3H)) LCMS (M+1): 476

20 BIOLOGY EXAMPLES:

As described herein the compounds of general formula (I) show fungicidal activities which are exerted with respect to numerous phytopathogenic fungi which attack on important agricultural crops. The compounds of the present invention were assessed for their activity as described in the following tests:

25 Biological Test Examples for fungal pathogens

Example 1: *Pyricularia oryzae* (Rice blast):

Compounds were dissolved in 0.3% dimethyl sulfoxide and then added to potato dextrose agar medium just prior to dispensing it into petri dishes. 5mL medium with the compound in the desired concentration was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded

with a 5mm size mycelial disc taken from the periphery of an actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and then the radial growth was measured and compared to that of the untreated control.

Compounds 12 33 80 87 92 103 113 114 136 138 140 142

5 146 161 at 300ppm gave a minimum of 70% control in these tests when compared to the untreated check which showed extensive disease development.

Example 2: *Botrytis cinerea* (Gray mold):

Compounds were dissolved in 0.3% dimethyl sulfoxide and then added to potato dextrose agar medium just prior to dispensing it into petri dishes. 5mL medium with the compound in the desired concentration was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with a 5mm size mycelial disc taken from the periphery of an actively growing virulent culture plate. Plates were incubated in growth chambers at 22°C temperature and 90% relative humidity for seven days and then the radial growth was measured and compared to that of the untreated control.

10 Compound 80 at 300ppm gave a minimum of 70% control in these tests when compared to the untreated check which showed extensive disease development.

Example 3: *Alternaria solani* (early blight of tomato/potato):

Compounds were dissolved in 0.3% dimethyl sulfoxide and then added to potato dextrose agar medium just prior to dispensing it into petri dishes. 5mL medium with the compound in the desired concentration was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with a 5mm size mycelial disc taken from the periphery of an actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and then the radial growth was measured and compared to that of the untreated control.

20 Compounds 2 85 89 92 94 108 113 114 131 138 142 143
146 148 149 at 300ppm gave a minimum of 70% control in these tests when compared to the untreated check which showed extensive disease development.

Example 4: *Colletotrichum capsici* (anthracnose):

Compounds were dissolved in 0.3% dimethyl sulfoxide and then added to potato dextrose agar medium just prior to dispensing it into petri dishes. 5mL medium with the compound in the desired concentration was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with a 5mm size mycelial disc taken from the periphery of an actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and then the radial growth was measured and compared to that of the untreated control.

30 Compounds 46 50 65 69 111 112 116 117 at 300ppm gave a minimum of 70% control in these tests when compared to the untreated check which showed extensive disease development.

35

Example 5: *Corynespora cassiicola* (Leaf spot of tomato/soybean):

Compounds were dissolved in 0.3% dimethyl sulfoxide and then added to potato dextrose agar medium just prior to dispensing it into petri dishes. 5mL medium with the compound in the desired concentration was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with a 5mm size mycelial disc taken from the periphery of an actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 70% relative humidity for seven days and then the radial growth was measured and compared to that of the untreated control. Compounds 18 50 100 111 117 at 300ppm gave a minimum of 70% control in these tests when compared to the untreated check which showed extensive disease development

Example 7: *Fusarium culmorum* (Foot rot of cereals):

Compounds were dissolved in 0.3% dimethyl sulfoxide and then added to potato dextrose agar medium just prior to dispensing it into petri dishes. 5mL medium with the compound in the desired concentration was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with a 5mm size mycelial disc taken from the periphery of an actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and then the radial growth was measured and compared to that of the untreated control. Compounds 50 116 117 at 300ppm gave a minimum of 70% control in these tests when compared to the untreated check which showed extensive disease development.

Example 8: *Phakopsora pachyrhizi* test on Soybean

Compounds were dissolved in 2% dimethyl sulfoxide/acetone and then mixed with water containing an emulsifier to a calibrated spray volume of 50 mL. This 50 mL spray solution was poured into spray bottles for further applications.

To test the preventive activity of compounds, healthy young Soybean plants raised in the greenhouse were sprayed with the active compound preparation at the stated application rates inside the spray cabinets using hollow cone nozzles. One day after treatment, the plants were inoculated with a spore suspension containing 2×10^5 *Phakopsora pachyrhizi* conidia. The inoculated plants were then kept in a greenhouse chamber at 22-24 °C temperature and 80-90 % relative humidity for disease expression.

A visual assessment of the compound's performance was carried out by rating the disease severity (0-100% scale) on treated plants 3, 7, 10 and 15 days after application. Efficacy (% control) of the compounds was calculated by comparing the disease rating in the treatment with the one of the untreated control. The sprayed plants were also assessed for plant compatibility by recording symptoms like necrosis, chlorosis and stunting. Compounds 1 2 3 4 5 6
7 8 9 10 11 13 14 15 16 17 18 19
20 21 22 23 24 25 26 27 28 29 30 31


	32	33	34	35	36	38	40	41	42	43	44	45
	46	47	48	57	58	59	63	64	65	66	67	68
	69	70	71	72	73	75	76	77	78	79	82	83
	85	87	88	89	90	93	94	99	100	101	103	104
5	105	106	107	109	110	111	112	116	120	121	122	126
	127	129	130	150	164	165	166	at 500 ppm gave a minimum of 70%				

control in these tests when compared to the untreated check which showed extensive disease development.

10 Having described the invention with reference to certain preferred aspects, other aspects will become apparent to one skilled in the art from consideration of the specification. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.

CLAIMS:

1) A compound of formula (I),



Formula (I)

5 wherein,

R¹ is C₁-C₂-haloalkyl;

L¹ is a direct bond, -CR²R³-, -C(=W¹)-, -CR²R³C(=W¹)-, -O-, -S(=O)₀₋₂-, or -NR^{4a}-; wherein, the expression “-” at the start and the end of the group indicates the point of attachment to either oxadiazole ring or A;


10 W¹ is O or S;

A is a fused heterobicyclic ring having N at one or more bridgehead; wherein said ring is optionally substituted with one or more identical or different groups of R^A;

R^A is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, SF₅, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy-C₁-C₄-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-haloalkoxycarbonyl, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₁-C₆-haloalkylsulfanyl, C₁-C₆-haloalkylsulfonyl, C₁-C₆-alkylsulfanyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylamino, C₁-C₆-dialkylamino, C₃-C₈-cycloalkylamino, C₁-C₆-alkyl-C₃-C₈-cycloalkylamino, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylaminocarbonyl, C₁-C₆-dialkylaminocarbonyl, C₁-C₆-alkoxycarbonyloxy, C₁-C₆-alkylaminocarbonyloxy, C₁-C₆-dialkylaminocarbonyloxy, and 3- to 6- membered carbocyclic or heterocyclic ring, wherein, said 3- to 6- membered carbocyclic or heterocyclic ring may be optionally substituted with one or more identical or different substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxyalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₁-C₆-haloalkylsulfanyl, C₁-C₆-haloalkylsulfonyl, C₁-C₆-alkylsulfanyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₃-C₆-cycloalkylamino, C₁-C₆-alkyl-C₃-C₆-cycloalkylamino, C₁-C₆ alkylcarbonyl, C₁-C₆ alkoxycarbonyl, C₁-C₆

alkylaminocarbonyl, di-C₁-C₆-alkylaminocarbonyl, C₁-C₆-alkoxycarbonyloxy, C₁-C₆-alkylaminocarbonyloxy and di-C₁-C₆-alkylaminocarbonyloxy;

L² is a direct bond or is selected from the group consisting of -C(=O)-, -C(=S)-, -O-, -S(=O)_{0.2}-, -



5
 , -NR¹⁰-(C=W²)-NR¹⁰-, -NR¹⁰-S(=O)_{0.2}-NR¹⁰-, -(C=W²)-NR¹⁰-NR¹⁰-, -S(=O)_{0.2}-NR¹⁰-NR¹⁰-, -NR¹⁰-NR¹⁰-(C=W²)-, -NR¹⁰-NR¹⁰-S(=O)_{0.2}-, -NR¹⁰-(C=W²)-NR¹⁰-NR¹⁰-, -NR¹⁰-S(=O)_{0.2}-NR¹⁰-NR¹⁰-, -NR¹⁰-NR¹⁰-(C=W²)-NR¹⁰-, -NR¹⁰-NR¹⁰-S(=O)_{0.2}-NR¹⁰-, -O(C=W²)-NR¹⁰-, and -NR¹⁰-(C=W²)-O-;

Y is a direct bond or -NR¹⁰-, or -O-, or -S(O)_{0.2}- or -C(=NOR¹¹)-;

10
 k is an integer ranging from 0 to 4; expressions “-”, “#” and “*” indicate point of attachments;
 W² is O or S;

L³ is a direct bond or is selected from the group consisting of -CR^{8a}R^{9a}-, -CR^{8a}R^{9a}C(=O)-, -C(=O)-, -C(=S)-, -O-, -S(=O)_{0.2}-, -S(O)_{0.1}(=NR¹⁰)-, -S(=N-CN)-, -S(=N-NO₂)-, -S(=N-COR^{8a})-, -S(=N-COOR¹¹)-, -S(=N-(S(=O)₂R¹²))-, -NR¹⁰-, -NR¹⁰(C(=O))O- and -CR^{8a}(=N)O-;

15
 R¹⁰ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkenyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, phenyl-C₁-C₆-alkyl, phenyl, pyridinyl, C(=O)-(C₁-C₆-alkyl), C(=O)-(C₁-C₆-alkoxy) and -N(R^{10a})₂-; wherein, R^{10a} is independently selected from the group consisting of hydrogen, hydroxyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl and C₁-C₆-alkylthio; each group of R¹⁰ is optionally substituted with identical or different radical selected from the group consisting of halogen, hydroxy, oxo, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy and C₃-C₆-cycloalkyl;

20
 R¹¹ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₁-C₆-alkylthio, C₃-C₈-cycloalkenyl, phenyl-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, phenyl and naphthyl;

25
 R¹² is selected from the group consisting of hydrogen, NR^sR^h, wherein, R^s and R^h are independently selected from the group consisting of hydrogen, hydroxyl, cyano, C₁-

C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₃-C₈-cycloalkyl; (C=O)-Rⁱ, wherein, Rⁱ is
 selected from the group consisting of hydrogen, halogen, cyano, C₁-C₄-alkyl, C₂-C₄-
 alkenyl, C₂-C₄-alkynyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl, C₂-C₄-haloalkynyl, C₃-C₆-
 cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; C_{1,8}-alkyl-
 S(O)₀₋₂R^j, wherein R^j is selected from the group consisting of hydrogen, halogen,
 cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₃-C₈-
 cycloalkyl; C₁-C₆-alkyl-(C=O)-Rⁱ, CRⁱ=NR⁸, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-
 alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₁-C₆-alkoxy, C₁-C₆-
 haloalkoxy, C₃-C₈-cycloalkyl, C₄-C₈-cycloalkenyl, C₇-C₁₉-aralkyl, bicyclic C₅-C₁₂-
 alkyl, C₇-C₁₂-alkenyl and fused or non-fused or bicyclic C₃-C₁₈-carbocyclic ring or ring
 system; wherein one or more C atoms of the carbocyclic ring or ring system may be
 replaced by N, O, S(=O)₀₋₂, S(=O)₀₋₁, (=NR¹⁰), C(=O), C(=S), C(=CR⁸R⁹) and
 C=NR¹⁰;

R¹² may optionally be substituted with one or more identical or different
 substituents selected from the group consisting of hydrogen, halogen, cyano,
 nitro, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl,
 C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy-C₁-C₄-alkyl, C₁-C₆-
 hydroxyalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-halocycloalkyl,
 C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-haloalkoxycarbonyl, C₁-C₆-alkylthio,
 C₁-C₆-haloalkylthio, C₁-C₆-haloalkylsulfinyl, C₁-C₆-haloalkylsulfonyl, C₁-C₆-
 alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino,
 C₃-C₈-cycloalkylamino, C₁-C₆-alkyl-C₃-C₈-cycloalkylamino, C₁-C₆-
 alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylaminocarbonyl, di-C₁-C₆-
 alkylaminocarbonyl, C₁-C₆-alkoxycarbonyloxy, C₁-C₆-
 alkylaminocarbonyloxy, di-C₁-C₆-alkylaminocarbonyloxy, 5- to 11-
 membered spirocyclic ring, and 3- to 6- membered carbocyclic or
 heterocyclic ring;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-
 C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₁-C₆-
 alkylthio, C₃-C₈-cycloalkenyl, phenyl-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, phenyl, naphthyl and a
 3- to 10- membered saturated, partially unsaturated or aromatic mono- or bicyclic carbocyclic ring
 or heterocyclic ring, wherein the ring members of the heteroaryl of the heteroaryl-C₁-C₆-alkyl and
 the heterocyclic ring include C, N, O and S(O)₀₋₂ and the C ring members of the carbocyclic ring or
 the heterocyclic ring may be replaced by one or more C(=O) and C(=S); and wherein R⁸ and R⁹ are
 independently unsubstituted or substituted with one or more identical or different R^{8a} or R^{9a};
 wherein R^{8a} and R^{9a} are selected from the group consisting of halogen, cyano, nitro, hydroxyl,

sulfanyl, amino, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkyl, amino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino, NHSO₂-C₁-C₆-alkyl, -C(=O)-C₁-C₆-alkyl, C(=O)-C₁-C₆-alkoxy, C₁-C₆-alkylsulfonyl, hydroxy-C₁-C₆-alkyl, -C(=O)-NH₂, C(=O)-NH(C₁-C₆-alkyl), C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, aminocarbonyl-C₁-C₆-alkyl and C₁-C₆-alkoxy-C₁-C₆-alkyl; or

R⁸ and R⁹ together with the atoms to which they are bound form C(=O) or a vinyl group or a saturated, monocyclic 3- to 7-membered heterocyclic ring or carbocyclic ring, wherein the ring members of heterocyclic include C, N, O and S(O)₀₋₂; and wherein the vinyl group, the heterocyclic ring or the carbocyclic ring is unsubstituted or substituted with one or more identical or different R^{8b}, wherein R^{8b} is selected from the group consisting of halogen, cyano, nitro, hydroxyl, sulfanyl, amino, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkyl, SO₂-C₁-C₆-alkyl, NHSO₂-C₁-C₆-alkyl, -C(=O)-C₁-C₆-alkyl, C(=O)-C₁-C₆-alkoxy, C₁-C₆-alkylsulfonyl, SO₂-C₆H₄CH₃ and SO₂-aryl;

R⁵ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkyl-C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkenyl, C₃-C₈-halocycloalkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₈-cycloalkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkyl-C₁-C₆-thioalkyl, C₁-C₆-alkylsulfinyl-C₁-C₆-alkyl, C₁-C₆-alkylsulfonyl-C₁-C₆-alkyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-haloalkylamino-C₁-C₆-alkyl, C₃-C₈-cycloalkylamino, C₃-C₈-cycloalkylamino-C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxy-C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-hydroxyalkenyl, C₂-C₆-hydroxyalkynyl, C₃-C₈-halocycloalkoxy, C₃-C₈-cycloalkyl-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, C₂-C₆-haloalkenyloxy, C₂-C₆-alkynyloxy, C₂-C₆-haloalkynyloxy, C₁-C₆-alkoxy-C₁-C₆-alkoxy, C₁-C₆-alkylcarbonylalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkylthio, C₁-C₆-alkylsulfinyl, C₁-C₆-haloalkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-haloalkylsulfonyl, C₃-C₈-cycloalkylsulfonyl, C₃-C₈-cycloalkylsulfinyl, tri-C₁-C₆-alkylsilyl, C₁-C₆-alkylsulfonylamino, C₁-C₆-haloalkylsulfonylamino, C₁-C₆-alkylcarbonylthio, C₁-C₆-alkylsulfonyloxy, C₁-C₆-alkylsulfinyloxy, C₆-C₁₀-arylsulfonyloxy, C₆-C₁₀-arylsulfinyloxy, C₆-C₁₀-arylsulfonyl, C₆-C₁₀-arylsulfinyl, C₆-C₁₀-arylthio, C₁-C₆-cyanoalkyl, C₂-C₆-alkenylcarbonyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylthio, C₁-C₆-alkylthio-C₁-C₆-alkoxy, C₂-C₆-haloalkenylcarbonyloxy, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₂-C₆-alkynyl, C₂-C₆-alkynylthio, C₃-C₈-halocycloalkylcarbonyloxy, C₂-C₆-alkenylamino, C₂-C₆-alkynylamino, C₁-C₆-haloalkylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino, C₁-C₆-alkoxyamino, C₁-C₆-haloalkoxyamino, C₁-C₆-alkoxycarbonylamino, C₁-C₆-alkylcarbonyl-C₁-C₆-alkylamino, C₁-

C₆-haloalkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkylamino, C₂-C₆-alkenylthio, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxycarbonylamino, di(C₁-C₆-haloalkyl)amino-C₁-C₆-alkyl, C₃-C₈-halocycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy(C₁-C₆-alkyl)aminocarbonyl, C₁-C₆-haloalkylsulfonylamino-C₁-C₆-alkyl, C₁-C₆-alkylsulfonylamino-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonylalkoxy, C₁-C₆-alkylaminothiocarbonylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-alkylthiocarbonyl, C₃-C₈-cycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxycarbonyl, di-C₁-C₆-alkylaminothiocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkoxy, C₁-C₆-alkoxy-C₁-C₆-haloalkoxy, C₃-C₈-halocycloalkoxy-C₁-C₆-alkyl, di-C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkoxy-C₂-C₆-alkenyl, C₁-C₆-alkylthiocarbonyloxy, C₁-C₆-haloalkoxy-C₁-C₆-alkoxy, C₁-C₆-haloalkylsulfonyloxy, C₁-C₆-alkoxy-C₁-C₆-haloalkyl, di(C₁-C₆-haloalkyl)amino, di-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkylaminocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₆-alkylamino, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyloxy, tri-C₁-C₆-alkylsilyloxy, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyl, cyano(C₁-C₆-alkoxy)-C₁-C₆-alkyl, di-C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkoxysulfonyl, C₃-C₈-halocycloalkoxycarbonyl, C₁-C₆-alkyl-C₃-C₈-cycloalkylcarbonyl, C₃-C₈-halocycloalkylcarbonyl, C₂-C₆-alkenyloxy-C₁-C₆-alkoxy, C₂-C₆-alkynyloxy-C₁-C₆-alkoxy, C₁-C₆-cyanoalkoxycarbonyl, C₁-C₆-alkylthio-C₁-C₆-alkoxycarbonyl, C₂-C₆-alkynylcarbonyloxy, C₂-C₆-haloalkynylcarbonyloxy, cyanocarbonyloxy, C₁-C₆-cyanoalkylcarbonyloxy, C₃-C₈-cycloalkylsulphonyloxy, C₃-C₈-cycloalkyl-C₁-C₆-alkylsulphonyloxy, C₃-C₈-halocycloalkylsulphonyloxy, C₂-C₆-alkenylsulphonyloxy, C₂-C₆-alkynylsulphonyloxy, C₁-C₆-cyanoalkylsulphonyloxy, C₂-C₆-haloalkenylsulphonyloxy, C₂-C₆-haloalkynylsulphonyloxy, C₂-C₆-alkynylcycloalkyloxy, C₂-C₆-cyanoalkenyloxy, C₂-C₆-cyanoalkynyloxy, C₁-C₆-alkoxycarbonyloxy, C₂-C₆-alkenyloxy-C₁-C₆-alkoxy, C₂-C₆-alkynyloxy-C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyloxy, sulfilimines, sulfoximines and SF₅ or Z¹Q¹; R⁵ may be optionally substituted with one or more R⁶;

25 Z¹ is a direct bond, CR^{2a}R^{3a}, N, O, C(O), C(S), C(=CR^{2a}R^{3a}) or S(O)₀₋₂;

30 Q¹ is selected from the group consisting of phenyl, benzyl, naphthalenyl, a 5- or 6-membered aromatic ring, an 8- to 11-membered aromatic multi-cyclic ring system, an 8- to 11-membered aromatic fused ring system, a 5- or 6-membered heteroaromatic ring, an 8- to 11-membered heteroaromatic multi-cyclic ring system and an 8- to 11-membered heteroaromatic fused ring system; wherein the heteroatom of the heteroaromatic rings is selected from N, O or S, and each ring or ring system may be optionally substituted with one or more substituents independently selected from R¹³, or

35 Q¹ is selected from the group consisting of a 3- to 7-membered non-aromatic carbocyclic ring, a 4-, 5-, 6- or 7-membered non-aromatic heterocyclic ring, an 8- to 15-membered non-aromatic multi-cyclic ring system, an 5- to 15 membered spirocyclic ring system,

and an 8- to 15-membered non-aromatic fused ring system, wherein, the heteroatom of the non-aromatic rings is selected from N, O or S(O)₀₋₂, and C ring member of the non-aromatic carbocyclic or non-aromatic heterocyclic rings or ring systems may be replaced with C(O), C(S), C(=CR^{2b}R^{3b}) or C(=NR^{4b}), and each ring or ring system may be optionally substituted with one or more substituents independently selected from R¹³;

R², R³, R^{2a}, R^{3a}, R^{2b} and R^{3b} are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl, C₂-C₄-haloalkynyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;

R² and R³; R^{2a} and R^{3a}; and or R^{2b} and R^{3b} together with the atoms to which they are attached may form 3- to 5- membered non-aromatic carbocyclic ring or heterocyclic ring which may be optionally substituted with halogen, C₁-C₂-alkyl, C₁-C₂-haloalkyl or C₁-C₂-alkoxy;

R^{4a} and R^{4b} are independently selected from the group consisting of hydrogen, cyano, hydroxy, NR^bR^c, (C=O)-R^d, S(O)₀₋₂R^e, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, tri-C₁-C₆-alkylamino and C₃-C₈-cycloalkyl;

R^b and R^c are independently selected from the group consisting of hydrogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₃-C₈-cycloalkyl and C₃-C₈-halocycloalkyl;

R^d is selected from the group consisting of hydrogen, hydroxy, halogen, NR^bR^c, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₃-C₈-cycloalkyl and C₃-C₈-halocycloalkyl;

R^e is selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy and C₃-C₈-cycloalkyl and C₃-C₈-halocycloalkyl;

R⁶ and R¹³ are independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkyl-C₃-C₈-cycloalkyl, C₃-C₈-halocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkyl-C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₈-cycloalkenyl, C₃-C₈-halocycloalkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₈-cycloalkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkyl-C₁-C₆-thioalkyl, C₁-C₆-alkylsulfinyl-C₁-C₆-alkyl, C₁-C₆-alkylsulfonyl-C₁-C₆-alkyl, C₁-C₆-alkylamino, di-C₁-C₆-

alkylamino, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-haloalkylamino-C₁-C₆-alkyl, C₃-C₈-cycloalkylamino, C₃-C₈-cycloalkylamino-C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxy-C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-hydroxyalkenyl, C₂-C₆-hydroxyalkynyl, C₃-C₈-halocycloalkoxy, C₃-C₈-cycloalkyl-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, C₂-C₆-haloalkenyloxy, C₂-C₆-alkynyloxy, C₂-C₆-haloalkynyloxy, C₁-C₆-alkoxy-C₁-C₆-alkoxy, C₁-C₆-alkylcarbonylalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkylthio, C₁-C₆-alkylsulfinyl, C₁-C₆-haloalkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-haloalkylsulfonyl, C₃-C₈-cycloalkylsulfonyl, C₃-C₈-cycloalkylsulfinyl, tri-C₁-C₆-alkylsilyl, C₁-C₆-alkylsulfonylamino, C₁-C₆-haloalkylsulfonylamino, C₁-C₆-alkylcarbonylthio, C₁-C₆-alkylsulfonyloxy, C₁-C₆-alkylsulfinyloxy, C₆-C₁₀-arylsulfonyloxy, C₆-C₁₀-arylsulfinyloxy, C₆-C₁₀-arylsulfonyl, C₆-C₁₀-arylsulfinyl, C₆-C₁₀-arylthio, C₁-C₆-cyanoalkyl, C₂-C₆-alkenylcarbonyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylthio, C₁-C₆-alkylthio-C₁-C₆-alkoxy, C₂-C₆-haloalkenylcarbonyloxy, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₂-C₆-alkynyl, C₂-C₆-alkynylthio, C₃-C₈-halocycloalkylcarbonyloxy, C₂-C₆-alkenylamino, C₂-C₆-alkynylamino, C₁-C₆-haloalkylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino, C₁-C₆-alkoxyamino, C₁-C₆-haloalkoxyamino, C₁-C₆-alkoxycarbonylamino, C₁-C₆-alkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-haloalkylcarbonyl-C₁-C₆-alkylamino, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkylamino, C₂-C₆-alkenylthio, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyl, C₁-C₆-haloalkoxycarbonylamino, di(C₁-C₆-haloalkyl)amino-C₁-C₆-alkyl, C₃-C₈-halocycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy(C₁-C₆-alkyl)aminocarbonyl, C₁-C₆-haloalkylsulfonylaminocarbonyl, C₁-C₆-alkylsulfonylaminocarbonyl, C₁-C₆-alkoxycarbonylalkoxy, C₁-C₆-alkylaminothiocarbonylamino, C₃-C₈-cycloalkyl-C₁-C₆-alkylamino-C₁-C₆-alkyl, C₁-C₆-alkylthiocarbonyl, C₃-C₈-cycloalkenyloxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxycarbonyl, di-C₁-C₆-alkylaminothiocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkoxy, C₁-C₆-alkoxy-C₁-C₆-haloalkoxy, C₃-C₈-halocycloalkoxy-C₁-C₆-alkyl, di-C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkoxy-C₂-C₆-alkenyl, C₁-C₆-alkylthiocarbonyloxy, C₁-C₆-haloalkoxy-C₁-C₆-alkoxy, C₁-C₆-haloalkylsulfonyloxy, C₁-C₆-alkoxy-C₁-C₆-haloalkyl, di(C₁-C₆-haloalkyl)amino, di-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkylaminocarbonylamino, C₁-C₆-haloalkoxy-C₁-C₆-haloalkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₆-alkylamino, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyloxy, tri-C₁-C₆-alkylsilyloxy, tri-C₁-C₆-alkylsilyl-C₂-C₆-alkynyl, cyano(C₁-C₆-alkoxy)-C₁-C₆-alkyl, di-C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkoxysulfonyl, C₃-C₈-halocycloalkoxycarbonyl, C₁-C₆-alkyl-C₃-C₈-cycloalkylcarbonyl, C₃-C₈-halocycloalkylcarbonyl, C₂-C₆-alkenyloxycarbonyl, C₂-C₆-alkynyloxycarbonyl, C₁-C₆-cyanoalkoxycarbonyl, C₁-C₆-alkylthio-C₁-C₆-alkoxycarbonyl, C₂-C₆-alkynylcarbonyloxy, C₂-C₆-haloalkynylcarbonyloxy, cyanocarbonyloxy, C₁-C₆-cyanoalkylcarbonyloxy, C₃-C₈-cycloalkylsulphonyloxy, C₃-C₈-cycloalkyl-C₁-C₆-alkylsulphonyloxy, C₃-C₈-halocycloalkylsulphonyloxy, C₂-C₆-alkenylsulphonyloxy, C₂-C₆-alkynylsulphonyloxy, C₁-C₆-cyanoalkylsulphonyloxy, C₂-C₆-haloalkenylsulphonyloxy, C₂-

C₆-haloalkynylsulphonyloxy, C₂-C₆-alkynylcycloalkyloxy, C₂-C₆-cyanoalkenyloxy, C₂-C₆-cyanoalkynyloxy, C₁-C₆-alkoxycarbonyloxy, C₂-C₆-alkenyloxy carbonyloxy, C₂-C₆-alkynyloxy carbonyloxy, C₁-C₆-alkoxy-C₁-C₆-alkylcarbonyloxy, sulfilimines, sulfoximines and SF₅;

5 and/or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof;

with the proviso that following compounds are excluded from the definition of compound of formula (I);

10 N-(2-methoxyethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide and ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate.

2) The compound of formula (I) as claimed in claim 1, wherein

R¹ selected from the group consisting of CF₃, CHF₂, CF₂Cl, CF₂CF₃, CH₂F, CH₂CF₃, CHClCF₃ and CCl₂CF₃;

15 L¹ is a direct bond, -CR²R³-;

A is a fused heterobicyclic ring having N at one or more bridgehead; wherein said ring is optionally substituted with one or more identical or different groups of R^A;

20 R^A is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, SF₅, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl and C₁-C₆-haloalkyl;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl and C₁-C₆-alkylthio; or


25 R⁸ and R⁹ together with the atoms to which they are bound form C(=O) or a vinyl group or a saturated, monocyclic 3- to 7-membered heterocyclic ring or carbocyclic ring, wherein the ring members of heterocyclic include C, N, O and S(O)₀₋₂; and wherein the vinyl group, the heterocyclic ring or the carbocyclic ring is unsubstituted or substituted with one or more identical or different R^{8b}, wherein R^{8b} is selected from the group consisting of halogen, cyano, nitro, hydroxyl, sulfanyl, amino, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio and C₃-C₈-cycloalkyl.

30

3) The compound of formula (I) as claimed in claim 1, wherein

R¹ selected from the group consisting of CF₃, CHF₂, CF₂Cl, CHClCF₃ and CCl₂CF₃;

L¹ is a direct bond;

A is ; wherein “#” and “*” indicate point of attachments and said ring is optionally substituted with one or more identical or different groups of R^A;

R^A is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, SF₅, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylalkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy-C₁-C₄-alkyl and C₁-C₆-hydroxyalkyl;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl and C₃-C₈-cycloalkyl; or

R⁸ and R⁹ together with the atoms to which they are bound form C(=O) or a vinyl group.

- 4) The compound of formula (I) as claimed in claim 1, wherein said compound of formula (I) is selected from N-(3-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-methoxyphenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(p-tolyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-fluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2,4-difluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-fluorophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-3-yl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-benzyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-4-yl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorophenyl)-N-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-methyl-N-(2-phenoxyethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-cyanophenyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2,4-difluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(p-tolyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-

oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-benzyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N,N-dimethyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chloro-2-fluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-cyanophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-methoxyphenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-3-yl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2,6-difluorophenyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-fluorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(pyridin-4-yl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; azetidin-1-yl(7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone; N-(2-methoxyethyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-isobutyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-neopentyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-isopentyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-methoxybenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-chlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-methoxybenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-fluorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-(dimethylamino)benzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3,4-dichlorobenzyl)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; ethyl 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate hydrobromide; 3-(2-(((3-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((phenylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 5-(trifluoromethyl)-3-(2-(((4-(trifluoromethyl)phenyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazole; 3-(2-(((4-methoxybenzyl)thio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((propylthio)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-

(((4-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxyphenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxybenzyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-((propylsulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 5-(trifluoromethyl)-3-(2-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazole; 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(4-(trifluoromethyl)benzyl)imidazo[1,2-a]pyridine-2-carboxamide; morpholino(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone; N-(2-methoxyethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-isobutyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-cyclopentyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; (3-methoxypyrrolidin-1-yl)(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone; azetidin-1-yl(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methanone; N-(cyclopropylmethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-benzyl-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(1-phenylethyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(1-cyanocyclopropyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(2-methoxyethyl)-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-chlorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(3-methoxybenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(4-chlorobenzyl)-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-isobutyl-N-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; ethyl 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylate; 3-(2-(ethoxymethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 4-methoxy-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 4-chloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 2-(4-chlorophenyl)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)acetamide; 3-chloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 3,4-dichloro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-

yl)methyl)benzamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)picolinamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)propionamide; 4-(trifluoromethoxy)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 4-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 2-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)oxazole-4-carboxamide; 3-fluoro-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 2-phenyl-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)acetamide; 4-(dimethylamino)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; 3-methyl-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)butanamide; 4-(trifluoromethyl)-N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)benzamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)nicotinamide; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)isonicotinamide; 3-(2-(((4-methoxyphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-((phenylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-chlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((propylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((benzylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxybenzyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,4-dichlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,5-dichlorophenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((isobutylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((cyclopentylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((cyclohexylthio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-ethylphenyl)thio)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((phenylsulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,4-dichlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-chlorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-chlorophenyl)sulfonyl)methyl)imidazo[1,2-

a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxybenzyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((cyclohexyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((4-methoxyphenyl)sulfonyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3,4-dichlorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((3-chlorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; 3-(2-(((2-fluorophenyl)sulfinyl)methyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole; N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(dimethyl(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(1-oxidotetrahydro-2H-1 λ^6 -thiopyran-1-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-chlorophenyl)(2-methoxyethyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(isopropyl(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(methyl(oxo)(4-(trifluoromethyl)phenyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3,5-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(1-oxidotetrahydro-1 λ^6 -thiophen-1-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-bromophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3,4-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(4-oxido-1,4 λ^6 -oxathian-4-ylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((2-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-methoxypyridin-2-yl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-(methyl(oxo)(o-tolyl)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((3-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; (3-fluorophenyl)(methyl)((2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; N-((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)butyramide; imino(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)pivalamide; 4-methoxy-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 4-chloro-2-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 3-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 3-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; 4-chloro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-4-(trifluoromethoxy)benzamide ; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-2-(trifluoromethyl)benzamide; N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)-3-(trifluoromethyl)benzamide; 2-fluoro-N-(methyl(oxo)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfaneylidene)benzamide; imino(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; imino(4-methoxyphenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (4-chlorophenyl)(imino)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (4-fluorophenyl)(imino)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(4-methoxybenzyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)((1-methyl-1H-pyrazol-4-yl)methyl)- λ^6 -sulfanone; (4-chlorobenzyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-

methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)((1-methyl-1H-1,2,4-triazol-3-yl)methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(phenyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(2,4-difluorophenyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(4-fluorophenyl)(methyl)- λ^6 -sulfanone; tert-butyl((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)((1-methyl-1H-imidazol-4-yl)methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)dimethyl- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(cyclopropylmethyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(2,6-dichlorophenyl)(methyl)- λ^6 -sulfanone; (2-chloro-4-fluorophenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; (2-chloro-4-(trifluoromethyl)phenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(4-methylbenzyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(4-methoxyphenyl)(methyl)- λ^6 -sulfanone; benzyl((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(pyridin-3-yl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(isoxazol-4-ylmethyl)(methyl)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(oxazol-4-ylmethyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(thiazol-4-ylmethyl)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)(pyrimidin-5-yl)- λ^6 -sulfanone; (3-chloro-4-(trifluoromethyl)phenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-

methylimidazo[1,2-a]pyridin-3-yl)imino)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(isopropyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(ethyl)(methyl)- λ^6 -sulfanone; ((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylimidazo[1,2-a]pyridin-3-yl)imino)(2-methoxyethyl)(methyl)- λ^6 -sulfanone; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((4-methoxybenzyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-((4-chlorobenzyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl((1-methyl-1H-1,2,4-triazol-3-yl)methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((2,4-difluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((4-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-(tert-butyl(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(3,3,3-trifluoropropyl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl((1-methyl-1H-imidazol-4-yl)methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(dimethyl(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((cyclopropylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((2,6-dichlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-((2-chloro-4-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; N-((2-chloro-4-(trifluoromethyl)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(4-methylbenzyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-(benzyl(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(pyridin-3-yl)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-

oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((isoxazol-4-ylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; N-(((1,2,4-oxadiazol-3-yl)methyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxazol-4-ylmethyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(thiazol-4-ylmethyl)- λ^6 -sulfaneylidene)acetamide; N-((2-chloro-6-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl(oxo)(pyrimidin-5-yl)- λ^6 -sulfaneylidene)acetamide; N-((3-chloro-4-(trifluoromethyl)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(isopropyl(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(ethyl(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-((2-methoxyethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 2-(7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-N-(methyl((1-methyl-1H-pyrazol-4-yl)methyl)(oxo)- λ^6 -sulfaneylidene)acetamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(m-tolyl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((2,4-difluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((3-(dimethylamino)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(dimethyl(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(ethyl(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; N-(tert-butyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-((cyclopropylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; N-(benzyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-

(methyl(oxo)(pyrimidin-5-yl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(pyridazin-4-yl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(pyrazin-2-yl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; 7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(methyl(oxo)(pyridin-4-yl)- λ^6 -sulfaneylidene)imidazo[1,2-a]pyridine-2-carboxamide; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(4-methoxybenzyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)((1-methyl-1H-pyrazol-4-yl)methyl)- λ^6 -sulfanone; (4-chlorobenzyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)((1-methyl-1H-1,2,4-triazol-3-yl)methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(phenyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(2,4-difluorophenyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(4-fluorophenyl)(methyl)- λ^6 -sulfanone; tert-butyl(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)((1-methyl-1H-imidazol-4-yl)methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)dimethyl- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(cyclopropylmethyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(2,6-dichlorophenyl)(methyl)- λ^6 -sulfanone; (2-chloro-4-fluorophenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (2-chloro-4-(trifluoromethyl)phenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(4-methylbenzyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(4-methoxyphenyl)(methyl)- λ^6 -sulfanone; benzyl(((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(pyridin-3-yl)- λ^6 -sulfanone; (((7-(5-

(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(isoxazol-4-ylmethyl)(methyl)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(oxazol-4-ylmethyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(thiazol-4-ylmethyl)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)(pyrimidin-5-yl)- λ^6 -sulfanone; (3-chloro-4-(trifluoromethyl)phenyl)((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(isopropyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(ethyl)(methyl)- λ^6 -sulfanone; (((7-(5-(chlorodifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(2-methoxyethyl)(methyl)- λ^6 -sulfanone; (4-methoxybenzyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((1-methyl-1H-pyrazol-4-yl)methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (4-chlorobenzyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((1-methyl-1H-1,2,4-triazol-3-yl)methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(phenyl)- λ^6 -sulfanone; (2,4-difluorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (4-fluorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; methyl((1-methyl-1H-imidazol-4-yl)methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; dimethyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2,6-dichlorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2-chloro-4-fluorophenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2-chloro-4-(trifluoromethyl)phenyl)(methyl)((2-methyl-7-(5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone;
methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(4-(trifluoromethoxy)phenyl)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(4-methylbenzyl)- λ^6 -sulfanone; (4-
5 methoxyphenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; benzyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(pyridin-3-yl)- λ^6 -sulfanone; (isoxazol-4-ylmethyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(oxazol-4-ylmethyl)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(thiazol-4-ylmethyl)- λ^6 -sulfanone; (2-chloro-6-
15 methoxyphenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; methyl((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)(pyrimidin-5-yl)- λ^6 -sulfanone; (3-chloro-4-(trifluoromethyl)phenyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; isopropyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone;
20 ethyl(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (2-methoxyethyl)(methyl)((2-methyl-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)imino)- λ^6 -sulfanone; (isopropylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((cyclopropylmethyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((isoxazol-4-ylmethyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2-methoxyethyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(methylimino)- λ^6 -sulfanone; (ethylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(((1-methyl-1H-imidazol-4-yl)methyl)imino)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((3,3,3-trifluoropropyl)imino)- λ^6 -sulfanone; ((4-
35 methoxybenzyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(((1-methyl-1H-pyrazol-4-yl)methyl)imino)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-

yl)- λ^6 -sulfanone; ((4-chlorobenzyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(((1-methyl-1H-1,2,4-triazol-3-yl)methyl)imino)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(phenylimino)- λ^6 -sulfanone; ((2,4-difluorophenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((4-fluorophenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; (tert-butylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(pyridin-3-ylimino)- λ^6 -sulfanone; (benzylimino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((4-methoxyphenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((4-methylbenzyl)imino)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((4-(trifluoromethoxy)phenyl)imino)- λ^6 -sulfanone; ((2-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2-chloro-4-fluorophenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2,6-dichlorophenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; ((2-chloro-6-methoxyphenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((thiazol-4-ylmethyl)imino)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)((oxazol-4-ylmethyl)imino)- λ^6 -sulfanone; (((1,2,4-oxadiazol-3-yl)methyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; methyl(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)(pyrimidin-5-ylimino)- λ^6 -sulfanone; ((3-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)(2-methyl-6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-3-yl)- λ^6 -sulfanone; (isopropylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((cyclopropylmethyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((isoxazol-4-ylmethyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-methoxyethyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(methylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (ethylimino)(methyl)((6-(5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone;
 methyl(((1-methyl-1H-imidazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)((3,3,3-trifluoropropyl)imino)- λ^6 -sulfanone;
 5 ((4-methoxybenzyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(((1-methyl-1H-pyrazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((4-chlorobenzyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(((1-methyl-1H-1,2,4-triazol-3-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone;
 10 methyl(phenylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2,4-difluorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((4-fluorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (tert-butylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(pyridin-3-ylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (benzylimino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((4-methoxyphenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((4-methylbenzyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((4-(trifluoromethoxy)phenyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-chloro-4-fluorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2,6-dichlorophenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((2-chloro-6-methoxyphenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone ;
 25 methyl((thiazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl((oxazol-4-yl)methyl)imino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; (((1,2,4-oxadiazol-3-yl)methyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; methyl(pyrimidin-5-ylimino)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; ((3-chloro-4-(trifluoromethyl)phenyl)imino)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone; N-(methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)-7-(5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((4-chlorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((4-methoxyphenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(m-tolyl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((2-fluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((2,4-difluorophenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((3-(dimethylamino)phenyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(dimethyl(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(ethyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(tert-butyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-((cyclopropylmethyl)(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(benzyl(methyl)(oxo)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyrimidin-5-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyridazin-4-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyrazin-2-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; N-(methyl(oxo)(pyridin-4-yl)- λ^6 -sulfaneylidene)-7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxamide; methyl(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (4-chlorophenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (4-methoxyphenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(m-tolyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (2-fluorophenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (2,4-difluorophenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (3-(dimethylamino)phenyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; dimethyl((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; ethyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; benzyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyrimidin-5-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyridazin-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyrazin-2-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(pyridin-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)imino)- λ^6 -sulfanone; methyl(phenyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(3-methylbenzyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-4-ylmethyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyrimidin-4-ylmethyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-3-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridin-2-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(5-(trifluoromethyl)pyridin-2-yl)- λ^6 -sulfanone; (5-methoxypyridin-2-yl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (5-fluoropyridin-2-yl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyrimidin-5-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyridazin-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(1-methyl-1H-pyrazol-4-yl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; isoxazol-4-yl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-methoxythiazol-4-yl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; dimethyl(((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; ethyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; (2-methoxyethyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; benzyl(methyl)((7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (3-methoxybenzyl)(methyl)((7-(5-(trifluoromethyl)-1,2,4-


oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (3-
fluorobenzyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
yl)methyl)imino)- λ^6 -sulfanone; isopropyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (cyclopropylmethyl)(methyl)((6-(5-
5 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
(isoxazol-4-ylmethyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-methoxyethyl)(methyl)((6-(5-(trifluoromethyl)-
1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; dimethyl((6-(5-
(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
10 ethyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
yl)methyl)imino)- λ^6 -sulfanone methyl((1-methyl-1H-imidazol-4-yl)methyl)((6-(5-
(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
methyl((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
yl)methyl)imino)(3,3,3-trifluoropropyl)- λ^6 -sulfanone; (4-methoxybenzyl)(methyl)((6-(5-
15 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
methyl((1-methyl-1H-pyrazol-4-yl)methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (4-chlorobenzyl)(methyl)((6-(5-
(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
methyl((1-methyl-1H-1,2,4-triazol-3-yl)methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
20 yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(phenyl)((6-(5-
(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
(2,4-difluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-
2-yl)methyl)imino)- λ^6 -sulfanone; (4-fluorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-
oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; tert-butyl(methyl)((6-(5-
25 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
methyl(pyridin-3-yl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
yl)methyl)imino)- λ^6 -sulfanone; benzyl(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-
yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (4-methoxyphenyl)(methyl)((6-(5-
(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
30 methyl(4-methylbenzyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-
yl)methyl)imino)- λ^6 -sulfanone; methyl(4-(trifluoromethoxy)phenyl)((6-(5-(trifluoromethyl)-
1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-chloro-4-
(trifluoromethyl)phenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-chloro-4-fluorophenyl)(methyl)((6-(5-
35 (trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone;
(2,6-dichlorophenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-
a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; (2-chloro-6-methoxyphenyl)(methyl)((6-(5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(thiazol-4-ylmethyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(oxazol-4-ylmethyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; ((1,2,4-oxadiazol-3-yl)methyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone; methyl(pyrimidin-5-yl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone and (3-chloro-4-(trifluoromethyl)phenyl)(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)imino)- λ^6 -sulfanone.

- 5
- 10 5) The compound of formula (I) as claimed in claim 1, wherein said compound is used as fungicide.
- 6) A combination comprising the compound of formula (I) as claimed in claim 1 and at least one further pesticidally active substance selected from the group consisting of fungicides, insecticides, nematocides, acaricides, biopesticides, herbicides, safeners, plant growth regulators, antibiotics, fertilizers and nutrients.
- 15 7) A composition for controlling or preventing plant diseases comprising the compound of formula (I) as claimed in claim 1 and at least one agrochemically acceptable auxiliary.
- 8) The composition as claimed in claim 7, wherein said composition may further comprises at least one additional active ingredient.
- 9) The composition as claimed in claim 7, wherein said composition is applied to seed and the amount of compound of the formula (I) in said composition is ranges from 0.1 g ai to 10 kg ai per 20 100 kg of seeds.
- 10) The composition as claimed in claim 7, wherein the plant diseases is caused by rust pathogens selected from the group comprising of *Hemileia vastatrix* (Coffee rust), *Uromyces appendiculatus/fabae/ phaseoli* (rust of beans) *Puccinia spp.* (rusts) on various plants selected from *P. triticina* (brown or leaf rust), *P. striiformis* (stripe or yellow rust), *P. Hordei* (dwarf rust), 25 *P. graminis* (stem or black rust) or *P. recondita* (brown or leaf rust) on cereals selected from wheat, barley or rye and *Phakopsora spp.* on various plants, in particular *Phakopsora pachyrhizi* and *P. meibomia* (soybean rust) on soybeans.
- 11) A method for controlling or preventing phytopathogenic fungi, wherein the method comprises 30 treating the fungi or the materials, plants, plant parts, locus thereof, soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula (I) claimed in claim 1 or the combination claimed in claim 6 or the composition claimed in claim 7.
- 12) A method for controlling or preventing infestation of plants by phytopathogenic micro-organisms in agricultural crops and/or horticultural crops wherein an effective amount of at least one 35 compound of formula (I) claimed in claim 1 or the combination claimed in claim 6 or the composition claimed in claim 7, is applied to the seeds of plants.


13) A process for the preparation of the compound of formula (I) as claimed in claim 1, wherein said process comprising the steps of:

- a) reacting a compound of formula i with a alpha-halo carbonyl compound of formula v to afford a compound of formula ii;




wherein, L¹ is direct bond; and A is

- b) reacting the compound of formula ii with a hydroxyl amine to afford a compound of formula iii;



wherein, L¹ is direct bond; and A is


- c) reacting a compound of formula iii with an acid anhydride of formula (d) or with an acid chloride compound of formula (e) to afford compound of formula iv;




wherein, L¹ is direct bond; A is

; and X is Cl, Br or I.

- d) reacting the compound of formula iv with sulphoximine compound of formula (a) to afford compound of formula (I);







wherein, L¹ is direct bond; and A is

14) A process for the preparation of compound of formula (I) as claimed in claim 1, wherein said process comprising the steps of:

a) reacting a compound of formula i with a compound of formula ix to afford a compound of formula vi;



5



wherein, L¹ is direct bond; and A is


b) reacting the compound of formula vi with a hydroxyl amine to afford a compound of formula vii;

10



wherein, L¹ is direct bond; and A is


c) reacting the compound of formula vii with an acid anhydride of formula (d) or with an acid chloride compound of formula (e) to afford compound of formula viii;




15

wherein, L¹ is direct bond; A is ; X = Br, Cl or I;

d) reacting the compound of formula viii with a compound of formula (a) to afford compound of formula (I);




wherein, L¹ is direct bond; A is




; and L² is

15) A process for the preparation of compound of formula (I) as claimed in claim 1, wherein said process comprising the steps of:


- 5 a) reacting a compound of formula i with a compound of formula x to afford a compound of formula xi;




wherein, L¹ is direct bond; A is



- 10 b) reacting the compound of formula xi with a hydroxyl amine to afford a compound of formula xii;




wherein, L¹ is direct bond; A is




; and X is Cl, Br, I;


- c) reacting the compound of formula xii with an acid anhydride of formula (d) or with an acid chloride compound of formula (e) to afford compound of formula xiii;




15 wherein, L¹ is direct bond; X is Cl, Br, I; and A is





- d) reacting the compound of formula xiii with a compound of formula (f) to afford compound of formula xiv;



wherein, L¹ is direct bond; A is ; X is Cl, Br, I;


- 5 e) oxidizing the compound of formula xiv with a suitable oxidizing agent to afford a compound of formula (I);



wherein, L¹ is direct bond; A is ; L² is -S(=O)₀₋₂₋.


- 16) A process for the preparation of compound of formula (I) as claimed in claim 1, wherein said process comprising the steps of:

- a) reacting a compound of formula xii with a suitable alkali metal azide compound to afford a compound of formula xv;




L¹ is direct bond; A is ;



- 15 b) reacting the compound of formula xv with a suitable reducing agent to afford a compound of formula xvi;



L¹ is direct bond; A is ;

- 20 c) reacting the compound of formula xvi with a carboxylic acid of formula (b) or with a carboxylic acid chloride compound of formula (c) to afford compound of formula (I);





L¹ is direct bond; A is ; L² is  L^{2e} in which Y is -NR¹⁰ and L³ is C(=O)-.

17) A process for the preparation of compound of formula (I) as claimed in claim 1, wherein said process comprising the steps of:

5


a) reacting a compound of formula iv with a suitable reducing reagent to afford a compound of formula xvii;




wherein, L¹ is direct bond; A is ;

10


b) reacting the compound of formula xvii with a suitable oxidizing reagent to afford a compound of formula xviii;





wherein, L¹ is direct bond; A is ;


15

c) reacting the compound of formula xviii with a sulfoximine compound of formula (a) to afford compound of formula (I);




wherein, L¹ is direct bond; A is ; L² is  L^{2a}.

18) A compound of formula (B);




Formula (B)

wherein,



5 L¹ is direct bond;



R⁸ and R⁹ are independently selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl and C₃-C₈-cycloalkyl;

k is an integer ranging from 0 and 1;

10 R is selected from the group consisting of hydrogen, azide, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₁-C₆-alkylthio, C₁-C₆-haloalkylthio, C₃-C₈-cycloalkyl, amino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino, NHSO₂-C₁-C₆-alkyl, -S(=O)(=NH)-C₁-C₆-alkyl; -C(=O)-C₁-C₆-alkyl, C(=O)-C₁-C₆-alkoxy, C₁-C₆-alkylsulfonyl, hydroxy-C₁-C₆-alkyl, -C(=O)-NH₂, C(=O)-NH(C₁-C₆-alkyl), C₁-C₆-alkylthio-C₁-C₆-alkyl, C₁-C₆-alkylamino-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, aminocarbonyl-C₁-C₆-alkyl and C₁-C₆-alkoxy-C₁-C₆-alkyl;

15

with the proviso that the following compounds are excluded from the definition of compound of formula (I);

ethyl (Z)-2-(6-(N'-hydroxycarbamimidoyl)imidazo[1,2-a]pyridin-2-yl)acetate, 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid and ethyl (Z)-2-(7-(N'-hydroxycarbamimidoyl)imidazo[1,2-a]pyridin-2-yl)acetate.

20

19) The compound of formula (B) as claimed in claim 1, wherein said compound of formula (B) is selected from 7-(N'-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylic acid, ethyl 2-(7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetate, 7-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 7-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 7-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 2-(chloromethyl)-N'-hydroxyimidazo[1,2-a]pyridine-7-carboximidamide, 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(2-

25

(azidomethyl)imidazo[1,2-a]pyridin-7-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole, ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetate, 6-(*N'*-hydroxycarbamimidoyl)imidazo[1,2-a]pyridine-2-carboxylic acid, ethyl 2-(6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)acetate, 6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 6-(5-(trifluoromethyl)-4,5-dihydro-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridine-2-carbaldehyde, 3-(2-(chloromethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 2-(chloromethyl)-*N'*-hydroxyimidazo[1,2-a]pyridine-6-carboximidamide, 3-(2-(azidomethyl)imidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole and imino(methyl)((6-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)- λ^6 -sulfanone.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2020/053296

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D471/04 A01N43/90 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C07D A01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2019/155066 A1 (BAYER AG [DE]) 15 August 2019 (2019-08-15) claims 1,3,11,12; examples I-036 -----	1-19
X	WO 2017/222950 A1 (MERCK SHARP & DOHME [US]; WALJI ABBAS [US] ET AL.) 28 December 2017 (2017-12-28) page 6, line 22 - page 7, line 13; example 35 -----	1-3
X	EP 2 003 132 A1 (ASTELLAS PHARMA INC [JP]) 17 December 2008 (2008-12-17) tables 3,4 -----	18
X	WO 2009/055418 A1 (SMITHKLINE BEECHAM CORP [US]; ADAMS NICHOLAS D [US] ET AL.) 30 April 2009 (2009-04-30) example 45c -----	18
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search <p align="center">29 July 2020</p>	Date of mailing of the international search report <p align="center">06/08/2020</p>	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <p align="center">Johnson, Claire</p>	

INTERNATIONAL SEARCH REPORT

International application No PCT/IB2020/053296

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 382 603 A1 (EISAI CO LTD [JP]) 21 January 2004 (2004-01-21) production example 244; paragraph [0674] -----	18
Y	WO 2011/057145 A2 (UNIV NOTRE DAME DU LAC [US]; DOW AGROSCIENCES LLC [US] ET AL.) 12 May 2011 (2011-05-12) Schemes 1, 2; paragraph [0060]; claim 1 paragraph [0062] paragraph [0017] paragraph [0110] -----	4-17,19
Y	WO 2018/202491 A1 (BASF SE [DE]) 8 November 2018 (2018-11-08) cited in the application page 87 - page 89; claims 1,13 -----	4-17,19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2020/053296

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2019155066 A1	15-08-2019	TW 201936589 A	16-09-2019
		UY 38084 A	30-08-2019
		WO 2019155066 A1	15-08-2019

WO 2017222950 A1	28-12-2017	NONE	

EP 2003132 A1	17-12-2008	AU 2007236707 A1	18-10-2007
		BR PI0709866 A2	26-07-2011
		CA 2648303 A1	18-10-2007
		EP 2003132 A1	17-12-2008
		ES 2453372 T3	07-04-2014
		JP 5099005 B2	12-12-2012
		JP WO2007116866 A1	20-08-2009
		KR 20090007740 A	20-01-2009
		MX 356221 B	18-05-2018
		NO 342171 B1	09-04-2018
		PL 2003132 T3	31-10-2014
		PT 2003132 E	26-05-2014
		TW 200815423 A	01-04-2008
		US 2009076070 A1	19-03-2009
US 2010168159 A1	01-07-2010		
WO 2007116866 A1	18-10-2007		

WO 2009055418 A1	30-04-2009	EP 2211615 A1	04-08-2010
		JP 2011500823 A	06-01-2011
		US 2010311736 A1	09-12-2010
		WO 2009055418 A1	30-04-2009

EP 1382603 A1	21-01-2004	AT 402164 T	15-08-2008
		EP 1382603 A1	21-01-2004
		EP 2048142 A2	15-04-2009
		ES 2310202 T3	01-01-2009
		JP 4310109 B2	05-08-2009
		JP WO2002088107 A1	19-08-2004
		US 7074801 B1	11-07-2006
		WO 02088107 A1	07-11-2002

WO 2011057145 A2	12-05-2011	CN 102762556 A	31-10-2012
		CN 106866667 A	20-06-2017
		CN 110483499 A	22-11-2019
		EP 2496578 A2	12-09-2012
		EP 3257854 A1	20-12-2017
		HK 1248676 A1	19-10-2018
		IL 219564 A	31-01-2017
		RU 2012122653 A	10-12-2013
		US 2012220457 A1	30-08-2012
		US 2016318925 A1	03-11-2016
		US 2018354944 A1	13-12-2018
		WO 2011057145 A2	12-05-2011
ZA 201204028 B	27-11-2013		

WO 2018202491 A1	08-11-2018	AR 111850 A1	28-08-2019
		WO 2018202491 A1	08-11-2018
